false FY 0001530766

 2023-06-30

 2024-04-15

 us-gaap: RelatedPartyMember

 us-gaap: RelatedPartyMember

 BSGM:SeriesCNinePercentageConvertiblePreferredStockMember

 BSGM:SeriesCNinePercentageConvertiblePreferredStockMember

 us-gaap: SeriesAPreferredStockMember

 us-gaap: SeriesAPreferredStockMember

 us-gaap: SeriesBPreferredStockMember

 us-gaap: SeriesBPreferredStockMember

 us-gaap: SeriesDPreferredStockMember

 us-gaap: SeriesDPreferredStockMember

 us-gaap: SeriesEPreferredStockMember

 us-gaap: SeriesEPreferredStockMember

 us-gaap: SeriesFPreferredStockMember

 us-gaap: SeriesFPreferredStockMember

 us-gaap: ProductMember

 us-gaap: ProductMember

 BSGM:AttheMarketOfferingMember

 BSGM:AttheMarketOfferingMember

 2019-01-01
 2019-12-31

 2020-01-01
 2020-12-31

 2019-01-01
 2019-12-31

 2020-01-01
 2020-12-31

 2023-06-01

 2023-09-30

 2024-03-05
 2024-03-05

 2024-05-12

 2024-01-31
 2024-01-31

 BSGM:CustomerOneMember

 BSGM:CustomerTwoMember

 BSGM:CustomerThreeMember

 BSGM:CustomerOneMember

 BSGM:CustomerTwoMember

 BSGM:CustomerThreeMember

 BSGM:CustomerOneMember

 BSGM:CustomerTwoMember

 BSGM:CustomerThreeMember

 BSGM:CustomerOneMember

 BSGM:CustomerTwoMember

 us-gaap: PatentsMember

 2023-09-30

 us-gaap: ProductMember

 us-gaap: ProductMember

 us-gaap: WarrantMember

 us-gaap: WarrantMember

 us-gaap: RestrictedStockMember

 us-gaap: RestrictedStockMember

 us-gaap: ComputerEquipmentMember

 us-gaap: ComputerEquipmentMember

 us-gaap: FurnitureAndFixturesMember

 us-gaap: FurnitureAndFixturesMember

 us-gaap: MachineryAndEquipmentMember

 us-gaap: MachineryAndEquipmentMember

 BSGM:TestingAndDemoEquipmentMember

 BSGM:TestingAndDemoEquipmentMember

 us-gaap: LeaseholdImprovementsMember

 us-gaap: LeaseholdImprovementsMember

 us-gaap: BuildingMember

 us-gaap: BuildingMember

 BSGM:OperatingLeaseMember

 us-gaap: OtherCurrentAssetsMember

 us-gaap: OtherCurrentAssetsMember

 us-gaap: OtherCurrentAssetsMember

 us-gaap: OtherCurrentAssetsMember

 2013-01-09

 2013-01-09
 2013-01-09

 2020-12-31

 us-gaap: AccountsPayableMember

 2022-11-03

 2022-11-04

 2022-11-03
 2022-11-03

 BSGM:SharesToBeIssuedMember

 BSGM:UnderwritingAgreementMember

 2022-06-24
 2022-06-24

 BSGM:UnderwritingAgreementMember

 2022-06-24

 BSGM:SalesAgreementMember

 2022-05-17

 BSGM:SalesAgreementMember

 2022-05-17
 2022-05-17

 BSGM:SalesAgreementMember

 2022-05-18
 2022-11-29

 srt: DirectorMember

 BSGM:SecuritiesPurchaseAgreementsMember

 BSGM:SecuritiesPurchaseAgreementsMember

 BSGM:SecuritiesPurchaseAgreementsMember

 2023-07-26

 2022-10-11
 2023-07-26

 BSGM:SeriesACommonStockMember

 BSGM:SeriesBCommonStockMember

 BSGM:SeriesBCommonStockMember

 BSGM:EngagementAgreementMember
 BSGM:WainwrightAndCoLLCMember

 BSGM:EngagementAgreementMember
 BSGM:WainwrightAndCoLLCMember

 BSGM:EngagementAgreementMember
 BSGM:WainwrightAndCoLLCMember

 BSGM:SalesAgreementMember

 2023-08-18
 2023-08-18

 BSGM:ControlledEquityOfferingSalesAgreementMember
 BSGM:CantorFitzgeraldAndCoMember

 2023-08-18

 BSGM:ControlledEquityOfferingSalesAgreementMember
 BSGM:CantorFitzgeraldAndCoMember

 2023-08-22
 2023-09-06

 BSGM:ControlledEquityOfferingSalesAgreementMember
 BSGM:CantorFitzgeraldAndCoMember

 2023-09-06

 BSGM:AtTheMarketIssuanceSalesAgreementMember
 BSGM:AscendiantCapitalMarketsLLCMember

 2023-09-15
 2023-09-15

 BSGM:AscendiantCapitalMarketsLLCMember

 2023-09-15

 BSGM:AtTheMarketIssuanceSalesAgreementMember
 BSGM:AscendiantCapitalMarketsLLCMember

 2023-09-21
 2023-09-25

 BSGM:AtTheMarketIssuanceSalesAgreementMember
 BSGM:AscendiantCapitalMarketsLLCMember

 2023-09-21

 2023-07-19

 BSGM:EquityIncentive2012PlanMember

 2012-10-19

 2022-10-19
 2022-10-19

 BSGM:EquityIncentive2012PlanMember

 2022-12-27

 2022-12-27
 2022-12-27

 BSGM:EquityIncentive2012PlanMember

 BSGM:EmployeeMember

 BSGM:EmployeeMember

 BSGM:WarrantsAt4066Member

 BSGM:WarrantsAt4066Member

 us-gaap: WarrantMember

 us-gaap: PerformanceSharesMember

 2023-01-29
 2023-01-29

 2023-03-27
 2023-03-27

 2023-06-26
 2023-06-26

 2023-08-15
 2023-08-15

 2023-08-15
 2023-08-15

 BSGM:EquityIncentive2012PlanMember

 2019-09-24
 2019-09-24

 2019-09-24
 2019-09-24

 2023-09-24

 2023-06-30

 2023-06-01
 2023-06-30

 2023-07-01

 BSGM:OptionsUnder999Member

 BSGM:OptionsUnder999Member

 BSGM:Options1000To1999Member

 BSGM:Options1000To1999Member

 BSGM:Options2000To2999Member

 BSGM:Options2000To2999Member

 BSGM:Options3000To3999Member

 BSGM:Options3000To3999Member

 BSGM:Options4000To4999Member

 BSGM:Options4000To4999Member

 BSGM:Options5000To5999Member

 BSGM:Options5000To5999Member

 BSGM:Options6000To6999Member

 BSGM:Options6000To6999Member

 BSGM:Options7000To7999Member

 BSGM:Options7000To7999Member

 BSGM:OptionsOver7999Member

 BSGM:OptionsOver7999Member

 2021-01-01
 2021-01-01

 BSGM:WarrantsAt3573Member

 BSGM:WarrantsAt3573Member

 BSGM:WarrantsAt4066Member

 BSGM:WarrantsAt4066Member

 BSGM:WarrantsAt4455Member

 BSGM:WarrantsAt4455Member

 BSGM:WarrantsAt4466Member

 BSGM:WarrantsAt4466Member

 BSGM:WarrantsAt46626Member

 BSGM:WarrantsAt46626Member

 BSGM:WarrantsAt49252Member

 BSGM:WarrantsAt49252Member

 BSGM:WarrantsAt4929Member

 BSGM:WarrantsAt4929Member

 BSGM:WarrantsAt51358Member

 BSGM:WarrantsAt51358Member

 BSGM:WarrantsAt7181Member

 BSGM:WarrantsAt7181Member

 BSGM:WarrantsAt7502Member

 BSGM:WarrantsAt7502Member

 BSGM:WarrantsAt7963Member

 BSGM:WarrantsAt7963Member

 BSGM:WarrantsAt9000Member

 BSGM:WarrantsAt9000Member

 BSGM:WarrantsAt9596Member

 BSGM:WarrantsAt9596Member

 BSGM:WarrantsAt100992Member

 BSGM:WarrantsAt100992Member

 BSGM:WarrantsAt1026Member

 BSGM:WarrantsAt1026Member

 BSGM:WarrantsAt104678Member

 BSGM:WarrantsAt104678Member

 BSGM:WarrantsAt1130Member

 BSGM:WarrantsAt1130Member

 BSGM:WarrantsAt1328Member

 BSGM:WarrantsAt1328Member

 BSGM:WarrantsAt1400Member

 BSGM:WarrantsAt1400Member

 BSGM:WarrantsAt4800Member

 BSGM:WarrantsAt4800Member

 BSGM:WarrantsAt6160Member

 BSGM:WarrantsAt6160Member

 BSGM:RangeOneMember

 BSGM:RangeOneMember

 BSGM:RangeTwoMember

 BSGM:RangeTwoMember

 2023-06-01
 2023-06-30

 2023-07-01
 2023-07-30

 BSGM:MasterServicesAgreementMember

 BSGM:MasterServicesAgreementMember

 2023-10-01
 2023-10-01

 BSGM:MasterServicesAgreementMember

 BSGM:MasterServicesAgreementMember

 BSGM:TwentyTwentySeventeenKnowHowLicenseAgreementMember

 2017-03-15
 2017-03-15

 BSGM:TwentyTwentySeventeenKnowHowLicenseAgreementMember

 2017-03-15
 2017-03-15

 BSGM:TwentyTwentySeventeenKnowHowLicenseAgreementMember

 BSGM:TwentyTwentySeventeenKnowHowLicenseAgreementMember

 BSGM:EPSoftwareAgreementMember

 2019-11-20

 BSGM:EPSoftwareAgreementMember

 BSGM:EPSoftwareAgreementMember

 BSGM:ToolsAgreementMember

 2021-01-01

 BSGM:ToolsAgreementMember

 2019-11-20

 BSGM:ToolsAgreementMember

 BSGM:ToolsAgreementMember

 BSGM:ViralClearPatentAgreementMember

 2019-11-20

 BSGM:ViralClearPatentAgreementMember

 2021-01-01

 BSGM:ViralClearPatentAgreementMember

 BSGM:ViralClearPatentAgreementMember

 BSGM:FirstCountryMember

 BSGM:SecondCountryMember

 BSGM:ConsultingAgreementMember

 2023-06-17
 2023-06-17

 BSGM:ConsultingAgreementMember

 2023-12-04
 2023-12-04

 2024-02-22
 2024-02-22

 2024-03-22
 2024-03-22

 2024-03-22
 2024-03-22

 us-gaap: CorporateMember

 us-gaap: CorporateMember

 us-gaap: CorporateMember

 us-gaap: CorporateMember

 srt: ChiefFinancialOfficerMember

 srt: ChiefFinancialOfficerMember

 srt: ExecutiveVicePresidentMember

 2023-11-02
 2023-11-02

 srt: ExecutiveVicePresidentMember

 srt: ExecutiveVicePresidentMember

 2024-03-05

 2024-03-12

 2024-03-07

 2024-03-07
 2024-03-07

 2024-01-12
 2024-01-12

 2024-01-12

 2024-01-04
 2024-01-04

 BSGM:FormerEmployeesMember

 2024-02-05
 2024-02-05

 BSGM:ConsultantsMember

 2024-01-01
 2024-01-31

 2024-02-01
 2024-02-28

 BSGM:OfficersEmployeeAndKeyConsultantsMember

 BSGM:KeyConsultantsMember

 BSGM:OfficersAndKeyConsultantsMember

 BSGM:ConsultantsMember

 BSGM:ConsultantsMember

 2024-03-15
 2024-03-15

 BSGM:EmployeesMember

 2024-04-01
 2024-04-01

 2024-04-01
 2024-04-01

 BSGM:Integer

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 WASHINGTON,
D.C. 20549

 FORM

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the Fiscal Year Ended December 31, 2023

 Or

 TRANSITION
REPORT UNDER SECTON 13.08 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from _______ to ______

 Commission
File Number 001-38659

 BIOSIG
TECHNOLOGIES, INC.

 (Exact
name of registrant as specified in its charter)

 Delaware

 26-4333375

 (State
 or other jurisdiction of incorporation

 or
 organization)

 (IRS
 Employer Identification No.)

 Greens Farms Road 1st Floor

 Westport,
 CT

 06880

 (203) 409-5444

 (Address
 of principal executive offices)

 (Zip
 Code)

 (Registrant's
 telephone number, including area code)

 Securities
registered pursuant to Section 12(b) of the Act:

 Title
 of each class

 Trading
 Symbol(s)

 Name
 of each exchange on which registered

 Common
 Stock, par value $0.001 per share

 BSGM

 The
 NASDAQ Capital Market

 Securities
registered pursuant to Section 12(g) of the Act: None

by check mark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. Yes No

by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes No

by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes No

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller
reporting company," and "emerging growth company" in Rule 12b–2 of the Exchange Act.

 Large
 accelerated filer

 Accelerated
 filer

 Non-accelerated
 filer

 Smaller
 reporting company

 Emerging
 growth company

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness
of its internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 The
aggregate market value of the voting and non-voting common equity held by non-affiliates as of June 30, 2023, based on the price at which
the common stock was last sold on such date, is $ 76,956,461. For purposes of this computation, all officers, directors, and 5 percent
beneficial owners of the registrant are deemed to be affiliates. Such determination should not be deemed an admission that such directors,
officers, or 5 percent beneficial owners are, in fact, affiliates of the registrant.

 As
of April 15, 2024, there were 11,198,174 shares of the registrant's common stock outstanding.

 TABLE
OF CONTENTS

 PAGE

 Item
 1.

 Business

 Item
 1A.

 Risk Factors

 Item
 1B.

 Unresolved Staff Comments

 Item
 1C.

 Cybersecurity

 Item
 2.

 Properties

 Item
 3.

 Legal Proceedings

 Item
 4.

 Mine Safety Disclosures

 Item
 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item
 6.

 Reserved

 Item
 7.

 Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item
 7A.

 Quantitative and Qualitative Disclosures about Market Risk

 Item
 8.

 Financial Statements and Supplementary Data

 – F-36

 Item
 9.

 Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

 Item
 9A.

 Controls and Procedures

 Item
 9B.

 Other Information

 Item
 9C.

 Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 Item
 10.

 Directors, Executive Officers and Corporate Governance

 Item
 11.

 Executive Compensation

 Item
 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item
 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item
 14.

 Principal Accounting Fees and Services

 Item
 15.

 Exhibits, Financial Statement Schedules

 Item
 16.

 Form 10-K Summary

 Signatures

 PART
I

 Note
on Forward-Looking Statements

 This
Annual Report on Form 10-K (including the section regarding Management's Discussion and Analysis of Financial Condition and Results
of Operations) contains forward-looking statements regarding our business, financial condition, results of operations and prospects.
Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks,"
"estimates" and similar expressions or variations of such words are intended to identify forward-looking statements, but
are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this Annual Report on Form
10-K. Additionally, statements concerning future matters are forward-looking statements.

forward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our management, such statements can
only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and
uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the
forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation,
those specifically addressed under the heading "Risk Factors" below, as well as those discussed elsewhere in this Annual
Report on Form 10-K. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date
of this Annual Report on Form 10-K. We file reports with the Securities and Exchange Commission ("SEC"). The SEC maintains
an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that
file electronically with the SEC, including us.

 We
undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise
after the date of this Annual Report on Form 10-K. Readers are urged to carefully review and consider the various disclosures made throughout
the entirety of this Annual Report on Form 10-K, which attempt to advise interested parties of the risks and factors that may affect
our business, financial condition, results of operations and prospects.

 Unless
the context indicates otherwise, references in this Annual Report to "BioSig," the "Company," "we,"
"our" and "us" mean BioSig Technologies, Inc., and its predecessor entities.

 ITEM
1 – BUSINESS

 Corporate
Structure

 We
were formed as BioSig Technologies, Inc., a Nevada corporation, in February 2009 and in April 2011 we merged with our wholly owned subsidiary,
BioSig Technologies, Inc., a Delaware corporation, with the Delaware corporation continuing as the surviving entity. BioSig is principally
devoted to improving the standard of care in electrophysiology, or EP, with our PURE EP System's enhanced signal acquisition,
digital signal processing, and analysis during catheter ablation of cardiac arrhythmias. The Company has generated minimal revenue to
date and consequently its operations are subject to all risks inherent in business enterprise in early commercialization stage.

 On
November 7, 2018, we formed a subsidiary under the laws of the State of Delaware, originally under the name of NeuroClear Technologies,
Inc., for the purpose of pursuing additional applications of the PURE EP signal processing technology outside of the field of
cardiac electrophysiology. In March 2020, it was renamed ViralClear Pharmaceuticals, Inc. ("ViralClear"). As of April 16,
2024, the Company retains 69.08% ownership of ViralClear. ViralClear's Business Overview can be found on page 15.

 On
July 2, 2020, the Company formed an additional subsidiary, NeuroClear Technologies, Inc., a Delaware corporation, which was renamed to
BioSig AI Sciences, Inc. ("BioSig AI") on May 31, 2023. The subsidiary was established to pursue clinical needs of cardiac
and neurological disorders through recordings and analyses of action potentials. BioSig AI aims to contribute to the advancements of
AI-based diagnoses and therapies. In June and July 2023, BioSig AI sold an aggregate of 2,205,000 shares of its common stock for net
proceeds of $1,971,277 to fund initial operations. At April 15, 2024, the Company had a majority interest in BioSig AI of 84.5%.

 Business
Overview

Technologies is a medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment
of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology
(EP), we are committed to addressing healthcare's biggest priorities — saving time, saving costs, and saving lives.

 Our
first product, the PURE EP System, is an FDA 510(k) cleared non-invasive class II device consisting of a unique combination of
hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals
paving the way for personalized patient care. Integrating with existing systems in the EP lab, PURE EP is designed to accurately
pinpoint even the most complex signals to maximize procedural success and efficiency.

 By
capturing critical cardiac signals—even the most complex, the PURE EP System is designed to enhance clinical decision-making
and improve clinical workflow for all types of arrhythmias - even the most challenging procedures for cardiac arrhythmias, like ventricular
tachycardia (VT) and atrial fibrillation (AF).

 Our
owned patent portfolio now includes 36 (issued/allowed) issued utility patents (24 utility patents where BioSig is at least one of the
applicants). Twenty five additional U.S. and foreign utility patent applications are pending covering various aspects of our PURE EP
System for recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures (25 U.S. and foreign
utility patent applications where either BioSig, Mayo, or both is at least one of the applicants). We also have one U.S. patent and one
U.S. Pending application directed to artificial intelligence (AI). We also have 30 issued worldwide design patents, which cover various
features of our display screens and graphical user interface for enhanced visualization of biomedical signals (30 design patents where
BioSig is at least one of the applicants). Finally, we have licenses to 12 (issued/allowed) patents and 9 additional worldwide utility
patent applications from Mayo Foundation for Medical Education and Research that are pending (12 issued/allowed patents and 9 applications
where only Mayo is the applicant). These patents and applications are generally directed to electroporation and stimulation.

Developments

 PURE
EP Software Version 7 in late 2023 was launched by the Company's commercial and operations team and represents the most
advanced iteration of the Company's digital signal processing technology. Despite having a field team of 15 persons, PURE EP sales,
leasing and/or subscriptions to the software were mostly limited to our research partners at Mayo Clinic, Texas Cardiac Arrhythmia Institute,
Cleveland Clinic, and Kansas City Heart Rhythm Institute.

 Given
the very challenging hospital market post-COVID where capital budgets and purchasing has been restricted due to budget shortfalls, the
Company began to seek partners already in the EP field that have an established field force to increase the penetration of PURE EP into
the hospital systems. This approach would also increase the efficiency in the lab given that established companies already have clinical
support within the lab during the procedure and we feel that adding PURE EP would drive the partner's sales at no additional support
cost.

 Reverse
stock split

 On
December 18, 2023, the Company held its 2023 annual meeting of stockholders, at which meeting the Company's stockholders approved
an amendment (the "Reverse Stock Split Amendment") to the Company's Amended and Restated Certificate of Incorporation
(the "Certificate of Incorporation") to effect a reverse stock split of all of the issued and outstanding shares of the Company's
common stock, at a ratio in the range of 1-for-2 to 1-for-10, with the exact exchange ratio and timing to be determined by the Company's
board of directors in its discretion and included in a public announcement (the "Reverse Stock Split"). Following the annual
meeting, the Board determined to effect the Reverse Stock Split at a ratio of 1-for-10 and approved the corresponding final form of the
Reverse Stock Split Amendment. On January 31, 2024, the Company filed the Reverse Stock Split Amendment with the Secretary of State of
the State of Delaware to effect the Reverse Stock Split, effective as of 4:05 p.m. (New York time) on February 1, 2024.

 As
a result of the Reverse Stock Split, every ten (10) shares of issued and outstanding Common Stock was automatically combined into one
(1) issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares will be issued
as a result of the Reverse Stock Split. Any fractional shares that would otherwise have resulted from the Reverse Stock Split will be
rounded up to the next whole number. The Reverse Stock Split will reduce the number of shares of Common Stock outstanding from 93,344,435
shares to approximately 9,378,513 shares, subject to adjustment for the rounding up of fractional shares. The number of authorized shares
of Common Stock under the Certificate of Incorporation will not change as a result of the Reverse Stock Split.

 Proportionate
adjustments was made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of
outstanding stock options, restricted stock units, and warrants granted by the Company, the per share conversion price and the number
of shares of common stock that may be issued upon conversion of outstanding shares of convertible preferred stock issued by the Company
and the number of shares of Common Stock reserved for future issuance under the Company's 2023 Long-Term Incentive Plan.

 The
Common Stock began trading on a Reverse Stock Split-adjusted basis on The Nasdaq Capital Market on February 2, 2024. The trading symbol
for the Common Stock will remain "BSGM." The new CUSIP number for the Common Stock following the Reverse Stock Split is 09073N300.

 Notices
of Delisting

 On
March 5, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq (the "Staff") stating that
the Company has not regained compliance with Listing Rule 5550(a)(2) because the Company's common stock did not meet the minimum
bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market, and the Company is not eligible for a second
180 day cure period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $5,000,000 minimum stockholders' equity
initial listing requirement for The Nasdaq Capital Market, and that accordingly, Nasdaq would delist the Company's common stock
unless the Company requested an appeal of this determination. On March 11, 2024, the Company submitted a request for a hearing before
the Nasdaq Hearings Panel to appeal the Staff's delisting determination.

 On
March 12, 2024, the Company received a letter from the Staff stating that based upon the Staff's review of the Company and pursuant
to Listing Rule 5101, the Staff believes that the Company no longer has an operating business and is a "public shell," and
that the continued listing of its securities is no longer warranted, in view of work force reductions and resignations of members of
the board of directors and officers (see below).

 The
letter further stated that the Company no longer meets the requirement of Rule 5550(b)(2) to maintain a minimum Market Value of Listed
Securities of $35 million, if none of the other standards set forth in Rule 5550(b) is met.

 The
Staff stated that the foregoing matters serve as an additional basis for delisting the Company's common stock from The Nasdaq Stock
Market, and that the Hearings Panel will consider this matter in rendering a determination regarding the Company's continued listing

 The
Company intends also to appeal the foregoing determinations. The requested hearing before the Hearings Panel will be held on May 7, 2024.

 Delisting
from Nasdaq Stock Market could negatively impact the Company's ability to raise additional financing to fund future operations.

 Lack
of funding, workforce reductions, resignations of members of the Company's board of directors and certain officers

 On
January 28, 2024 and February 20, 2024, management of the Company commenced a workforce reduction intended to reduce significantly the
annual cash burn which was completed as of February 20, 2024. The workforce reduction consisted of the departure of sixteen employees,
effective as of January 31, 2024 and included the departure of John Sieckhaus, the Company's Chief Operating Officer, and Gray
Fleming, the Company's Chief Commercial Officer and twenty six employees effective February 20, 2024. The effect of the workforce
reductions had significantly reduce operations in the short-term.

 On
February 15, 2024, Steve Buhaly resigned from his position as the Chief Financial Officer of the Company effective as of the same date.

 On
February 19, 2024, David Weild IV, Donald E. Foley, Patrick J. Gallagher and James J. Barry, resigned from their positions as directors
of the Company, effective as of the same date.

 On
February 20, 2024, James L. Klein and Frederick D. Hrkac resigned from their positions as directors of the Company, effective as of the
same date.

 On
February 20, 2024 due to lack of funding, the company had laid off the entire workforce except for the CEO.

 On
February 27, 2024, the company re-appointed Frederick D. Hrkac as a director and the president and principal executive officer. Additionally,
on February 27, 2024, Kenneth L. Londoner resigned from his positions as director, executive chairman and chief executive officer of
the Company and from any and all committees, offices, appointments, designations, responsibilities or other capacities related to the
Company or any of its subsidiaries, effective as of the same date.

 Currently,
the Company has 4 employees and 4 key consultants. Dependent upon funding, Mr. Hrkac would plan on hiring a team of 4-6 persons to
execute the business development strategy of finding partners for the commercialization of PURE EP, develop new products in
the field of Pulse Field Ablation and to continue to integrate PURE EP into today's lab equipment.

 Pending
Legal Proceedings

 On
December 4, 2023, the Company received a threat of litigation for the termination of employment with the Company alleging the termination
of employment was in retaliation for bringing to the attention of the Company's board of directors and executives a series of wrongful
and questionable practices by members of the Company's board of directors, Chief Executive Officer and Chief Financial Officer.
The claimant sought compensation of in the amount of $775,782. After an investigation with the parties threatened conducted by the Board
and guidance of legal counsel, it was concluded that the claim was without merit.

 On
February 22, 2024, the Company received a threat of litigation seeking restitution for losses resulting from unlawful actions taken by
the Company's board of directors. The claimant contends that he and others have sustained losses totaling $1,440,000. On
March 22, 2024, the claimant sent another letter to the Company referencing the previous letter and requesting several documents. The
Company believes that these claims are without merit.

 On
March 22, 2024, plaintiff, Michael Gray Fleming (the "Plaintiff"), filed a lawsuit in Hennepin County, Minnesota District
Court naming the Company, its former Chief Executive Officer and former Chief Financial Officer as defendants. The Plaintiff contends
that the Company failed to meet its obligations in issuing the Plaintiff stock certificates at the end of the restricted period under
the terms of a restricted stock award agreement, and is seeking $144,000 in damages and compensation for damages reasonably believed
to exceed $50,000. The Company believes that these claims are without merit. The Company's
intent is to contest the allegations vigorously and, as of the date of this report, is unable to provide an evaluation of the outcome
of the litigation within the probate or remote range or to provide an estimate of the amount of or a range of potential loss that might
be incurred by the Company.

 Private
Placements

 On
January 12, 2024, the Company entered into a securities purchase agreement with certain accredited and institutional investors, pursuant
to which the Company sold to the investors an aggregate of 260,720 shares of the Company's common stock and warrants to purchase
up to 130,363 shares of common stock, at a purchase price of $3.989 per share and a warrant to purchase one-half of a share. The warrants
have an exercise price of $3.364 per share, will become exercisable six months after the date of issuance and will expire five and one-half
years following the date of issuance. The gross proceeds from this offering were $1,040,000.

 In
2023, the Company entered into multiple Securities Purchase Agreements with certain institutional and accredited investors, pursuant
to which the Company sold to the investors an aggregate of 1,613,906 shares of common stock at an average purchase price of $8.7571
per share, and warrants to purchase up to an aggregate of 806,981 shares of common stock at an average exercise price of $8.1324 per
share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date
of issuance, in exchange for aggregate consideration of $13,140,441, net of transactional expenses of $727,333.44 (the
"2023 PIPEs").

to certain engagement agreements, dated October 11, 2022, February 24, 2023 and July 26, 2023, the Company had entered into with Laidlaw
& Company (UK) Ltd. ("Laidlaw"), the Company issued to Laidlaw in connection with the 2023 PIPEs, warrants to purchase
an aggregate of 77,405 shares of common stock at an average exercise price of $7.85 per share. The Laidlaw warrants become exercisable
six months after the date of issuance and will expire five and one-half years following the date of issuance.

 On
November 8, 2023, the Company entered into a Securities Purchase Agreement with an institutional investor, pursuant to which the Company
sold in a registered direct offering (the "Offering"), (i) 699,693 shares (the "Shares") of the Company's
common stock, $0.001 par value per share (the "Common Stock"), (ii) Series A warrants (the "Series A Warrants")
to purchase up to 699,693 shares of Common Stock, and (iii) Series B Warrants (the "Series B Warrants", and together with
the Series A Warrants, the "Series Warrants") to purchase up to 699,693 shares of Common Stock, at a purchase price of $3.573
per Share and associated Series Warrants. The Series Warrants have an exercise price of $3.573 per share and will become exercisable
on the effective date of stockholder approval for the issuance of the shares upon exercise of the Series Warrants (or, if permitted by
the applicable rules and regulations of the Nasdaq Stock Market, upon payment by the holder of $1.25 per share in addition to the applicable
exercise price). The Series A Warrants will expire five years from the date of issuance and the Series B Warrants will expire eighteen
months from the date of issuance.

 H.C.
Wainwright & Co., LLC (the "Placement Agent") acted as the Company's exclusive placement agent in the Offering.
In connection with the Offering, the Company paid the Placement Agent a cash fee equal to seven percent (7.0%) of the aggregate gross
proceeds raised in the Offering and a management fee equal to one percent (1.0%) of the aggregate gross proceeds raised in the Offering.
The Company had also paid the Placement Agent $50,000 for non-accountable expenses and $15,950 for clearing fees. In addition, the Company
issued the Placement Agent or its designees, warrants to purchase up to 48,979 shares of Common Stock (equal to 7.0% of the aggregate
number of Shares sold in the Offering), which warrants have the same terms and conditions as the Series A Warrants, except that such
warrants have an exercise price of $4.466 per share, which represents 125% of the offering price per Share and accompanying Series Warrants
(the "Placement Agent Warrants", and together with Series Warrants, the "Warrants").

 The
Shares and the Warrants (and shares issuable upon exercise of the Warrants) were offered and sold by the Company pursuant to a shelf
registration statement on Form S-3 (File No. 333-251859) (the "Shelf Registration Statement"), previously filed with the
Securities and Exchange Commission (the "SEC") on December 31, 2020, and declared effective by the SEC on January 12, 2021,
and the base prospectus included therein. A final prospectus supplement relating to the Offering, dated November 8, 2023, and the accompanying
prospectus, has been filed with the SEC. The closing of the Offering occurred on November 13, 2023. The net proceeds to the Company from
the Offering, after deducting fees and expenses, were approximately $2.2 million.

 Issuance
of debt

 On
March 7, 2024, the Company issued a promissory note to an investor and related party (10% plus shareholder) for $500,000. The Company
designated its 12% note due 2026, in accordance with exemptions from registration under the Securities Act of 1933, as amended (the "Securities
Act").

 The
note is due March 7, 2026. The Company promises to pay interest in cash on the unpaid principal amount of this note at a rate per annum
equal to twelve percent (12%), commencing to accrue on the date hereof and payable on the maturity date or earlier prepayment as provided
therein. The Note contains customary events of default.

 The
Company may prepay all or any portion of the principal amount of the Note at any time or from time to time without penalty.

 ATM
Sales Agreements

 On
August 18, 2023, the Company entered into a Controlled Equity Offering Sales Agreement (the "Cantor Sales Agreement")
with Cantor Fitzgerald & Co. to act as the Company's sales agent or principal ("Cantor"), with respect to the issuance
and sale of up to $30.0 million of the Company's shares of common stock, from time to time in an at-the-market public offering.

 The
Company agreed to pay Cantor a commission of equal to 3.0% of the gross proceeds from the sale of the shares of common stock pursuant
to the Cantor Sales Agreement.

 From
August 22, 2023 through September 6, 2023, the Company sold 21,881 shares of its common stock through the Cantor Sales Agreement for
net deficit of $(899), after transactional costs of $120,430.

 The
Company terminated the Cantor Sales Agreement with Cantor, effective as of September 15, 2023.

 On
September 15, 2023, the Company entered into an At-The-Market Issuance Sales Agreement (the "Ascendiant Sales Agreement")
with Ascendiant Capital Markets, LLC, to act as the Company's sales agent or principal ("Ascendiant"), with respect
to the issuance and sale of up to $30.0 million of the Company's shares of common stock, from time to time in an at-the-market
public offering.

 The
Company agreed to pay Ascendiant a commission of equal to 3.0% of the gross proceeds from the sale of the shares of common stock pursuant
to the Ascendiant Sales Agreement.

 From
September 21, 2023 through September 25, 2023, the Company sold 28,911 shares of its common stock through the Ascendiant Sales Agreement
for $60,876, after transactional costs of $70,806.

 The
Company terminated the Ascendiant Sales Agreement with Ascendiant, effective as of November 6, 2023.

AI Sciences, Inc.:

 In
June and July 2023, BioSig AI sold an aggregate of 2,205,000 shares of its common stock for net proceeds of $1,971,277 ($1.00 per share).
Prior to such sale, BioSig AI was a wholly owned subsidiary. At December 31, 2023, BioSig had a majority interest in BioSig AI of 84.5%.

to an engagement agreement, dated June 13, 2023, as amended on July 19, 2023, BioSig AI entered into with Laidlaw, BioSig AI issued to
Laidlaw warrants to purchase an aggregate of 130,500 shares of its common stock at an exercise price of $1.00 per share. The Laidlaw
warrants become exercisable immediately and will expire five years following the date of issuance.

 Our
Industry

 Pharmacological,
or medicine-based, therapies have traditionally been used as initial treatments for cardiac arrhythmias, but they often fail to adequately
control the arrhythmia and may have significant side effects. Catheter ablation is now often recommended for an arrhythmia that medicine
cannot control. Catheter ablation involves advancing several flexible catheters into the patient's blood vessels, usually either
in the femoral vein, internal jugular vein or subclavian vein. The catheters are then advanced towards the heart. Electrical impulses
are then used to induce the arrhythmia and local heating or freezing is used to ablate (destroy) the abnormal tissue that is causing
it. Catheter ablation for most of arrhythmias has a high success rate. For patients with complex arrhythmias like AF and VT, it is often
necessary to perform multiple procedures to achieve success.

 Catheter
ablation is performed by an electrophysiologist (a specially trained cardiologist) in a specialized room in an EP lab. According to Health
Research International, it is estimated that there are 7,340 global EP labs performing catheter ablations. According to experts, the
global electrophysiology market value is worth over $8 billion in 2023 predicted to be worth $16 billion by 2028, a CAGR of 15 percent.

 Catheter
Ablation of AF and VT

 Accurate
recording of electrograms is critical to efficient mapping and ablation of complex arrhythmias. We believe that the clearer recordings
and the very small amplitude of intracardiac signals—high frequency, small amplitude components in midst of large physiologic signals;
signals important to characterize critical substrate, such as fractionated atrial and ventricular electrograms; and high-frequency, low-amplitude
signals such as the Purkinje potentials—provided by the PURE EP System may improve outcomes during EP studies and ablation
procedures for a variety of arrhythmias.

 For
patients who are candidates for ablation, an EP study is necessary to define the targeted sites for the ablation procedure. Two common,
yet complex, conditions for which ablation procedures are performed are AF and VT. Most cardiac arrhythmias are well understood, and
ablation simply requires destroying a small area of heart tissue possessing electrical abnormality. In contrast, complex arrhythmias,
such as AF and VT, have complex pathophysiology and, because knowledge of their origins and mechanisms are incomplete, ablation treatments
for these arrhythmias are largely empirical. Furthermore, the length of these procedures, which typically last from 2-4 hours, exposes
the physician and staff to extensive radiation, requiring them to wear heavy lead vests. Consequently, ablating AF and VT has been regarded
as being difficult.

 AF
is the most common heart rhythm disorder in the world and increases the risk for stroke 5-fold. In 2017, there were a reported 37.57
million prevalent cases and 3.05 million incident cases of AF globally, contributing to over 287,000 deaths worldwide ( Global, regional,
and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990 – 2017: results from the Global
Burden of Disease Study 2017). In 2020, the Centers for Disease Control and Prevention stated that it is estimated that 12.1 million
people in the United States will have AF in 2030, more than 454,000 patients hospitalized annually as the primary diagnosis, and AF contributes
to an estimated 158,000 deaths each year. An increasing proportion of diagnosed AF cases are now being treated via ablation, as both
physician confidence and the devices used in these procedures improve. A growing amount of positive clinical data has demonstrated the
efficacy of AF ablation when compared to the traditional first-line treatment of anti-arrhythmic drugs.

 The
AF Ablation Long Term Registry is an international registry of 3,630 patients who underwent AF ablation between 2012 and 2015 –
the study reported a 41% rate of repeat ablation at 3 years post ablation. At 12-month follow-up, the outcome was judged to have been
successful in 74% of patients. However, almost 50% of the patients were still taking an antiarrhythmic drug. AF recurrences were less
common in patients with paroxysmal (31%) than with persistent (40%) or long-standing persistent (44%) AF.

 EP
Lab Environment and EP Recording Systems

 The
electrophysiology (EP) laboratory consists of sophisticated equipment that requires an electrophysiologist to mentally integrate information
from a number of sources during procedures. There are numerous monitors in an EP lab that provide and display this variety of information.
An electrophysiologist needs to evaluate the acquired cardiac signals and the patient's responses to any induced arrhythmias during
the procedure. However, it can be difficult for an electrophysiologist to synthesize the disparate information produced by the numerous
monitors in the lab and calculate the real-time, three-dimensional orientation of the anatomy and the location of the recording and ablation
catheters. As the number of EP procedures increase, a variety of diagnostic, therapeutic and highly specialized ablation catheters are
widely available and continue to be developed. In addition, remote robotic and magnetic navigation systems have been developed to address
limitations of dexterity in controlling the catheter tip, especially during complex arrhythmia ablation procedures. We believe that,
considering the improvements being made with respect to other equipment used in the EP lab and the continual increase of ablation procedures,
the EP recorders currently available on the market are not sufficiently advanced with respect to the quality of their recordings to deliver
adequate results. We believe that the PURE EP System will be able to deliver superior quality of recordings that will allow it
to successfully integrate with the other advanced equipment found in the EP lab.

 Generally,
some current electrophysiology recording systems can effectively support the treatment of arrhythmias such as atrial flutter and supraventricular
tachycardia, which show up as large-amplitude, low-frequency signals. However, more complex and prevalent arrhythmias, such as AF and
VT, which are characterized by low-amplitude, high-frequency signals, have not found an effective evaluation of all relevant signals.
This signal detection, acquisition, and isolation can be further complicated by equipment line noise and pacing signals. Current EP recorders
use low-pass, high-pass, and notch filters to remove noise and artifacts from the various electrical signal information. Unfortunately,
conventional filtering techniques can alter signals and make it difficult or impossible to see low-amplitude, high-frequency signals
that can be inherent in cardiac monitoring, the visualization of which signals could help treat atrial fibrillation and ventricular tachycardia.
It has been recently recognized that the assurance of waveform integrity, such as for the noise-free acquisition of intracardiac and
ECG signals in an EP environment, had not been previously accomplished due to contamination of various signals by artifacts and noise.

 The
requirement for optimal signal integrity is amplified during ablation treatments of AF and VT. One of the main objectives of the AF ablation
procedure is to precisely identify, ablate and eliminate pulmonary vein potentials and one of the main objectives of the VT procedure
is to map the arrhythmia substrate and precisely identify, ablate and eliminate small abnormal potentials. The information provided by
recorders is essential for an electrophysiologist to determine ablation strategy during termination of both pulmonary vein potentials
and VT. Therefore, it is important that the recording system's noise removal technique does not alter the appearance and fidelity
of these potentials. As a result, it is necessary that any new signal processing technology preserves signal fidelity as much as possible
during EP recordings; otherwise, the signals that are needed to guide the ablation procedures will be difficult to distinguish due to
noise interference.

 Our

 The
patented PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures,
such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated
potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated
to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time. The device aims to minimize
noise and artifacts from cardiac recordings and acquire high-fidelity cardiac signals. Improving fidelity of acquired cardiac signals
may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies
and ablation procedures.

 Cardiac
catheter ablation is a procedure that involves delivery of energy through the tip of a catheter that scars or destroys heart tissue to
correct heart rhythm disturbances. In August 2018, we received 510(k) clearance from the FDA to market our PURE EP System.

 Our
PURE EP System can record raw (unaltered) cardiac signals with multiple display options, low noise, and a large input signal dynamic
range. This is achieved using a low-noise amplifier topology with minimal filtering to band-limit the signal and a high-resolution A/D
converter. In addition, the PURE EP System can provide large-signal (e.g., from a defibrillator) input protection and radio frequency
(RF) signal (e.g., from ablation) noise suppression. There is no need for gain switching in this architecture, and the full range of
input signals is digitized with high resolution.

 We
are focused on improving intracardiac signal acquisition and enhancing diagnostic information for catheter ablation procedures for all
arrhythmias, especially complex types like ventricular tachycardia, VT and atrial fibrillation, AF. VT is a fast, abnormal heart rate
in the heart's lower chambers. VT does not give your heart enough time to fill with blood before it contracts again. This can affect
blood flow to the rest of your body and is potentially life-threatening. AF is the most common cardiac arrhythmia associated with a fivefold
risk of stroke. AF occurs when the upper chambers of the heartbeat irregularly, and do not pump all of the blood to the lower chambers,
causing some blood to pool and potentially form clots. If a clot breaks loose, it can travel through the bloodstream to the brain and
lead to a stroke. Strokes related to AF are often more severe compared to strokes with other underlying causes.

 We
believe that the PURE EP System and its advanced signal processing tools may contribute to improvements in patient outcomes in
connection with catheter ablation due to the following advantages over currently available devices on the market:

 Less
 noise: PURE EP 's low-noise proprietary architecture was engineered to enable acquisition of high-fidelity signals
 in the original, unfiltered format. PURE EP's Main System Unit (MSU) topology incorporates advanced shielding and very low
 noise front-end components.

 Wider
 range: An expanded dynamic range retains cardiac signal details and reduces saturation. PURE EP combines a low-noise
 signal architecture with a fixed range up to 500mV, so signals are rarely clipped or limited by quantization noise.

 Higher
 definition: PURE EP supports a large frequency bandwidth and linear signal acquisition to accurately display complex
 fractionated signals, even at lower amplitudes and higher frequencies.

 Unipolar
 signals: PURE EP incorporates an innovative WCT+ design for acquiring unipolar signals, relying on a common
 front-end circuitry similar to how bipolar intracardiac signals are acquired.

 Customizable
 software and filters: PURE EP offers software modules and specialty digital filters, so electrophysiologists can customize
 their interface and optimize signals for mapping, signal interpretation and during therapy delivery.

 Seamless
 integration: PURE EP integrates with existing EP labs and workflows. It is compatible and complementary with EP recording
 systems, mapping systems, robotic equipment, and multi-display panels.

 We
believe that PURE EP 's features may allow physicians to better determine precise ablation targets, strategy, and end point
of procedures with the objective of reducing the need for patients to undergo multiple procedures, and to allow for less experienced
EP physicians to perform more complex procedures. The PURE EP System is intended to operate in conjunction with the existing EP
lab equipment.

 Initial
Analysis

 According
to S. J. Asirvatham, MD, et. al. ("Signals and Signal Processing for the Electrophysiologist," Circ Arrhythm Electrophysiol.
(2011) 4:965-973), recording environments in a typical electrophysiology laboratory presents challenging situations. S. J. Asirvatham,
MD, et. al., state, "Successful mapping and ablation in the electrophysiology laboratory is critically dependent on acquiring multiple,
low-amplitude, intracardiac signals in the presence of numerous sources of electric noise and interference and displaying these signals
in an uncomplicated and clinically relevant fashion, with minimal artifacts. This represents a significant engineering challenge and,
in real-life electrophysiology laboratory, is not always successful."

 Proof
of Concept Testing

 In
the second and third quarters of 2013, we performed and finalized testing of our proof of concept unit by initially using an electrocardiogram/intracardiac
simulator at our lab, and subsequently by obtaining pre-clinical recordings from the lab at the University of California at Los Angeles.
We believe that our proof of concept unit performed well as compared to GE's CardioLab recording system, in that the electrocardiogram
and intracardiac signals displayed on our proof of concept unit showed less baseline wander, noise and artifacts compared to signals
displayed on GE's CardioLab recording system. Subsequently, we determined the final design of the PURE EP System prototype to use
for end-user preference studies, additional pre-clinical studies and research studies.

 Prototype
Testing

 After
conducting research of peer-reviewed EP publications (see Initial Analysis in Our Products section above), we contacted Samuel
J. Asirvatham. M.D. (who we believed to be an expert in the field of signal-based catheter ablation), at Mayo Clinic in Rochester, Minnesota.
Since the end of 2014, we have collaborated with Dr. Asirvatham and other physicians affiliated with Mayo Clinic in Rochester, Minnesota
and Jacksonville, Florida. We have performed pre-clinical studies at Mayo Clinic since 2015 to validate technology within the PURE EP
System prototype. These studies have been designed to determine clinical effectiveness for features within the PURE EP System. Since
March 2016, we have published nine manuscripts in collaboration with the physicians from Mayo Clinic evidencing our pre-clinical findings.
To date, we have conducted a total of twenty-four pre-clinical studies with the PURE EP System, twenty-one of which were conducted at
Mayo Clinic in Rochester, Minnesota. We also conducted a pre-clinical study at the Mount Sinai Hospital in New York, NY with emphasis
on the VT model; and two pre-clinical studies at the University of Pennsylvania in preparation for clinical studies to be conducted there.

 Clinical
Evaluations

 In
February 2019, we conducted the first clinical cases with our PURE EP System. The observational patient cases were performed by
Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David's
Medical Center in Austin, Texas. In April 2019, we announced the completion of our second set of observational patient cases, which were
performed at Prisma Health at Greenville Health System in South Carolina by Andrew Brenyo, MD, FHRS. Dr. Brenyo used the PURE EP
System during procedures on patients with ischemic ventricular tachycardias, AF, PVC, and atypical flutters.

 In
May 2019, we announced the completion of our third set of observational patient cases at Indiana University under the leadership of Prof.
John M. Miller, M.D., and Dr. Mithilesh K. Das, MBBS. Drs. Miller and Das used the PURE EP System during procedures on patients
with atypical flutter, atrioventricular nodal reentry tachycardia (AVNRT), AF, supraventricular tachycardia, premature ventricular contractions,
and a rare case of dual septal pathway. In August 2019, observational patient cases at Santa Barbara Cottage Hospital in California were
performed by Brett Andrew Gidney, M.D. The initial experience across these early evaluation centers showed the PURE EP System
functions as designed with positive feedback from EP users about the improved signal detection and fidelity.

 In
November 2019, we commenced our first clinical study for the PURE EP System titled, " Novel Cardiac Signal Processing
System for Electrophysiology Procedures (PURE EP 2.0 Study)." The PURE EP 2.0 Study was conducted at three U.S. hospitals:
Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas, Mayo Clinic in Jacksonville, Florida and Massachusetts
General Hospital in Boston, Massachusetts.

 In
April 2021, we announced the completion of the enrollment in the PURE EP 2.0 Study. Intracardiac signal data of clinical interest were
collected during 51 cardiac ablation procedures using the PURE EP System, the signal recording system, and the 3D mapping system
at the same time stamps. The samples were randomized and subjected to blinded, head-to-head evaluation by three independent electrophysiologists
to determine the overall quality and clinical utility of PURE EP signals when compared to conventional sources. Each reviewer
responded to the same 235 signal comparisons using a 10-point rating scale.

 Results
showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting
PURE EP signals over the signals from conventional sources. Further analysis of the responses from the blinded reviewers showed an 83%
(p-value <0.001) improved confidence when interpreting complex multi-component signals, leading to a better understanding of the catheter
position in relation to the ablation target. Additionally, there was a 73% (p-value <0.001) improved visualization of small, fractionated
potentials increasing the proper analysis of scar and abnormal conduction tissue characteristics.

 Over
3,000 procedures have been performed using the PURE EP System with more than 80 physicians at 21 hospitals across the United States.

 Technology
and Development Plan

 Our
technology team consists of engineers and consultants with expertise in digital signal processing, low power analog and digital circuit
design, software development, embedded system development, electromechanical design, testing and system integration, and the regulatory
requirements for medical devices. We have also entered into collaboration agreements with advisors and medical institutions in the fields
of cardiology and electrophysiology, including Mayo Clinic, Cleveland Clinic, and the Texas Cardiac Arrhythmia Institute in Austin, Texas.
Currently, we are contract manufacturing the complete PURE EP System with Plexus Corp.

 We
intend to continue additional research studies with our technology at Mayo Clinic, Texas Cardiac Arrhythmia Institute and Cleveland Clinic.
On November 20, 2019, we entered into licensing agreements with Mayo Clinic to establish a new product pipeline to complement the PURE
EP System and develop solutions for novel ways to treat autonomic nervous system disease. The research and development pipeline contemplated
pursuant to these agreements includes hardware, software, and algorithmic solutions to be integrated into the PURE EP platform technology.
We entered into a research agreement with Cleveland Clinic Foundation to investigate expanded clinical applications for the intracardiac
signals acquired by PURE EP System. Under the terms of the research agreement, Cleveland Clinic will conduct physician initiated
scientific research investigating PURE EP 's potential to address common limitations of signal processing and signal use
expansion during but not limited to electrophysiology ablation procedures. Results from this research could elucidate new clinical workflow
methods impacting the ablation process for numerous arrhythmia types.

 In
January 2021, we entered into a research agreement with Mayo Clinic regarding an AI research Program for our Novel Signal Recording System.
The program is a strategic collaboration with Mayo to develop a next-generation AI- and machine learning-powered software for our PURE
EP System. The collaboration includes an R&D program that will expand our proprietary hardware and software with advanced
signal processing capabilities and aim to develop novel technological solutions by combining the electrophysiological signals delivered
by PURE EP and other data sources. The development program is under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic's
Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory. We entered into a 10-year collaboration agreement with Mayo
Clinic in March 2017 and in November 2019, we signed a patent and know-how license agreement with Mayo Foundation for Medical Education
and Research in which such terms apply to this program. On April 9, 2021, and October 22, 2021, we conducted first pre-clinical data
collection studies under our AI program at Mayo Clinic.

 Customers

 In
December 2020, we announced that three PURE EP Systems were contracted for purchase by St. David's Healthcare in Austin,
Texas and were subsequently sold in February 2021. These units were our first commercial sales. We also sold three PURE EP Systems
to Mayo Foundation for Medical Education and Research in 2021 and leased two PURE EP Systems in 2022, one in July 2022 to Overland
Park Regional Medical Center and one in October 2022 to Methodist Hospital in San Antonio.

 Suppliers

 The
PURE EP System contains proprietary hardware and software modules that are assembled into the system. Hardware boards contain
components that are available from different distributors. The parts used to manufacture analog and digital boards are readily available
from several distributors or manufacturers. Plexus Corp is our manufacturing partner for the complete PURE EP System.

 Competition

 We
are marketing the PURE EP System as an additional information system for the EP lab. In general, the EP market is characterized
by intense competition. There are currently four large companies that share the majority of the EP recording market share in the US.
They produce the following electrophysiology recording systems, with an average selling price of approximately $160,000 (source: DRG
Medtech 360 Millennium report on EP Devices, issued in June 2019):

 GE
 Healthcare's family of CardioLab Recording Systems were initially developed in the early 1990s by Prucka Engineering, which
 was acquired by General Electric Company in 1999.

 The
 LabSystem PRO EP Recording System was originally designed in the late 1980s by C.R. Bard. C.R. Bard's electrophysiology business
 was acquired by Boston Scientific Corporation in 2013.

 HeNan
 HuaNan Medical Science and Technology Co., LTD. offers the GY-6000 multi-channel physiological recorder (not FDA approved).

 St.
 Jude Medical, Inc.'s EP-WorkMate Recording System was acquired from EP MedSystems, Inc. in 2008, which had received clearance
 for the product from the FDA in 2003. In January 2017, Abbott Laboratories acquired St Jude Medical, Inc.

 CathVision
 is developing an EP recording system, ECGenius System and recently obtained FDA 510(k) clearance in May 2022.

 Based
upon our analysis of data taken from patent applications filed with the U.S. Patent and Trademark Office ("USPTO") and 510(k)
approval applications filed with the FDA, and various publications, we believe that the above recording systems are built on relatively
old technologies and all use similar approach in applying hardware and digital filters to remove noise and artifacts. We reasonably believe
that such an approach sacrifices cardiac signal fidelity, and in the case of ablation, has a direct impact on the ablation strategy of
an electrophysiologist. The method to remove noise and artifacts used by the conventional recorders could be a contributing factor to
the multiple (or repeated) ablation procedures that are frequently required in order to completely cure patients from complex arrhythmias.
We are not currently aware of any other companies that are developing similar signal processing technologies for electrophysiology laboratories.

 Suppliers

 The
PURE EP System contains proprietary hardware and software modules that are assembled into the system. Hardware boards contain
components that are available from different distributors. The parts used to manufacture analog and digital boards are readily available
from several distributors or manufacturers. Plexus Corp is our manufacturing partner for the complete PURE EP System.

and Development Expenses

and development expenses for the fiscal years ended December 31, 2023, and 2022 were $5,092,376 and $5,821,460, respectively.

Business Overview

Pharmaceuticals, Inc.

Pharmaceuticals, Inc. ("ViralClear") is a majority-owned subsidiary of the Company originally known as NeuroClear Technologies,
Inc. The subsidiary was established November 2018 to pursue additional applications of the PURE EP signal processing technology
outside of EP. In March 2020, it was renamed ViralClear in connection with its prior objective to develop merimepodib, a broad-spectrum
anti-viral agent that showed potential to treat COVID-19. We had ceased the development of merimepodib in late 2020 and realigned ViralClear
with its original objective of pursuing additional applications of the PURE EP signal processing technology outside of cardiac
electrophysiology with an initial emphasis on developing a novel nerve recording system. As of April 16, 2024, the Company retains 69.08%
ownership of ViralClear. Currently, ViralClear's business objectives are being evaluated considering both the pharmaceutical and
medical device. The following overview describes the initial focus of the company which is on hold due to lack of resources.

is an early stage medical device company that had been developing N-SENSE, a novel sensing technology platform for high-speed
electroneurogram (ENG) recordings. The specifications for this new product were based on the core competencies of the PURE EP
signal processing technology, such as broad dynamic range of recorded signals and low signal-to-noise ratio and adapted to address disorders
of the autonomic nervous systems through recordings and analysis of action potentials, the impulses along the membrane of a muscle cell
or a nerve cell. These impulses are considered to carry valuable clinical information but may be difficult to detect through conventional
recording platforms.

aimed to address what we believe to be the two main challenges of bioelectronic medicine devices: achieving accurate and targeted stimulation
of specific nerves in a nerve bundle and implementing an effective feedback loop that can self-adjust for the optimal amount and timing
of stimulation. We believe that advancements in overcoming these challenges will improve the safety and efficacy of current treatments
and contribute to the developments of new therapy lines.

 On
December 18, 2020, we signed a research agreement with the University of Minnesota launching a program to develop novel therapies to
treat sympathetic nervous system disease. The program studies are expected to form a foundation for developing a new platform technology
to address disorders of the autonomic nervous system. We intend to develop new intellectual properties and products, including new hardware,
software, and algorithmic solutions, with the support of Plexus, a tier 1 US-based manufacturing partner and take it through FDA approval,
manufacturing, and commercialization. The R&D program is led by Richard W. Bianco, Ph. D., Professor, Director of Experimental Surgical
Services (ESS), Department of Surgery in the University of Minnesota Medical School, John W. Osborn, Ph. D., Professor, Department of
Surgery and Director of the Minnesota Consortium for Autonomic Neuromodulation (MCAN) in the University of Minnesota Medical School.

 In
February 2021, we conducted our first preclinical experiment at the University of Minnesota. Further studies to record and evaluate relevant
nerve activity were conducted in April and November 2021.

 We
had partnered with Plexus to design, develop, and manufacture N-SENSE, a novel sensing and stimulation platform technology.

 Our
product pipeline would focus on improving therapies through clearer ENG recordings – methods used to visualize directly recorded
electrical activities of neurons in the central nervous system (brain, spinal cord) and/or the peripheral nervous system (nerves, ganglions).
ENGs are usually obtained by placing an electrode directly in the neural tissue. ENGs consist of small, high frequency, low amplitude
signals, which have been proven hard to detect with conventional signal recording systems.

 Our
business strategy was to utilize our core signal processing technology to develop superior ENG recording and processing systems and includes
the following:

Develop N-SENSE, a novel nerve sensing and stimulation platform technology to be used in product candidates which qualify for
a nerve mapping and stimulation treatments including, but not limited to, renal denervation, deep brain stimulation and vagus nerve stimulation.

Pursue licensing opportunities and partnerships to leverage our expertise in high-fidelity signal processing for feedback loop systems
for development of products for commercial success.

 We
believe that the following clinical areas may benefit the most through the advancements in achieving accurate and targeted stimulation
and implementation of an effective self-adjusting feedback loop:

Renal denervation ("RDN"): RDN has been shown to reduce blood pressure and can be an effective treatment for resistant hypertension
sufferers who have failed drug therapy. The technique has proven to be effective, but clinical endpoints are still suboptimal. RDN device
market is expected to reach $7B by 2027 (CAGR 23.7%). 1

 Potential
 Application: A device that can measure sympathetic nerve activity will inform the need and potential benefit for performing a
 procedure. Additionally, a device that can stimulate and elicit a sympathetic response, such as blood pressure, will aid in the assessment
 of nerve denervation success, and help determine if additional ablation is necessary. Therefore, a device that can perform stimulation
 on a number of channels, and record nerve activity is needed.

Deep Brain Stimulation ("DBS"): DBS is a treatment that involves implanting electrodes (leads) within certain areas of the
brain to deliver electrical pulses, which has demonstrated improvements in the treatment of movement disorders, such as the Parkinson's
disease, tremors and dystonia.

 Potential
 Application: a new high-speed board-based platform for improved accuracy in lead implantation. Precise positioning of the electrodes
 during the surgical procedure is important in the success of lead implantation, and highly accurate signal readers can aid in the
 prediction of the activation of axons surrounding the implanted lead.

 1Source:
iHealthcareAnalyst, Inc. Feb. 2020

 We
 believe that DBS may also be applicable to a substantial number of neurological and psychiatric disorders correlated with dysfunctional
 circuitry; comparable to a heart pacemaker that uses electric pulses to ultimately regulate brain activity.

 Other
 applications under our investigation include chronic pain management, ADHD, eating disorders, Alzheimer's, addiction, epilepsy.
 Alzheimer's as an application for DBS is currently undergoing clinical trials at several national and international institutions
 that target the hippocampal outflow pathways by increasing ACh availability, influencing the limbic system, and improving lead placements.

 We
may seek additional research collaborations with other academic centers active in one or more fields of clinical interests described
above.

 Industry
and Market Overview

 The
global neurostimulation devices market is predicted to grow at 15.23% CAGR during the forecast period with the market size reaching $18.667
billion by 2025 from $7.974 billion in 2019. North America is dominating the neurostimulation devices market with highest market share
due to robust healthcare infrastructure, growing R&D activity and presence of major healthcare players. The neurostimulation market
is primarily driven by deep brain and spinal cord stimulation. The overall neurostimulation market is expected to grow due to societal
factors such as an increase in the geriatric population, as well as the associated increase in the prevalence of chronic diseases.

 The
segment of the neurostimulation market for central nervous system (CNS), which include nVNS and DBS, is projected to exceed $14.5 billion
in 2029 from a market value of $5 billion in 2019. 2

 Non-invasive
Vagus Nerve Stimulation

 We
believe there is a significant opportunity for nVNS based on the potential market size for the treatments for the diseases that nVNS
may be applicable. Currently, approximately 1,500 million people worldwide suffer from chronic pain while 1,100 million people worldwide
suffer from migraines.

 Most
of the currently available VNS products have achieved limited commercial success to date. LivaNova currently sells VNS devices that operate
in 3 modes, including a non-rechargeable implantable pulse generator (IPG), SenTiva, which uses a limited closed-loop technology and
comes with a wrist-worn magnet and a wireless programming wand. Cerbomed has commercialized a transcutaneous auricular VNS device, NEMOS,
which consists of a handheld stimulation unit and an ear electrode worn as an earphone. Cerbomed received the European clearance (CE
mark) for the VNS treatment of epilepsies and depression in 2010 and for the treatment of pain in 2012. NEMOS has been commercially available
in Germany and Austria since 2013 and has expanded to Great Britain, France, and Spain.

 The
VNS patent domain is currently dominated by U.S. companies such as Medtronic, LivaNova, and Boston Scientific. Medtronic holds certain
patents in closed-loop DBS technology, Medtronic currently markets IPGs such as RestoreSensor SureScan MRI, which is indicted for spinal
cord stimulation as an aid in the management of chronic, intractable pain of the trunk and/or limbs and which automatically adjusts stimulation
based on the patient's needs and preferences in different body positions, and Activa PC, which is a deep brain stimulator, for
investigational loop.

 We
believe that digital health wearable markets present potential opportunities for our technology. We plan to develop technology that can
provide a signaling feedback loop designed to deliver appropriate stimulation to the vagus nerve through audio and to seek licensing
opportunities with consumer electronic market players.

 2Source:
 Bioelectronic Medicine 2019 – 2029. IDTechEx report, Dr. Nadia Tsao.

 Deep
Brain Stimulation:

 Deep
brain stimulator market is one of the fastest growing sectors in the neurostimulation market worldwide, growing at 9.3% annually and
expected to reach $2.3 billion in worldwide market size by 2028. According to the World Health Organization, globally, 264 million people
suffer from depression while 50 million people suffer from epilepsy. Parkinson's disease and essential tremor are FDA-approved
indications for DBS, and the deep brain stimulator market is largely dominated by Medtronic, Abbott, and Boston Scientific. These companies
have been working on innovations in their electrodes to avoid stimulation of adjacent structures (electric field shaping) which are the
root cause of unwanted side effects of DBS. The industry is working on decreasing the size of the implant of the DBS device, which may
lead to a skull-mounted implant. Medtronic's Activa systems consist of dual-channel or single channel IPGs. Abbott sells two devices
known as the Infinity DBS IPG and Brio Rechargeable IPG. The Infinity DBS IPG is designated to manage movement disorders including Parkinson's
disease, essential tremor, and dystonia. It utilizes the Bluetooth technology to communicate with a controller and can receive updates
through an application. The system allows for currents to be steered towards target areas while avoiding peripheral stimulation. The
Brio Rechargeable IPG delivers constant currents to maintain the desired stimulation level. It has shown clinical efficacy in Parkinson's
disease and dystonia. Boston Scientific offers the Vercise directional lead in unison with their Neural Navigator systems ranging from
8 to 16 electrode leads and a directional system. Medtronic's Percept PC Deep Brain Stimulation ("DBS") system includes
their BrainSense technology making it the first and only DBS neurostimulation system that has the ability to chronically capture and
record brain signals while providing therapy to patients with neurologic disorders associated with Parkinson's Disease ("PD"),
among others.

 According
to the National Institute of Health, future technical innovation in deep brain stimulators will focus on improving the practicability
the device, including extension of battery life, reduced size of the devices and development of a device for delivering more tailored
and adaptive stimulation and the integration of wireless technology. Clinically, the main challenge will be meeting the needs of an ageing
population worldwide and expanding indications for DBS to circuitopathies other than Parkinson's disease, including depression
and Alzheimer disease. Even within established indications such as Parkinson's disease, key questions remain unanswered because
biomarkers that predict clinical responses and aid in patient selection and stimulation parameter settings are still largely lacking.

 We
believe that our technology may help advance clinical response to DBS due to more precise stimulation and improve overall safety of the
DBS procedures.

 On
March 5, 2021, we announced that the U.S. Patent Office had allowed a utility patent which has been exclusively licensed from the Mayo
Foundation for Medical Education and Research. The patent application number 16/805,017 entitled, "Systems and Methods for Electroporation"
 was filed on February 28, 2020. The patent describes and claims methods and materials for improving the treatment of hypertension
via electroporation of nerves in the renal area. Electroporation is an emerging technique that has demonstrated efficacy in treatments
for several critical conditions and is currently being evaluated for the treatments of autonomic nervous disorders, including hyper-
and hypotension / syncope.

AI Sciences Overview

AI Sciences, Inc.

 On
July 2, 2020, the Company formed NeuroClear Technologies, Inc., a Delaware corporation, which was renamed to BioSig AI Sciences, Inc.
("BioSig AI") on May 31, 2023. The subsidiary was established to pursue clinical needs of cardiac and neurological disorders
through recordings and analyses of action potentials. BioSig AI aims to contribute to the advancements of AI-based diagnoses and therapies.
In June and July 2023, BioSig AI sold an aggregate of 2,205,000 shares of its common stock for net proceeds of $1,971,277 to fund initial
operations. At April 16, 2024, the Company had a majority interest in BioSig AI of 84.5%.

AI is a medical technology company that was developing AI solutions for the hospital marketplace utilizing structured, semi-structured,
and unstructured data. BioSig AI's business operations have currently been placed on hold due to lack of resources. The Company's
former established technology team with external partners and collaborators were joined to advance the research and development of an
artificial intelligence ("AI") medical device platform.

 On
July 20, 2023, BioSig AI was included in Nvidia's Inception partnership program which aimed to provide our team access to engineering
and technology support. In less than a month after closing the initial funding, the team had identified opportunities to bring a proprietary
AI platform to market. In addition, BioSig AI had signed a collaboration agreement with a global technology organization who started
to build important data infrastructure to enable scaling of the platform in high-volume, data intensive hospital centers. This collaboration
effort was discontinued, however, is currently being re-evaluated with the new team forming since March 2024.

 According
to Data Bridge Market Research, the market for AI in healthcare, estimated at $9.6 billion in 2022, is expected to reach $272.9 billion
by 2030, at a CAGR of 51.9% during the forecast period. 1

 Data Bridge Market Research. Global Artificial Intelligence in Healthcare Market – Industry Trends and Forecast to 2030.
January 2023.

 Intellectual

 Patents

 Our
success depends in large part on our ability to establish and maintain the proprietary nature of our technology. In November 2017, we
engaged 3LP Advisors LLC, now Sherpa Technology Group LLC as our intellectual property advisor. We have also retained Sterne Kessler
Goldstein & Fox P.L.L.C., a patent firm based in Washington DC, to help develop and execute a strategy for the development of our
patent portfolio.

 Our
owned patent portfolio now includes 36 (issued/allowed) issued utility patents (24 utility patents where BioSig is at least one of the
applicants). Twenty five additional U.S. and foreign utility patent applications are pending covering various aspects of our PURE EP
System for recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures (25 U.S. and foreign
utility patent applications where either BioSig, Mayo, or both is at least one of the applicants). We also have one U.S. patent and one
U.S. Pending application directed to artificial intelligence (AI). We also have 30 issued worldwide design patents, which cover various
features of our display screens and graphical user interface for enhanced visualization of biomedical signals (30 design patents where
BioSig is at least one of the applicants). Finally, we have licenses to 12 (issued/allowed) patents and 9 additional worldwide utility
patent applications from Mayo Foundation for Medical Education and Research that are pending (12 issued/allowed patents and 9 applications
where only Mayo is the applicant). These patents and applications are generally directed to electroporation and stimulation.

and ViralClear signed three patent and know-how license agreements with Mayo Foundation for Medical Education and Research in November
2019. Under the terms of such agreements, BioSig exclusively licensed additional patents and applications of the Mayo Clinic related
to novel ways for ablation therapy and to treat autonomic nervous system disease including hardware, software and algorithmic solutions
to be integrated into the PURE EP platform technology. BioSig intends to take the licensed intellectual properties and products, which
have been developed by Mayo Clinic over the last decade, through FDA approval, manufacturing, and commercialization. The development
program is run under the leadership of Dr. Asirvatham. On March 5, 2021, we announced that the U.S. Patent Office had allowed a utility
patent that ViralClear has exclusively licensed from the Mayo Foundation for Medical Education and Research. The patent application number
16/805,017 entitled, "Systems and Methods for Electroporation" was filed on February 28, 2020. The patent describes
and claims methods and materials for improving the treatment of hypertension via electroporation of nerves in the renal area. Electroporation
is an emerging technique that has demonstrated efficacy in treatments for several critical conditions and is currently being evaluated
for the treatments of autonomic nervous disorders, including hyper- and hypotension / syncope.

 Trademarks

 Our
trademark for "BIOSIG TECHNOLOGIES" was registered on April 25, 2017.

 Our
trademark for "PURE EP" was registered on January 26, 2016.

 Our
trademark for the standard mark, "BIOSIG" was registered March 19, 2019.

 Our
trademark for "SEE MORE, CLEARLY" was registered on April 4, 2023.

 Our
trademark for "WCT+" was registered on February 20, 2024.

 On
November 5, 2018, we filed a standard mark trademark application for "NEUROCLEAR" and on January 29, 2019, NeuroClear filed
a stylized/design trademark application for the NeuroClear logo; extensions for statements of use have been filed.

 Our
trademark for "ALLIANCE FOR ADVANCING BIOELECTRONIC MEDICINE" was registered on October 24, 2024.

 In
July 2021, we received EU certificates of registration for the following trademarks: "ACCUVIZ", "WCT+", and "COMBIO".

 In
July 2021, we received UK certificates of registration for the following trademarks: "SMARTFINDER",
"ACCUVIZ", "WCT+", and "COMBIO".

 Government
Regulation

 The
U.S. government regulates healthcare and related products through various agencies, including but not limited to the following: (i) the
U.S. Food and Drug Administration (FDA), which enforces the federal Food, Drug and Cosmetic Act (FDCA) and related laws; (ii) the Centers
for Medicare & Medicaid Services (CMS), which administers the Medicare and Medicaid programs; (iii) the Office of Inspector General
(OIG), which enforces various laws aimed at curtailing fraudulent or abusive practices, including by way of example, the Anti-Kickback
Statute, the Physician Self-Referral Law, commonly referred to as the Stark law, the Civil Monetary Penalty Law (including the beneficiary
inducement prohibition) (CMP), and the laws that authorize the OIG to exclude healthcare providers and others from participating in federal
healthcare programs; and (iv) the Office of Civil Rights (OCR), which administers the privacy aspects of the Health Insurance Portability
and Accountability Act of 1996 (HIPAA). All of the aforementioned are agencies within the Department of Health and Human Services (HHS).
Healthcare is also provided or regulated, as the case may be, by the Department of Defense through its TRICARE program, the Department
of Veterans Affairs, especially through the Veterans Health Care Act of 1992, the Public Health Service within HHS under Public Health
Service Act § 340B (42 U.S.C. § 256b), the Department of Justice through the Federal False Claims Act and various criminal
statutes, and state governments under the Medicaid and other state sponsored or funded programs. Various states also have state laws
equivalent to certain healthcare fraud and abuse laws, including but not limited to state equivalents of the Anti-Kickback Statute and
the Stark law, as well as more general state laws regulating all healthcare activities and certain healthcare products, including medical
devices.

 In
addition to being regulated by the FDA, advertising and promotion of certain types of medical devices in the United States is also regulated
by the Federal Trade Commission (FTC) and by state regulatory and enforcement authorities. Recently, promotional activities for FDA-regulated
products of other companies have been the subject of enforcement action brought under healthcare laws and consumer protection statutes.
Further, competitors can initiate litigation relating to advertising claims under the federal Lanham Act and similar state laws.

 FDA
Regulation

 Our
solutions include software and hardware which will be used for patient diagnosis and, accordingly, are subject to regulation by the FDA
and other regulatory agencies. FDA regulations govern, among other things, the following activities that we perform and will continue
to perform in connection with:

 design and development;

 testing;

 manufacturing;

 labeling and packaging;

 handling, storage, and installation;

 Pre-market
 clearance or approval;

 Advertising
 and promotion; and

 sales, distribution, and servicing.

 FDA
Pre-market Clearance and Approval Processes

 The
FDA classifies all medical devices into one of three classes based on the risks associated with the medical device and the controls deemed
necessary to reasonably ensure the device's safety and effectiveness. Those three classes are:

 Class
 I devices present a low risk and are not life-sustaining or life-supporting. The majority of Class I devices are subject only to
 "general controls" (e.g., prohibition against adulteration and misbranding, registration and listing, good manufacturing
 practices, labeling, and adverse event reporting. General controls are baseline requirements that apply to all classes of medical
 devices.)

 Class
 II devices present a moderate risk and are devices for which general controls alone are not sufficient to provide a reasonable assurance
 of safety and effectiveness. Devices in Class II are subject to both general controls and "special controls" (e.g., special
 labeling, compliance with performance standards, and post market surveillance. Unless exempted, Class II devices typically require
 FDA clearance before marketing, through the premarket notification (510(k)) process).

 Class
 III devices present the highest risk. These devices generally are implantable, life-sustaining, life-supporting, or for a use that
 is of substantial importance in preventing impairment of human health, and/or they present a potential unreasonable risk of illness
 or injury. Class III devices are devices for which general controls, by themselves, are insufficient and for which there is insufficient
 information to determine that application of special controls would provide a reasonable assurance of safety and effectiveness. Class
 III devices are subject to general controls and typically require FDA approval of a premarket approval ("PMA") application
 before marketing.

 Unless
it is exempt from premarket review requirements, a medical device must receive marketing authorization from the FDA prior to being commercially
marketed, distributed, or sold in interstate commerce in the United States. The most common pathways for obtaining marketing authorizations
are 510(k) and PMA. With the enactment of the Food and Drug Administration Safety and Innovation Act (FDASIA), the de novo pathway
was made available for certain low-to-moderate risk devices that do not qualify for 510(k) clearance due to the absence of a predicate
device.

 510(k)
Clearance Process

 The
510(k) review process compares a new device to an existing legally marketed device (or, "predicate device"). "Substantial
equivalence" means that the proposed new device: (i) has the same intended use as the predicate device; (ii) has the same or similar
technological characteristics as the predicate device; (iii) is as safe and effective as the predicate device, as shown by the supporting
information submitted within the 510(k); and (iv) does not raise different questions of safety and effectiveness than the predicate device.

 To
obtain 510(k) clearance, one must submit a 510(k) containing sufficient information and data to demonstrate that the proposed device
is substantially equivalent to a legally marketed predicate device. This data generally includes non-clinical performance testing (e.g.,
software validation, bench testing electrical safety testing), but may also include clinical data. Typically, it takes approximately
three-to-six months for the FDA to complete its review of a 510(k) submission; however, it can take significantly longer and not all
510(k) submissions are accepted by the FDA for review, and not all are cleared following FDA review. During its review of a 510(k), the
FDA may request additional information, including clinical data, which may significantly prolong the review process. After completing
its review of a 510(k), the FDA may issue an order, in the form of a letter (i) finding the proposed device to be substantially equivalent
to the predicate device and stating that the device can be marketed in the U.S., or (ii) finding the proposed device not substantially
equivalent to the predicate device and stating that device cannot be marketed in the U.S. We received 510(k) clearance for the PURE EP
System on August 8, 2018.

 After
a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute
a major change in its intended use, will require a new 510(k) clearance or could require a pre-market approval, which requires more data
and is generally a significantly longer process than the 510(k) clearance process. The FDA requires each manufacturer to make this determination
initially, but the FDA can review any such decision and can disagree with a manufacturer's determination. If the FDA disagrees
with a manufacturer's determination, it can require the manufacturer to cease marketing and/or recall the modified device until
510(k) clearance or a pre-market approval is obtained.

 A
device that reaches market through the 510(k) process is not considered to be "approved" by the U.S. Food and Drug Administration.
They are generally referred to as "cleared" or "510(k) cleared" devices. Nevertheless, it can be marketed and
sold in the U.S.

 The
Premarket Approval Pathway

 The
PMA process is the most stringent type of device marketing application required by the FDA. Whether PMA is granted is based on a determination
by the FDA that the PMA application contains sufficient valid scientific evidence to ensure that the device is safe and effective for
its intended use(s). A PMA application generally includes extensive information about the device including the results of clinical testing
conducted on the device and a detailed description of the manufacturing process.

 After
a PMA application is accepted for review, the FDA begins an in-depth review of the submitted information. FDA regulations provide 180
days to review the PMA application and make a determination; however, in practice, the review time is typically longer (e.g., 1-3 years).
During this review period, the FDA may request additional information or clarification of information already provided. Also, during
the review period, an advisory panel of experts from outside the FDA may be convened to review and evaluate the data supporting the application
and provide recommendations as to whether the data provide a reasonable assurance that the device is safe and effective for its intended
use. In addition, the FDA generally will conduct a preapproval inspection of the manufacturing facility to ensure compliance with the
quality system regulation (QSR), which imposes comprehensive development, testing, control, documentation and other quality assurance
requirements for the design and manufacturing of a medical device.

 Based
on its review, the FDA may (i) issue an order approving the PMA, (ii) issue a letter stating the PMA is "approvable" (e.g.,
minor additional information is needed), (iii) issue a letter stating the PMA is "not approvable," or (iv) issue an order
denying PMA. A company may not market a device subject to PMA review until the FDA issues an order approving the PMA application. As
a condition to approval, the FDA may impose post-approval requirements intended to ensure the continued safety and effectiveness of the
device including, among other things, restrictions on labeling, promotion, sale and distribution, and requiring the collection of additional
clinical data. Failure to comply with the conditions of approval can result in materially adverse enforcement action, including withdrawal
of the approval.

 Most
modifications to a PMA approved device, including changes to the design, labeling, or manufacturing process, require prior approval before
being implemented. Prior approval is obtained through submission of a PMA supplement. The type of information required to support a PMA
supplement and the FDA's time for review of a PMA supplement vary depending on the nature of the modification.

 We
obtained FDA clearance related to the PURE EP System via the 510(k) process in 2018 and we do not anticipate a PMA for it or other devices
at this time.

 Pervasive
and continuing FDA regulation

 After
a medical device is placed on the market, numerous FDA regulatory requirements apply, including, but not limited to, the following:

 Quality
 System Regulation (QSR), which requires manufacturers to follow design, testing, control, documentation and other quality assurance
 procedures during the manufacturing process;

 Establishment
 Registration, which requires establishments involved in the production and distribution of medical devices intended for commercial
 distribution in the U.S. to register with the FDA;

 Medical
 Device Listing, which requires manufacturers to list the devices they have in commercial distribution with the FDA;

 Labeling
 regulations, which prohibit "misbranded" devices from entering the market, as well as mandate the inclusion of certain
 content in device labels and labeling and prohibit the promotion of products for unapproved or "off-label" uses and impose
 other restrictions on labeling; and

 Medical
 Device Reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to
 a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were
 to recur.

 Failure
to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include one or more of the following
sanctions:

 Fines,
 injunctions, and civil penalties;

 Mandatory
 recall or seizure of our products;

 Administrative
 detention or banning of our products;

 Operating
 restrictions, partial suspension or total shutdown of production;

 Refusing
 our request for 510(k) clearance or pre-market approval of new product versions;

 Revocation
 of 510(k) clearance or pre-market approvals previously granted; and

 Criminal
 penalties.

 We
are subject to unannounced device inspections by the FDA, as well as other regulatory agencies overseeing the implementation of, and
compliance with, applicable state public health regulations. These inspections may include our suppliers' facilities.

 U.S.
Healthcare Laws and Regulations

 In
the United States, there are various healthcare fraud and abuse laws that apply to medical device manufacturers, such as us, with respect
to our financial relationships with hospitals, physicians, patients, marketers and sales agents, and other potential purchasers or acquirers
of our products or those who are in a position to refer or recommend our products. Federal and state anti-kickback laws prohibit the
payment or receipt of kickbacks, bribes or other remuneration intended to induce the purchase or recommendation of healthcare products
and services. The U.S. government has published regulations that identify exemptions or "safe harbors," which describe various
payment and business practices that, although they potentially implicate the federal Anti-Kickback Statute, are not treated as offenses
under the statute, and thereby, protected from enforcement actions under the federal Anti-Kickback Statute. To qualify, the activity
must fit squarely within the safe harbor. Arrangements that do not meet a safe harbor are not necessarily illegal but will be evaluated
on a case-by-case basis, and the federal safe harbors may not apply to state anti-kickback laws. Other provisions of state and federal
law impose civil and criminal penalties for presenting, or causing to be presented, to third-party payors (including the government)
for reimbursement claims that are false or fraudulent, or for items or services that were not provided as claimed. False claims allegations
under federal, and some state, laws may be brought on behalf of the government by private persons, or "whistleblowers," who
could then receive a share of any recovery. In addition, the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA)
imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services. The Physician Self-Referral Law, commonly referred to as the Stark law, is a strict liability
statute that prohibits physicians from referring patients to receive certain services defined as "designated health services"
payable by Medicare or Medicaid from entities with which the physician or an immediate family member has a financial relationship, unless
a specific exception applies. Violations of these laws can lead to civil and criminal penalties, including but not limited to punitive
sanctions, damage assessments, money penalties, imprisonment, denial of payment, exclusion from participation in federal healthcare programs,
or some combination thereof.

 International
Regulation

 International
sales of medical devices are subject to foreign government regulations, which vary substantially from country to country. The time required
to obtain approval by a foreign country may be longer or shorter than that required for FDA approval, and the requirements may differ
significantly.

 The
European Union has adopted legislation, in the form of directives to be implemented in each member state, concerning the regulation of
medical devices within the European Union. The directives include, among others, the Medical Device Directive that establishes standards
for regulating the design, manufacture, clinical trials, labeling, and vigilance reporting for medical devices. Our PURE EP system may
be affected by this legislation. Under the European Union Medical Device Directive, medical devices are classified into four classes,
I, IIa, IIb, and III, with class I being the lowest risk and class III being the highest risk. Under the Medical Device Directive, a
competent authority is nominated by the government of each member state to monitor and ensure compliance with the Medical Device Directive.
The competent authority of each member state then designates a notified body to oversee the conformity assessment procedures set forth
in the Medical Device Directive, whereby manufacturers demonstrate that their devices comply with the requirements of the Medical Device
Directive and are entitled to bear the CE mark. CE is an abbreviation for Conformit Europ enne (or European Conformity)
and the CE mark, when placed on a product, indicates compliance with the requirements of the applicable directive. Medical devices properly
bearing the CE mark may be commercially distributed throughout the European Union. Failure to obtain the CE mark will preclude us from
selling the PURE EP System and related products in the European Union.

 Administrative
 detention or banning of our products;

 Operating
 restrictions, partial suspension or total shutdown of production;

 Refusing
 our request for 510(k) clearance or pre-market approval of new product versions;

 Revocation
 of 510(k) clearance or pre-market approvals previously granted; and

 Criminal
 penalties.

 We
are subject to unannounced device inspections by the FDA, as well as other regulatory agencies overseeing the implementation of, and
compliance with, applicable state public health regulations. These inspections may include our suppliers' facilities.

 U.S.
Healthcare Laws and Regulations

 In
the United States, there are various healthcare fraud and abuse laws that apply to medical device manufacturers, such as us, with respect
to our financial relationships with hospitals, physicians, patients, marketers and sales agents, and other potential purchasers or acquirers
of our products or those who are in a position to refer or recommend our products. Federal and state anti-kickback laws prohibit the
payment or receipt of kickbacks, bribes or other remuneration intended to induce the purchase or recommendation of healthcare products
and services. The U.S. government has published regulations that identify exemptions or "safe harbors," which describe various
payment and business practices that, although they potentially implicate the federal Anti-Kickback Statute, are not treated as offenses
under the statute, and thereby, protected from enforcement actions under the federal Anti-Kickback Statute. To qualify, the activity
must fit squarely within the safe harbor. Arrangements that do not meet a safe harbor are not necessarily illegal but will be evaluated
on a case-by-case basis, and the federal safe harbors may not apply to state anti-kickback laws. Other provisions of state and federal
law impose civil and criminal penalties for presenting, or causing to be presented, to third-party payors (including the government)
for reimbursement claims that are false or fraudulent, or for items or services that were not provided as claimed. False claims allegations
under federal, and some state, laws may be brought on behalf of the government by private persons, or "whistleblowers," who
could then receive a share of any recovery. In addition, the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA)
imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services. The Physician Self-Referral Law, commonly referred to as the Stark law, is a strict liability
statute that prohibits physicians from referring patients to receive certain services defined as "designated health services"
payable by Medicare or Medicaid from entities with which the physician or an immediate family member has a financial relationship, unless
a specific exception applies. Violations of these laws can lead to civil and criminal penalties, including but not limited to punitive
sanctions, damage assessments, money penalties, imprisonment, denial of payment, exclusion from participation in federal healthcare programs,
or some combination thereof.

 International
Regulation

 International
sales of medical devices are subject to foreign government regulations, which vary substantially from country to country. The time required
to obtain approval by a foreign country may be longer or shorter than that required for FDA approval, and the requirements may differ
significantly.

 The
European Union has adopted legislation, in the form of directives to be implemented in each member state, concerning the regulation of
medical devices within the European Union. The directives include, among others, the Medical Device Directive that establishes standards
for regulating the design, manufacture, clinical trials, labeling, and vigilance reporting for medical devices. Our PURE EP system may
be affected by this legislation. Under the European Union Medical Device Directive, medical devices are classified into four classes,
I, IIa, IIb, and III, with class I being the lowest risk and class III being the highest risk. Under the Medical Device Directive, a
competent authority is nominated by the government of each member state to monitor and ensure compliance with the Medical Device Directive.
The competent authority of each member state then designates a notified body to oversee the conformity assessment procedures set forth
in the Medical Device Directive, whereby manufacturers demonstrate that their devices comply with the requirements of the Medical Device
Directive and are entitled to bear the CE mark. CE is an abbreviation for Conformit Europ enne (or European Conformity)
and the CE mark, when placed on a product, indicates compliance with the requirements of the applicable directive. Medical devices properly
bearing the CE mark may be commercially distributed throughout the European Union. Failure to obtain the CE mark will preclude us from
selling the PURE EP System and related products in the European Union.

 Employees

 As
of April 15, 2024, we had 4 full-time employees. Additionally, we use consultants as needed to perform various specialized services.
None of our employees are represented under a collective bargaining agreement.

 Corporate
and Other Information

 We
were incorporated in Nevada in February 2009 and in April 2011 we merged with our wholly owned subsidiary, BioSig Technologies, Inc.,
a Delaware corporation, with the Delaware corporation continuing as the surviving entity. Our principal executive offices are located
at 55 Greens Farms Road 1 st Floor Westport, Connecticut 06880 and our telephone number is (203) 409-5444. Our website address
is www.biosig.com. Information contained on or accessible through our website is not a part of this Annual Report on Form 10-K, and the
inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.

 We
file or furnish electronically with the U.S. Securities and Exchange Commission (the "SEC") our annual reports on Form 10-K,
quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and other information. Our SEC filings are available to
the public over the Internet at the SEC's website at  We make available on our website at www.biosig.com, under
"Investors," free of charge, copies of these reports as soon as reasonably practicable after filing or furnishing these reports
with the SEC.

 ITEM
1A – RISK FACTORS

 RISK
FACTORS

 There
are numerous and varied risks, known and unknown, that may prevent us from achieving our goals. You should carefully consider the risks
described below and the other information included in this Annual Report on Form 10-K, including the consolidated financial statements
and related notes. If any of the following risks, or any other risks not described below, actually occur, it is likely that our business,
financial condition, and/or operating results could be materially adversely affected. The risks and uncertainties described below include
forward-looking statements and our actual results may differ from those discussed in these forward-looking statements.

 Risk
Factor Summary

 Below
is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address
all of the risks that we face. Additional discussion of risks summarized in this risk factor summary, and other risks that we face, can
be found below under the heading " Risk Factors " and should be carefully considered, together with other information
in this Annual Report on Form 10-K and our other filings with the SEC before making investment decisions regarding our common stock.

 There
 is substantial doubt about our ability to continue as a going concern.

 we are an early commercialization stage company with one product in commercialization process,
 we expect to incur substantial additional operating losses.

 Our
 PURE EP System and other product candidates are in continued development and may not be successfully
 developed or commercialized.

 We
 expect to derive our revenue from sales of our PURE EP System and other products we may develop.
 If we fail to generate revenue from these sources, our results of operations and the value
 of our business will be materially and adversely affected.

 We
 may need to finance our future cash needs through public or private equity offerings, debt
 financings or corporate collaboration and licensing arrangements. Any additional funds that
 we obtain may not be on terms favorable to us or our stockholders and may require us to relinquish
 valuable rights.

 We
 may be unable to develop our existing or future technology.

 We
 may experience delays in any phase of the preclinical or clinical development of a product,
 including during its research and development.

 We
 have completed one clinical trial of our product. The results of additional clinical studies
 may not support the usefulness of our technology.

 The
 medical device industry is subject to stringent regulation and failure to obtain regulatory
 approval will prevent commercialization of our products.

 We,
 and our third-party manufacturer(s), are, and will be, subject to extensive regulation by
 the FDA.

 The
 market for our technology and revenue generation avenues for our products may be slow to
 develop, if at all.

 Our
 estimate of the size of our addressable market may prove to be inaccurate.

 The
 EP market is highly competitive.

 If
 we do not effectively manage changes in our business, these changes could place a significant
 strain on our management and operations.

 Our
 strategic business plan may not produce the intended growth in revenue and operating income.

 We
 currently have limited sales, marketing or distribution operations and will need to expand
 our expertise in these areas.

 Our
 product development program depends upon third-party researchers, including Mayo, who are
 outside our control and whose negative performance could materially hinder or delay our pre-clinical
 testing or clinical trials.

 We
 may face risks associated with future litigation and claims.

 The
 Company has concluded that there is a material weakness in its internal control over financial
 reporting, which, if not remediated, could materially adversely affect its ability to timely
 and accurately report its results of operations and financial condition. The accuracy of
 the Company's financial reporting depends on the effectiveness of its internal controls
 over financial reporting.

 If
 we do not obtain protection for our intellectual property rights, our competitors may be
 able to take advantage of our research and development efforts to develop competing products.

 If
 we infringe upon the rights of third parties, we could be prevented from selling products
 and forced to pay damages and defend against litigation.

 We
 depend on our collaboration with Mayo Clinic for the research and development of additional
 advanced features of PURE EP System. If this collaboration is not successful, we may
 not be able to realize the market potential of such features and may not have rights to use
 any such developed advanced features.

 If
 we fail to comply with our obligations under our license agreements, we could lose the rights
 to intellectual property that is important to our business.

 We
 may be subject to damages resulting from claims that we or our employees have wrongfully
 used or disclosed alleged trade secrets of their former employers.

 Obtaining
 and maintaining patent protection depends on compliance with various procedures and other
 requirements, and our patent protection could be reduced or eliminated in case of non-compliance
 with these requirements.

 The
 market price for our common stock may fluctuate significantly, which could result in substantial
 losses by our investors.

 our shares of common stock are now listed on The Nasdaq Capital Market, we currently have
 a limited trading volume, which results in higher price volatility for, and reduced liquidity
 of, our common stock.

 Our
 failure to meet the continued listing requirements of Nasdaq could result in a delisting
 of our common stock, which could negatively impact the market price and liquidity of our
 common stock and our ability to access the capital markets.

 Future
 sales of our common stock in the public market or other financings could cause our stock
 price to fall.

 If
 we sell additional equity or debt securities to fund our operations, it may impose restrictions
 on our business.

 Risks
Related to Our Business and Industry

 There
is substantial doubt about our ability to continue as a going concern.

 Our
independent registered public accounting firm has issued an opinion on our consolidated financial statements included in this Annual
Report on Form 10-K that states that the consolidated financial statements were prepared assuming we will continue as a going concern.
Our consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America
applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of
business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of
and for the year ended December 31, 2023, we had a net loss of $28.7 million and net cash used in operating activities of $17.3 million.
Our consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that
may be necessary should we be unable to continue as a going concern. We also cannot be certain that additional financing, if needed,
will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our
operations. There remains substantial doubt about our ability to continue as a going concern for the next twelve months from the date
the consolidated financial statements were issued.

 To
date, we have experienced negative cash flow from development of our technology, as well as from the costs associated with building a
sales force to market our product and services. We expect to incur substantial net losses for the foreseeable future in order to further
develop and commercialize our product. We also expect that our selling, general and administrative expenses will continue to increase
due to the additional costs associated with market development activities and expanding our staff to sell and support our product. Our
ability to achieve or, if achieved, sustain profitability is based on numerous factors, many of which are beyond our control, including
the market acceptance of our products, competitive product development and our market penetration and margins. We may never be able to
generate sufficient revenue to achieve or, if achieved, sustain profitability.

of the numerous risks and uncertainties associated with further development and commercialization of our technology and any future tests,
we are unable to predict the extent of any future losses or when we will become profitable, if ever. We may never become profitable,
and you may never receive a return on an investment in our securities. An investor in our securities must carefully consider the substantial
challenges, risks and uncertainties inherent in the development and commercialization in the medical device industry. We may never successfully
commercialize our technology and our business may fail.

we are an early commercialization stage company with one product in commercialization process, we expect to incur substantial additional
operating losses.

 We
are an early commercialization stage company and we expect to incur substantial additional operating expenses over the next several years
as our marketing, commercialization, and customer development along with additional research and development increase for our PURE EP
System and other product candidates. The amount of our future losses and when, if ever, we will achieve profitability are uncertain.
Our products that have generated minimal commercial revenue, and, although we expect to generate revenues this year from the commercial
sale of our PURE EP System, may not be able to generate sufficient revenues to fund our operating expenses, if any. Our ability to generate
revenue and achieve profitability will depend on, among other things, the following:

 successful
 completion of the pre-clinical and clinical development of our products;

 obtaining
 necessary regulatory approvals from the FDA or other regulatory authorities;

 establishing
 manufacturing, sales, and marketing arrangements, either alone or with third parties; and

 raising
 sufficient funds to finance our activities.

 We
might not succeed at all, or at any, of these undertakings. If we are unsuccessful at some or all of these undertakings, our business,
prospects, and results of operations may be materially adversely affected.

 Our
PURE EP System and other product candidates are in continued development and may not be successfully developed or commercialized.

our main product candidate, the PURE EP System, received FDA 510(k) clearance from FDA, we are currently conducting clinical trials and
may conduct additional clinical trials, which may require substantial further capital expenditure, to establish the safety and efficacy
data needed to obtain acceptance by the medical community and coverage by third-party payors. The continued development of the PURE EP
System, and/or any other product candidates we may develop, is dependent upon our ability to obtain sufficient additional financing.
However, even if we are able to obtain the requisite financing to fund our development program, we cannot assure you that our current
or future product candidates will be successfully developed or commercialized. Our failure to develop, manufacture, receive regulatory
approval for, or successfully commercialize any of our product candidates could result in the failure of our business and a loss of all
of your investment in our company.

 We
expect to derive our revenue from sales of our PURE EP System and other products we may develop. If we fail to generate revenue from
these sources, our results of operations and the value of our business will be materially and adversely affected.

 As
of December 31, 2023, our cash and cash equivalents were approximately $0.2 million. Based on our currently expected level of operating
expenditures, we do not expect that our existing cash and cash equivalents will be sufficient to fund our operations in the near future.
Our revenue is generated from sales of our PURE EP System, for which we made first commercial sale in February 2021, and other products
we may develop. Future sales of these products, if any, will be subject to, among other things, commercial and market uncertainties that
may be outside our control. If we fail to generate our intended revenues from these products, our results of operations and the value
of our business and securities would be materially and adversely affected.

 We
may need to finance our future cash needs through public or private equity offerings, debt financings or corporate collaboration and
licensing arrangements. Any additional funds that we obtain may not be on terms favorable to us or our stockholders and may require us
to relinquish valuable rights.

 Until
PURE EP System or another product of ours become commercially viable, we will have to fund all of our operations and capital expenditures
from cash on hand, public or private equity offerings, debt financings, bank credit facilities or corporate collaboration and licensing
arrangements. However, we may need to raise additional funds more quickly if one or more of our assumptions prove to be incorrect or
if we choose to expand our product development efforts more rapidly than we presently anticipate. We also may decide to raise additional
funds before we require them if we are presented with favorable terms for raising capital.

 If
we seek to sell additional equity or debt securities, obtain a bank credit facility or enter into a corporate collaboration or licensing
arrangement, we may not obtain favorable terms for us and/or our stockholders or be able to raise any capital at all, all of which could
result in a material adverse effect on our business and results of operations. The sale of additional equity or debt securities, if convertible,
could result in dilution to our stockholders. The incurrence of indebtedness would result in increased fixed obligations and could also
result in covenants that would restrict our operations. Raising additional funds through collaboration or licensing arrangements with
third parties may require us to relinquish valuable rights to our technologies, future revenue streams, research programs or product
candidates, or to grant licenses on terms that may not be favorable to us or our stockholders. In addition, we could be forced to discontinue
product development, reduce or forego sales and marketing efforts and forego attractive business opportunities, all of which could have
an adverse impact on our business and results of operations.

 We
may be unable to develop our existing or future technology.

 Our
product, the PURE EP System, may not deliver the levels of accuracy and reliability needed to make it a successful product in the marketplace,
and the development of such accuracy and reliability may be indefinitely delayed or may never be achieved. In addition, we may experience
delays in the development of our technology for other reasons, including failure to obtain necessary funding and failure to obtain all
necessary regulatory approvals. Failure to develop this or other technology could have an adverse material effect on our business, financial
condition, results of operations and future prospects.

 We
may experience delays in any phase of the preclinical or clinical development of a product, including during its research and development.

 We
may experience delays in any phase of the preclinical or clinical development of a product, including during its research and development.
The completion of any of these studies may be delayed or halted for numerous reasons, including, but not limited to, the following:

 successful
 completion of the pre-clinical and clinical development of our products;

 the
 FDA or other regulatory authorities do not approve a clinical study protocol or place a clinical
 study on hold;

 patients
 do not enroll in a clinical study or results from patients are not received at the expected
 rate;

 patients
 discontinue participation in a clinical study prior to the scheduled endpoint at a higher
 than expected rate;

 patients
 experience adverse events from a product we develop;

 third-party
 clinical investigators do not perform the studies in accordance with the anticipated schedule
 or consistent with the study protocol and good clinical practices or other third-party organizations
 do not perform data collection and analysis in a timely or accurate manner;

 third-party
 clinical investigators engage in activities that, even if not directly associated with our
 studies, result in their debarment, loss of licensure, or other legal or regulatory sanction;

 regulatory
 inspections of manufacturing facilities, which may, among other things, require us to undertake
 corrective action or suspend the preclinical or clinical studies;

 in governmental regulations or administrative actions;

 the
 interim results of the preclinical or clinical study, if any, are inconclusive or negative;
 and

 the
 study design, although approved and completed, is inadequate to demonstrate effectiveness
 and safety.

 If
the preclinical and clinical studies that we are required to conduct to gain regulatory approval are delayed or unsuccessful, we may
not be able to market any product that we develop in the future. Preclinical studies and clinical trials are expensive and difficult
to design and implement and any delays or prolongment in our preclinical and clinical studies will require additional capital. There
is no assurance that we will be able to acquire additional capital to support our studies. The failure to obtain additional capital would
have a material adverse effect on the Company.

 We
have completed one clinical trial of our product. The results of additional clinical studies may not support the usefulness of our technology.

 In
November 2019, we commenced our first clinical study with PURE EP System and completed the clinical trial as of September 2021. Conducting
clinical trials is a long, expensive, and uncertain process that is subject to delays and failure at any stage. Clinical trials can take
months or years. The commencement or completion of any of our subsequent clinical trials may be delayed or halted for numerous reasons,
including:

 the
 FDA may not approve a clinical trial protocol or a clinical trial, or may place a clinical
 trial on hold;

 subjects
 may not enroll in clinical trials at the rate we expect, or we may not follow up on subjects
 at the rate we expect;

 subjects
 may experience unexpected adverse events;

 third-party
 clinical investigators may not perform our clinical trials consistent with our anticipated
 schedule or the clinical trial protocols and good clinical practices, or other third-party
 organizations may not perform data collection and analysis in a timely or accurate manner;

 interim
 results of any of our clinical trials may be inconclusive or negative;

 regulatory
 inspections of our clinical trials may require us to undertake corrective action or suspend
 or terminate the clinical trials if investigators find us to be in violation of regulatory
 requirements; or

 governmental
 regulations or administrative actions may change and impose new requirements, particularly
 with respect to reimbursement.

 Results
of pre-clinical studies do not necessarily predict future clinical trial results and previous clinical trial results may not be repeated
in subsequent clinical trials. We may experience delays, cost overruns and project terminations despite achieving promising results in
pre-clinical testing or early clinical testing. In addition, the data obtained from clinical trials may be inadequate to support a device's
approval or clearance, or to demonstrate safety and efficacy to the extent required to obtain third-party coverage and/or reimbursement.
The FDA may disagree with our interpretation of the data from our clinical trials, or may find the clinical trial design, conduct, or
results inadequate to demonstrate the safety and effectiveness of the product candidate. The FDA may also require additional pre-clinical
studies or clinical trials that could further delay clearance or approval of any product candidates we may develop in the future and/or
the PURE EP System to the extent we seek clearance/approval for different indications than that for which it is currently cleared. If
we are unsuccessful in receiving FDA clearance approval of a future product candidate, or a product's clearance or approval is
withdrawn, we would not be able to commercialize the product(s) in the U.S., which could seriously harm our business. Moreover, we face
similar risks in other jurisdictions in which we may sell or propose to sell our products.

 The
medical device industry is subject to stringent regulation and failure to obtain regulatory approval will prevent commercialization of
our products.

 Medical
devices are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act, by comparable
agencies in foreign countries and by other regulatory agencies and governing bodies. Under the Federal Food, Drug, and Cosmetic Act and
associated regulations, manufacturers of medical devices must comply with certain regulations that cover the composition, labeling, testing,
clinical study, manufacturing, packaging and distribution of medical devices. In addition, medical devices must receive FDA clearance
or approval before they can be commercially marketed in the U.S., and the FDA may require testing and surveillance programs to monitor
the effects of approved products that have been commercialized and can prevent or limit further marketing of a product based on the results
of these post-market evaluation programs. The process of obtaining marketing clearance or approval from the FDA for new products could
take a significant period of time, require the expenditure of substantial resources, involve rigorous pre-clinical and clinical testing,
require changes to the products and result in limitations on the indicated uses of the product. In addition, if we seek regulatory approval
in non-U.S. markets, we will be subject to further regulatory approvals that may require additional costs and resources. There is no
assurance that we will obtain necessary regulatory approvals in a timely manner, or at all.

 To
obtain 510(k) clearance for a medical device, a pre-market notification must be submitted to the FDA demonstrating that the device is
"substantially equivalent" to a previously cleared "predicate" device. A new device is substantially equivalent
to a predicate device "at least as safe and effective" as the predicate. The FDA considers a device substantially equivalent
to a predicate if it has the same intended use as the predicate and has either: (i) the same technological characteristics as the predicate
or (ii) different technological characteristics from the predicate, but the information submitted to the FDA does not raise new questions
of safety or effectiveness or demonstrates that the device is at least as safe and effective as the predicate.

 We
received 510(k) clearance to market our current lead product, the PURE EP System in the U.S. However, if we intend to market the PURE
EP System for additional medical uses or indications, we may need to submit additional 510(k) applications to the FDA that are supported
by satisfactory clinical trial results specifically for the additional indication. Clinical trials necessary to support 510(k) clearance
or PMA approval for any future product candidates, or any new indications for use for our PURE EP System, would be expensive and could
require the enrollment of large numbers of suitable patients who could be difficult to identify and recruit. Delays or failures in any
necessary clinical trials could prevent us from commercializing any modified product or new product candidate and could adversely affect
our business, operating results and prospects.

 The
results of our initial clinical trials may not provide sufficient evidence to allow the FDA to grant us such additional marketing clearances
and even additional trials requested by the FDA may not result in our obtaining 510(k) marketing clearance for our product. The failure
to obtain FDA marketing clearance for any additional indications for the PURE EP System or any other of our future products would have
a material adverse effect on our business.

 We,
and our third-party manufacturer(s), are, and will be, subject to extensive regulation by the FDA.

 In
addition to the pre-market regulations, once a device is approved or cleared for the applicable indications for use, numerous FDA regulations
apply, including but not limited to those relating to manufacturing, labeling, packaging, advertising, and record keeping. Notably, these
regulations apply to us, as well as our contract manufacturer(s). Even if regulatory approval or clearance of a product is obtained,
the approval or clearance may be subject to limitations on the uses for which the product may be marketed or contain requirements for
costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Any such requirements could reduce our
revenues, increase our expenses, and render the product not commercially viable. If we fail to comply with the applicable regulatory
requirements, or if previously unknown problems with any approved commercial products, manufacturers, or manufacturing processes are
discovered, we could be subject to administrative or judicially imposed sanctions or other negative consequences, including:

 restrictions
 on our products, manufacturers or manufacturing processes;

 warning
 letters and untitled letters;

 civil
 penalties and criminal prosecutions and penalties;

 fines;

 injunctions;

 product
 seizures or detentions;

 import
 or export bans or restrictions;

 voluntary
 or mandatory product recalls and related publicity requirements;

 suspension
 or withdrawal of regulatory approvals;

 total
 or partial suspension of production; and

 refusal
 to approve pending applications for marketing approval of new products or of supplements
 to approved applications.

 Regulations
are constantly changing, and in the future our business may be subject to additional regulations that increase our compliance costs.

 We
believe we understand the current laws and regulations to which our products will be subject in the future. However, federal, state and
foreign laws and regulations relating to the sale of our products are subject to future changes, as are administrative interpretations
of regulatory agencies. If we fail to comply with such federal, state or foreign laws or regulations, we may fail to obtain regulatory
approval for our products and, if we have already obtained regulatory approval, we could be subject to enforcement actions, including
injunctions preventing us from conducting our business, withdrawal of clearances or approvals and civil and criminal penalties. In the
event that federal, state, and foreign laws and regulations change, we may incur additional costs to seek government approvals, in addition
to the clearance from the FDA in order to sell or market our products. If we are slow or unable to adapt to changes in existing regulatory
requirements or the promulgation of new regulatory requirements or policies, we or our licensees may, following approval, lose marketing
approval for our products which will impact our ability to conduct business in the future.

 The
market for our technology and revenue generation avenues for our products may be slow to develop, if at all.

 The
market for our products may be slower to develop or smaller than estimated or it may be more difficult to build the market than anticipated.
The medical community may resist our products or be slower to accept them than we anticipate. Revenues from our products may be delayed
or costs may be higher than anticipated which may result in our need for additional funding. We anticipate that our principal route to
market will be through commercial distribution partners. These arrangements are generally non-exclusive and have no guaranteed sales
volumes or commitments. The partners may be slower to sell our products than anticipated. Any financial, operational or regulatory risks
that affect our partners could also affect the sales of our products. In the current economic environment, hospitals and clinical purchasing
budgets may exercise greater restraint with respect to purchases, which may result in purchasing decisions being delayed or denied. If
any of these situations were to occur this could have a material adverse effect on our business, financial condition, results of operations
and future prospects.

 Our
estimate of the size of our addressable market may prove to be inaccurate.

 While
our addressable market size estimate for the EP market was made in good faith and is based on assumptions and estimates we believe to
be reasonable, this estimate may not be accurate. If our estimates of the size of our addressable market are not accurate, our potential
for future growth may be less than we currently anticipate, which could have a material adverse effect on our business, financial condition,
and results of operations.

 If
we seek to market our products in foreign jurisdictions, we may need to obtain regulatory approval in these jurisdictions.

 In
order to market our products in the European Union and many other foreign jurisdictions, we may need to obtain separate regulatory approvals
and comply with numerous and varying regulatory requirements. Approval procedures vary among countries (except with respect to the countries
that are part of the European Economic Area) and can involve additional clinical testing. The time required to obtain approval may differ
from that required to obtain FDA approval. Should we decide to market our products abroad, we may fail to obtain foreign regulatory approvals
on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval
by one foreign regulatory authority, including obtaining CE Mark approval, does not ensure approval by regulatory authorities in other
foreign countries or by the FDA. We may be unable to file for, and may not receive, necessary regulatory approvals to commercialize our
products in any foreign market, which could adversely affect our business prospects. In addition, a new Medical Device Regulation was
published in 2017, which includes additional premarket and post-market requirements, as well as potential product reclassifications or
more stringent commercialization requirements that could delay or otherwise adversely affect our clearances and approvals.

 The
EP market is highly competitive.

 There
are a number of groups and organizations, such as healthcare, medical device and software companies in the EP market that may develop
a competitive offering to our products. The largest companies in the EP market are GE, Johnson & Johnson, Boston Scientific, Siemens,
Medtronic, and Abbott. All of these companies have significantly greater resources, experience and name recognition than we possess.
There is no assurance that they will not attempt to develop similar or superior products, that they will not be successful in developing
such products or that any products they may develop will not have a competitive advantage over our products. Moreover, our product may
not be viewed as superior to existing technology or new technology from our competitors and as a result we may not be able to justify
expected selling price our product, which may have a material adverse effect on market acceptance of our product. In addition, if we
experience delayed regulatory approvals or disputed clinical claims, we may not have a commercial or clinical advantage over competitors'
products that we believe we currently possess. Should a superior offering come to market, this could have a material adverse effect on
our business, financial condition, results of operations and future prospects.

 We
rely on key officers, consultants and scientific and medical advisors, and their knowledge of our business and technical expertise would
be difficult to replace.

 We
are highly dependent on our officers, consultants and scientific and medical advisors because of their expertise and experience in medical
device development. We do not have "key person" life insurance policies for any of our officers. Moreover, if we are unable
to obtain additional funding, we will be unable to meet our current and future compensation obligations to such employees and consultants.
In light of the foregoing, we are at risk that one or more of our consultants or employees may leave our company for other opportunities
where there is no concern about such employers fulfilling their compensation obligations, or for other reasons. The loss of the technical
knowledge and management and industry expertise of any of our key personnel could result in delays in product development, loss of customers
and sales and diversion of management resources, which could adversely affect our results of operations.

 We
may fail to attract and retain qualified personnel.

 We
expect to rapidly expand our operations and grow our sales, research and development and administrative operations. This expansion is
expected to place a significant strain on our management and will require hiring a significant number of qualified personnel. Accordingly,
recruiting and retaining such personnel in the future will be critical to our success. There is intense competition from other companies,
research and academic institutions, government entities and other organizations for qualified personnel in the areas of our activities.
Many of these companies, institutions and organizations have greater resources than we do, along with more prestige associated with their
names. If we fail to identify, attract, retain and motivate these highly skilled personnel, we may be unable to continue our marketing
and development activities, and this could have a material adverse effect on our business, financial condition, results of operations
and future prospects.

 If
we do not effectively manage changes in our business, these changes could place a significant strain on our management and operations.

 Our
ability to grow successfully requires an effective planning and management process. The expansion and growth of our business could place
a significant strain on our management systems, infrastructure and other resources. To manage our growth successfully, we must continue
to improve and expand our systems and infrastructure in a timely and efficient manner. Our controls, systems, procedures and resources
may not be adequate to support a changing and growing company. If our management fails to respond effectively to changes and growth in
our business, including acquisitions, there could be a material adverse effect on our business, financial condition, results of operations
and future prospects.

 Our
strategic business plan may not produce the intended growth in revenue and operating income.

 Our
strategies ultimately include making significant investments in sales and marketing programs to achieve revenue growth and margin improvement
targets. If we do not achieve the expected benefits from these investments or otherwise fail to execute on our strategic initiatives,
we may not achieve the growth improvement we are targeting and our results of operations may be adversely affected. We may also fail
to secure the capital necessary to make these investments, which will hinder our growth.

 In
addition, as part of our strategy for growth, we may make acquisitions and enter into strategic alliances such as joint ventures and
joint development agreements. However, we may not be able to identify suitable acquisition candidates, complete acquisitions or integrate
acquisitions successfully, and our strategic alliances may not prove to be successful. In this regard, acquisitions involve numerous
risks, including difficulties in the integration of the operations, technologies, services and products of the acquired companies and
the diversion of management's attention from other business concerns. Although we will endeavor to evaluate the risks inherent
in any particular transaction, there can be no assurance that we will properly ascertain all such risks. In addition, acquisitions could
result in the incurrence of substantial additional indebtedness and other expenses or in potentially dilutive issuances of equity securities.
There can be no assurance that difficulties encountered with acquisitions will not have a material adverse effect on our business, financial
condition and results of operations.

 We
currently have limited sales, marketing or distribution operations and will need to expand our expertise in these areas.

 We
currently have limited sales, marketing or distribution operations. We have begun implementing a market development program and are in
the process of building such operations in connection with the commercialization of PURE EP System, and we are expanding our expertise
in sales, marketing and distribution operations for commercial growth. To increase internal sales, distribution and marketing expertise
and be able to conduct these operations, we have begun to invest in and will have to invest significant amounts of financial and management
resources. In developing these functions ourselves, we could face a number of risks, including:

 we
 may not be able to attract and build an effective marketing or sales force;

 the
 cost of establishing, training and providing regulatory oversight for a marketing or sales
 force may be substantial; and

 there
 are significant legal and regulatory risks in medical device marketing and sales that we
 have never faced, and any failure to comply with applicable legal and regulatory requirements
 for sales, marketing and distribution could result in an enforcement action by the FDA, European
 regulators or other authorities that could jeopardize our ability to market our planned products
 or could subject us to substantial liability.

 Our
product development program depends upon third-party researchers, including Mayo Clinic, who are outside our control and whose negative
performance could materially hinder or delay our pre-clinical testing or clinical trials.

 We
do not have the ability to conduct all aspects of pre-clinical testing or clinical trials ourselves. We depend upon independent investigators
and collaborators, such as commercial third-parties, government, universities and medical institutions, to conduct our pre-clinical and
clinical trials under agreements with us. For our first clinical trial for the PURE EP System, titled "Novel Cardiac Signal Processing
System for Electrophysiology Procedures (PURE EP 2.0 Study)" which commenced in November 2019, we rely on third parties, including
TCARF and Mayo Clinic to conduct the patient cases. In addition, we are party to various license agreements with Mayo, pursuant to which
we rely on research and development information, materials, technical data, unpatented inventions, trade secrets, know-how and supportive
information of Mayo to develop, make, have made, use, offer for sale, sell, and import licensed products. These collaborators are not
our employees and we cannot control the amount or timing of resources that they devote to our programs. These investigators may not assign
as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. The failure
of any of these outside collaborators to perform in an acceptable and timely manner in the future, including in accordance with any applicable
regulatory requirements, such as good clinical and laboratory practices, or pre-clinical testing or clinical trial protocols, could cause
a delay or otherwise adversely affect our pre-clinical testing or clinical trials, our success in obtaining regulatory approvals and,
ultimately, the timely advancement of our development programs. In addition, these collaborators may also have relationships with other
commercial entities, some of whom may compete with us. If our collaborators assist our competitors at our expense, our competitive position
would be harmed.

 If
healthcare providers are unable to obtain sufficient reimbursement or other financial incentives from third-party healthcare payers related
to the use of our products, their adoption and our future product sales will be materially adversely affected.

 Widespread
adoption of the PURE EP System, and any other products we may develop in the future, by the medical community is unlikely to occur without
a financial incentive from third-party payors for the use of these products. Third-party payors include but are not limited to governmental
programs such as Medicare and Medicaid, commercial health insurers and private payors, workers' compensation programs, and other
organizations. Currently, the PURE EP System does not receive separate reimbursement from any third-party payor. Instead, healthcare
providers typically receive reimbursement for the procedure in which our product is used. Future regulatory action by CMS or other governmental
agencies, or unfavorable clinical data, among other things, may impact coverage and/or reimbursement policies for procedures performed
using our products. If healthcare providers are unable to obtain adequate coverage of, or reimbursement for, procedures performed using
our products, or if managed care organizations do not receive improved capitated payments due to more accurate patient risk assessment
using our products, we may be unable to sell our products at levels that are sufficient to allow us to achieve and maintain profitability,
and our business would suffer significantly.

 We
may face risks associated with future litigation and claims.

 We
may, in the future, be involved in one or more lawsuits, claims or other proceedings. These suits could concern issues including contract
disputes, employment actions, employee benefits, taxes, environmental, health and safety, personal injury and product liability matters.
Due to the uncertainties of litigation, we can give no assurance that we will prevail on any claims made against us in any such lawsuit.
Also, we can give no assurance that any other lawsuits or claims brought in the future will not have an adverse effect on our financial
condition, liquidity or operating results.

 The
risk that we may be sued on product liability claims is inherent in the development and commercialization of medical devices. Specifically,
we believe we will be subject to product liability claims or product recalls, particularly in the event of false positive or false negative
reports, because we plan to develop and manufacture medical diagnostic products. Once a product is approved for sale and commercialized,
the likelihood of product liability lawsuits increases. Product liability claims could be asserted directly by consumers, health-care
providers or others. We have obtained product liability insurance coverage; however such insurance may not provide full coverage for
our current or future clinical trials, products to be sold, and other aspects of our business. A product recall or a successful product
liability claim or claims that exceed our planned insurance coverage could have a material adverse effect on us. In addition, insurance
coverage is becoming increasingly expensive and we may not be able to maintain current coverage, or expand our insurance coverage to
include future clinical trials or the sale of new products or existing products in new territories, at a reasonable cost or in sufficient
amounts to protect against losses due to product liability or at all. A successful product liability claim or series of claims brought
against us could result in judgments, fines, damages and liabilities that could have a material adverse effect on our business, financial
condition and results of operations. In the event of an award against us during a time when we have no available insurance or insufficient
insurance, we may sustain significant losses of our operating capital. We may incur significant expense investigating and defending these
claims, even if they do not result in liability. Moreover, even if no judgments, fines, damages or liabilities are imposed on us, our
reputation could suffer, which could have a material adverse effect on our business, financial condition and results of operations, as
well as impair our reputation in the medical and investment communities.

 Our
business is subject to cybersecurity risks.

 Our
operations are increasingly dependent on information technologies and services. Threats to information technology systems associated
with cybersecurity risks and cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters,
terrorist attacks, utility outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as
existing systems are maintained, repaired, replaced, or upgraded. Risks associated with these threats include, among other things:

 theft
 or misappropriation of funds;

 loss,
 corruption, or misappropriation of intellectual property, or other proprietary, confidential
 or personally identifiable information (including supplier, or employee data);

 disruption
 or impairment of our and our business operations and safety procedures;

 damage
 to our reputation with our potential customers and the market;

 exposure
 to litigation;

 increased
 costs to prevent, respond to or mitigate cybersecurity events.

we utilize various procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving
and unpredictable. Moreover, we have no control over the information technology systems of our suppliers, and others with which our systems
may connect and communicate. As a result, the occurrence of a cyber incident could go unnoticed for a period time.

 We
presently maintain insurance coverage to protect against cybersecurity risks. However, we cannot ensure that it will be sufficient to
cover any particular losses we may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect
on our business, financial condition and results of operations.

 We
may be subject, directly or indirectly, to U.S. federal and state healthcare laws, including fraud and abuse, false claims, and privacy
laws and regulations. Prosecutions under such laws have increased in recent years and we may become subject to such litigation and enforcement.
If we are unable to, or have not fully complied with such laws, we could face substantial penalties.

 We
are subject, directly or indirectly, to various U.S. federal and state healthcare laws and regulations. These laws include fraud and
abuse laws, such as the federal Anti-Kickback Statute, federal False Claims Act, and federal Foreign Corrupt Practices Act. These laws
may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject, directly or indirectly,
to patient privacy regulations by both the federal government and the states in which we conduct our business. The healthcare laws that
may affect our ability to operate include, but are not limited to, the following.

 The
 federal Anti-Kickback Statute, which prohibits persons from knowingly and willfully soliciting,
 offering, receiving, or providing remuneration (including any kickback, bribe, or rebate),
 directly or indirectly, overtly or covertly, in cash or in kind, in exchange for or to induce
 either the referral of an individual, or the furnishing or arranging for a good or service,
 for which payment may be made under a federal healthcare program, such as the Medicare and
 Medicaid programs.

 The
 federal physician self-referral law, commonly referred to as the Stark Law, which prohibits
 a physician from making a referral for certain designated health services covered by the
 Medicare program, if the physician or an immediate family member has a financial relationship
 with the entity providing the designated health services, unless the financial relationship
 falls within an applicable exception to the prohibition.

 Federal
 civil and criminal false claims laws and civil monetary penalty laws, including the False
 Claims Act, which prohibits persons from knowingly filing, or causing to be filed, a false
 claim to, or the knowing use of false statements to obtain payment from, the federal government.
 Suits may be filed under the federal False Claims Act by the government or by an individual
 on behalf of the government (known as "qui tam" actions). Such individuals, commonly
 known as "relators" or "whistleblowers," may share in any amounts
 paid by the entity to the government in fines or settlement.

 The
 federal transparency requirements under the Patient Protection and Affordable Care Act and
 the Health Care and Education Reconciliation Act, including the provision known as the Physician
 Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical
 supplies covered under Medicare, Medicaid, or the Children's Health Insurance Program
 (CHIP) to record any information related to payments and other transfers of value to physicians
 and teaching hospitals, as well as ownership and investment interests held by physicians
 and their immediate family members, and to report this data annually to CMS for subsequent
 public disclosure. Manufacturers must also disclose investment interests held by physicians
 and their family members.

 The
 federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or
 transfer of remuneration to a Medicare or state healthcare program beneficiary if the person
 knows or should know it is likely to influence the beneficiary's selection of a particular
 provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare
 program, unless an exception applies.

 Federal
 criminal statutes created through the Health Insurance Portability and Accountability Act
 of 1996 (HIPAA), which prohibit knowingly and willfully executing, or attempting to execute,
 a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent
 pretenses, representations, or promises, any of the money or property owned by, or under
 the custody or control of, any healthcare benefit program, regardless of the payor (e.g.,
 public or private) and knowingly and willfully falsifying, concealing or covering up by any
 trick or device a material fact or making any materially false statements in connection with
 the delivery of, or payment for, healthcare benefits, items or services relating to healthcare
 matters.

 HIPAA,
 as amended by the Health Information Technology for Economic and Clinical Health Act of 2009
 and their respective implementing regulations, which imposes requirements on certain covered
 healthcare providers, health plans, and healthcare clearinghouses as well as their respective
 business associates that perform services for them that involve the use, or disclosure of,
 individually identifiable health information, relating to the privacy, security and transmission
 of individually identifiable health information.

 Other
 federal and state fraud and abuse laws, prohibitions on self-referral and kickbacks, fee-splitting
 restrictions, prohibitions on the provision of products at no or discounted cost to induce
 physician or patient adoption, and false claims acts, transparency, reporting, and disclosure
 requirements, which may extend to services reimbursable by any third-party payer, including
 private insurers.

 State
 and federal consumer protection and unfair competition laws, which broadly regulate marketplace
 activities and activities that could potentially harm consumers.

 Additionally,
we may be subject to state equivalents of each of the healthcare laws described above, among others, some of which may be broader in
scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute, some of
which apply to the referral of patients for healthcare services reimbursed by any source, not just governmental payors, including private
insurers. Several states impose marketing restrictions or require medical device companies to make marketing or price disclosures to
the state. There are ambiguities as to what is required to comply with these state requirements, and if we fail to comply with an applicable
state law requirement we could be subject to penalties.

of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
future business activities could be subject to challenge under one or more of such laws. In addition, healthcare reform legislation has
strengthened these laws. For example, the Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback
and criminal healthcare fraud statutes. As a result of such amendment, a person or entity no longer needs to have actual knowledge of
these statutes or specific intent to violate them in order to have committed a violation. Moreover, the Affordable Care Act provides
that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute
constitutes a false or fraudulent claim for purposes of the False Claims Act.

 Violations
of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspension
from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In
addition, private individuals have the ability to bring actions on behalf of the U.S. government under the False Claims Act as well as
under the false claims laws of several states.

 Efforts
to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial
costs. It is possible that governmental authorities will conclude that our existing or future business practices do not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. Any such actions
instituted against us could have a significant adverse impact on our business, including the imposition of civil, criminal and administrative
penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare
programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which
could adversely affect our ability to operate our business and our results of operations. Even if we are successful in defending against
such actions, we may nonetheless be subject to substantial costs, reputational harm and adverse effects on our ability to operate our
business. In addition, the approval and commercialization of any of our products outside the United States will also likely subject us
to non-U.S. equivalents of the healthcare laws mentioned above, among other non-U.S. laws.

 If
any of our employees, agents, or the physicians or other providers or entities with whom we do business are found to have violated applicable
laws, we may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs,
or, if we are not subject to such actions, we may suffer reputational harm for conducting business with persons or entities found, or
accused of being, in violation of such laws. Any such events could adversely affect our ability to operate our business and our results
of operations.

 In
addition, to the extent we commence commercial operations overseas, we will be subject to the federal Foreign Corrupt Practices Act and
other countries' anti-corruption/anti-bribery regimes, such as the U.K. Bribery Act. The federal Foreign Corrupt Practices Act
prohibits improper payments or offers of payments to foreign governments and their officials for the purpose of obtaining or retaining
business. Safeguards we implement to discourage improper payments or offers of payments by our employees, consultants, sales agents or
distributors may be ineffective, and violations of the federal Foreign Corrupt Practices Act and similar laws may result in severe criminal
or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation, business, financial
condition and results of operations.

 We
could be adversely affected if healthcare legislation or reform measures substantially change the market for medical care or healthcare
coverage in the U.S., negatively affecting our business or revenue for PURE EP or future products.

 The
Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, commonly
referred to as the "Healthcare Reform Law," includes a number of rules regarding health insurance, the provision of healthcare,
conditions to reimbursement for healthcare services provided to Medicare and Medicaid patients, and other healthcare policy reforms.
Through the law-making process, substantial changes have been and continue to be made to the current system for paying for healthcare
in the U.S., including changes made to extend medical benefits to certain Americans who lacked insurance coverage and to contain or reduce
healthcare costs (such as by reducing or conditioning reimbursement amounts for healthcare services and medical devices, and imposing
additional taxes, fees, and rebate obligations on medical device companies). This legislation was one of the most comprehensive and significant
reforms ever experienced by the U.S. in the healthcare industry and has significantly changed the way healthcare is financed by both
governmental and private insurers. This legislation has impacted the scope of healthcare insurance and incentives for consumers and insurance
companies, among others. Additionally, the Healthcare Reform Law's provisions were designed to encourage providers to find cost
savings in their clinical operations. Medical devices represent a significant portion of the cost of providing care. This environment
has caused changes in the purchasing habits of consumers and providers and resulted in specific attention to the pricing negotiation,
product selection and utilization review surrounding medical devices. This attention may result in our products we may commercialize
or promote, including our current commercial products, being chosen less frequently or the pricing being substantially lowered. At this
stage, it is difficult to estimate the full extent of the direct or indirect impact of the Healthcare Reform Law on us.

 These
structural changes could entail further modifications to the existing system of private payors and government programs (such as Medicare,
Medicaid, and the State Children's Health Insurance Program), creation of government-sponsored healthcare insurance sources, or
some combination of both, as well as other changes. Restructuring the coverage of medical care in the U.S. could impact the reimbursement
for medical devices, including our current commercial products, those we and our development or commercialization partners are currently
developing or those that we may commercialize or promote in the future. If reimbursement for our approved medical devices, products we
currently commercialize or promote, or any product we may commercialize or promote is substantially reduced or otherwise adversely affected
in the future, or rebate obligations associated with them are substantially increased, it could have a material adverse effect on our
reputation, business, financial condition or results of operations.

 Extending
medical benefits to those who currently lack coverage will likely result in substantial costs to the U.S. federal government, which may
force significant additional changes to the healthcare system in the U.S. Much of the funding for expanded healthcare coverage may be
sought through cost savings. While some of these savings may come from realizing greater efficiencies in delivering care, improving the
effectiveness of preventive care and enhancing the overall quality of care, much of the cost savings may come from reducing the cost
of care and increased enforcement activities. Cost of care could be reduced further by decreasing the level of reimbursement for medical
services or products (including those products currently being developed by us or our development or commercialization partners or any
product we may commercialize or promote, including our current commercial products), or by restricting coverage (and, thereby, utilization)
of medical services or products. In either case, a reduction in the utilization of, or reimbursement for, any medical device or any product
we may commercialize or promote, including our current commercial products, or for which we receive marketing approval in the future,
could have a material adverse effect on our reputation, business, financial condition or results of operations.

 Further,
the healthcare regulatory environment has seen significant changes in recent years and is still in flux. Legislative initiatives to modify,
limit, replace, or repeal the Healthcare Reform Law and judicial challenges have continued for over a decade. However, as of the Supreme
Court's ruling ordering the dismissal of, arguably, the most promising case challenging the Healthcare Reform Law to-date in June
2021, it appears that the Healthcare Reform Law will remain in-effect in its current form for the foreseeable future; however, we cannot
predict what additional challenges may arise in the future, the outcome thereof, or the impact any such actions may have on our business.
Additionally, the Biden administration has introduced various measures in recent years, focusing on healthcare and medical-product pricing,
in particular. It remains to be seen how these measures will affect our business and there is uncertainty as to what other healthcare
programs and regulations may be implemented or changed at the federal and/or state level in the U.S., but, it is possible that such initiatives
could have an adverse effect on our ability to obtain approval and/or successfully commercialize products in the U.S. in the future.
For example, any changes that reduce, or impede the ability of healthcare providers to obtain reimbursement for medical procedures in
which the products we currently, or intend to, commercialize are used, or that reduce medical procedure volumes, could adversely affect
our operations and/or future business plans. The financial impact of U.S. healthcare reform legislation over the next few years will
depend on a number of factors, including the policies reflected in implementing regulations and guidance and changes in sales volumes
for medical devices affected by the legislation. From time to time, legislation is drafted, introduced and passed in the U.S. Congress
that could significantly change the statutory provisions governing coverage, reimbursement, pricing, and marketing of medical device
products. In addition, third-party payor coverage and reimbursement policies are often revised or interpreted in ways that may significantly
affect our business and our products.

 As
a smaller reporting company, we are subject to scaled disclosure requirements that may make it more challenging for investors to analyze
our results of operations and financial prospects.

 Currently,
we are a "smaller reporting company," as defined by Rule 12b-2 of the Exchange Act. As a "smaller reporting company,"
we are able to provide simplified executive compensation disclosures in our filings and have certain other decreased disclosure obligations
in our filings with the SEC, including being required to provide only two years of audited financial statements in annual reports. Consequently,
it may be more challenging for investors to analyze our results of operations and financial prospects.

 Furthermore,
we are a non-accelerated filer as defined by Rule 12b-2 of the Exchange Act, and, as such, are not required to provide an auditor attestation
of management's assessment of internal control over financial reporting, which is generally required for SEC reporting companies
under Section 404(b) of the Sarbanes-Oxley Act. Because we are not required to, and have not, had our auditor's provide an attestation
of our management's assessment of internal control over financial reporting, a material weakness in internal controls may remain
undetected for a longer period.

 The
Company has concluded that there is a material weakness in its internal control over financial reporting, which, if not remediated, could
materially adversely affect its ability to timely and accurately report its results of operations and financial condition. The accuracy
of the Company ' s financial reporting depends on the effectiveness of its internal controls over financial reporting.

 Internal
controls over financial reporting can provide only reasonable assurance with respect to the preparation and fair presentation of financial
statements and may not prevent or detect misstatements. Failure to maintain effective internal controls over financial reporting, or
lapses in disclosure controls and procedures, could undermine the ability to provide accurate disclosure (including with respect to financial
information) on a timely basis, which could cause investors to lose confidence in the Company's disclosures (including with respect
to financial information), require significant resources to remediate the lapse or deficiency, and expose it to legal or regulatory proceedings.

 In
connection with the audit of its December 31, 2023 financial statements, the Company's management identified inadequate identification,
recording and reporting of stock based compensation due under consulting or other third-party contracts entered into by the Company,
but not yet ratified by the Company's Board of Directors which resulted in deficiencies, which, in aggregate, amounted to a material
weakness in the Company's internal control over financial reporting. Other material weaknesses along with stock based compensation
identified were the lack of segregation of duties and ineffective review processes over period end financial disclosure and reporting.

 The
Company's remediation efforts are ongoing and it will continue its initiatives to implement and document policies, procedures,
and internal controls. Remediation of the identified material weakness and strengthening the internal control environment will require
a substantial effort throughout 2023 and beyond, as necessary, and the Company will test the ongoing operating effectiveness of the new
and existing controls in future periods. The material weakness cannot be considered completely remediated until the applicable controls
have operated for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.
The Company cannot guarantee that it will be successful in remediating the material weakness it identified or that its internal control
over financial reporting, as modified, will enable it to identify or avoid material weaknesses in the future.

 The
Company cannot guarantee that its management will be successful in identifying and retaining appropriate personnel; that newly engaged
staff or outside consultants will be successful in identifying material weaknesses in the future; or that appropriate personnel will
be identified and retained prior to these deficiencies resulting in material and adverse effects on the Company's business.

 There
are inherent limitations in all control systems, and misstatements due to error or fraud may occur and not be detected.

 The
ongoing internal control provisions of Section 404 of the Sarbanes-Oxley Act of 2002 require us to identify material weaknesses in internal
control over financial reporting, which is a process to provide reasonable assurance regarding the reliability of financial reporting
for external purposes in accordance with accounting principles generally accepted in the United States. Our management, including our
chief executive officer and chief financial officer, does not expect that our internal controls and disclosure controls will prevent
all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. In addition, the design of a control system must reflect the fact that there are resource
constraints and the benefit of controls must be relative to their costs. Because of the inherent limitations in all control systems,
no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, in our company have
been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can
occur because of simple errors or mistakes. Further, controls can be circumvented by individual acts of some persons, by collusion of
two or more persons, or by management override of the controls. The design of any system of controls is also based in part upon certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated
goals under all potential future conditions. Over time, a control may be inadequate because of changes in conditions, such as growth
of the company or increased transaction volume, or the degree of compliance with the policies or procedures may deteriorate. Because
of inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 In
addition, discovery and disclosure of a material weakness, by definition, could have a material adverse impact on our financial statements.
Such an occurrence could discourage certain customers or suppliers from doing business with us and adversely affect how our stock trades.
This could in turn negatively affect our ability to access equity markets for capital.

 Risks
Related to Our Intellectual Property

 If
we do not obtain protection for our intellectual property rights, our competitors may be able to take advantage of our research and development
efforts to develop competing products.

 We
intend to rely on a combination of patents, trade secrets, and nondisclosure and non-competition agreements to protect our proprietary
intellectual property. Our owned patent portfolio now includes 36 (issued/allowed) issued utility patents (24 utility patents where BioSig
is at least one of the applicants). Twenty five additional U.S. and foreign utility patent applications are pending covering various
aspects of our PURE EP System for recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures
(25 U.S. and foreign utility patent applications where either BioSig, Mayo, or both is at least one of the applicants). We also have
one U.S. patent and one U.S. Pending application directed to artificial intelligence (AI). We also have 30 issued worldwide design patents,
which cover various features of our display screens and graphical user interface for enhanced visualization of biomedical signals (30
design patents where BioSig is at least one of the applicants). Finally, we have licenses to 12 (issued/allowed) patents and 9 additional
worldwide utility patent applications from Mayo Foundation for Medical Education and Research that are pending (12 issued/allowed patents
and 9 applications where only Mayo is the applicant). These patents and applications are generally directed to electroporation and stimulation.

 We
plan to file additional patent applications in the U.S. and in other countries as we deem appropriate for our products. Our applications
have and will include claims intended to provide market exclusivity for certain commercial aspects of the products, including the methods
of production, the methods of usage and the commercial packaging of the products. However, we cannot predict:

 the
 degree and range of protection any patents will afford us against competitors, including
 whether third parties will find ways to invalidate or otherwise circumvent our patents;

 if
 and when such patents will be issued, and, if granted, whether patents will be challenged
 and held invalid or unenforceable;

 whether
 or not others will obtain patents claiming aspects similar to those covered by our patents
 and patent applications; or

 whether
 we will need to initiate litigation or administrative proceedings which may be costly regardless
 of outcome.

 Furthermore,
the issuance of a patent, while presumed valid and enforceable, is not conclusive as to its validity or its enforceability and it may
not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors
may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies,
designs or methods. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants,
vendors, former employees and current employees.

 Patent
rights are territorial, and patent protection extends only to those countries where we have issued patents. Filing, prosecuting and defending
patents on our products and product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States.
Many countries, however, do not protect intellectual property to the same extent as the U.S. or Europe, and their litigation processes
differ. Competitors may successfully challenge or avoid our patents, or manufacture products in countries where we have not applied for
patent protection. Changes in the patent laws in the U.S. or other countries may diminish the value of our patent rights. As a result
of these and other factors, the scope, validity, enforceability, and commercial value of our patent rights are uncertain and unpredictable.

 Indeed,
several companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
The legal systems of some countries do not favor the enforcement of patents and other intellectual property rights, which could make
it difficult for BioSig to stop the infringement, misappropriation or other violation of BioSig's intellectual property rights
generally. Proceedings to enforce BioSig's intellectual property rights in foreign jurisdictions could result in substantial costs
and divert our efforts and attention from other aspects of BioSig's business, could put BioSig's patents at risk of being
invalidated or interpreted narrowly and BioSig's patent applications at risk of not issuing and could provoke third parties to
assert claims against BioSig. BioSig may not prevail in any lawsuits that it initiates, and the damages or other remedies awarded, if
any, may not be commercially meaningful.

 The
patent positions of medical device companies, including our patent position, involve complex legal and factual questions, and, therefore,
the issuance, scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents,
if issued, may be challenged, deemed unenforceable, invalidated, or circumvented. A third-party may submit prior art, or we may become
involved in opposition, derivation, reexamination, inter partes review, post-grant review, supplemental examination, or interference
proceedings challenging our patent rights or the patent rights of our licensors or development partners. The costs of defending or enforcing
our proprietary rights in these proceedings can be substantial, and the outcome can be uncertain. An adverse determination in any such
submission or proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology
or products and compete directly with us, or reduce our ability to manufacture or commercialize products. Furthermore, if the scope or
strength of protection provided by our patents and patent applications is threatened, it could discourage companies from collaborating
with us to license, develop or commercialize current or future products. The ownership of our proprietary rights could also be challenged.

 Furthermore,
our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers who do not
advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement
in a competitor's or potential competitor's product, particularly in litigation in countries other than the U.S. that do
not provide an extensive discovery procedure. Any litigation to enforce or defend our patent rights, if any, even if we were to prevail,
could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. We
may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially
meaningful.

 Our
success also depends upon the skills, knowledge and experience of our scientific and technical personnel, our consultants and advisors
as well as our licensors and contractors. To help protect our proprietary know-how and our inventions for which patents may be unobtainable
or difficult to obtain, we rely on trade secret protection and confidentiality agreements. To this end, it is our policy to require all
of our employees, consultants, advisors and contractors to enter into agreements which prohibit the disclosure of confidential information
and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our
business. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the
event of any unauthorized use or disclosure or the lawful development by others of such information. If any of our trade secrets, know-how
or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly
impaired and our business and competitive position would suffer.

 Given
the fact that we may pose a competitive threat, competitors, especially large and well-capitalized companies that own or control patents
relating to electrophysiology recording systems, may successfully challenge our current and planned patent applications, produce similar
products or products that do not infringe our future patents, or produce products in countries where we have not applied for patent protection
or that do not respect our patents.

 If
any of these events occurs, or we otherwise lose protection for our trade secrets or proprietary know-how, the value of our intellectual
property may be greatly reduced. Patent protection and other intellectual property protection are important to the success of our business
and prospects, and there is a substantial risk that such protections will prove inadequate.

 If
we infringe upon the rights of third parties, we could be prevented from selling products and forced to pay damages and defend against
litigation.

 Our
commercial success also depends upon our ability, and the ability of any third party with which we may partner, to develop, manufacture,
market and sell our products, if approved, and use our patent-protected technologies without infringing the patents of third parties.
We may not have identified all patents, published applications or published literature that affect our business by blocking our ability
to commercialize our products, by preventing the patentability of one or more aspects of our products to us or our licensors, or by covering
the same or similar technologies that may affect our ability to market our products. For example, we (or the licensor of a product to
us) may not have conducted a patent clearance search sufficient to identify potentially obstructing third party patent rights. Moreover,
patent applications in the United States are maintained in confidence for up to 18 months after their filing. In some cases, however,
patent applications remain confidential in the U.S. Patent and Trademark Office, or the USPTO, for the entire time prior to issuance
as a U.S. patent. Patent applications filed in countries outside of the United States are not typically published until at least 18 months
from their first filing date. Similarly, publication of discoveries in the scientific or patent literature often lags behind actual discoveries.
We cannot be certain that we or our licensors were the first to invent, or the first to file, patent applications covering our products.
We also may not know if our competitors filed patent applications for technology covered by our pending applications or if we were the
first to invent the technology that is the subject of our patent applications. Competitors may have filed patent applications or received
patents and may obtain additional patents and proprietary rights that block or compete with our patents.

 If
our products, methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantial
costs and we may be required to:

 obtain
 licenses, which may not be available on commercially reasonable terms, if at all;

 abandon
 an infringing product candidate;

 redesign
 our product candidates or processes to avoid infringement;

 cease
 usage of the subject matter claimed in the patents held by others;

 pay
 damages; and/or

 defend
 litigation or administrative proceedings which may be costly regardless of outcome, and which
 could result in a substantial diversion of our financial and management resources.

 We
may not have sufficient resources to bring these actions to a successful conclusion. Any of these events could substantially harm our
earnings, financial condition and operations.

 We
depend on our collaboration with Mayo Clinic for the research and development of additional advanced features of PURE EP
 System. If this collaboration is not successful, we may not be able to realize the market potential of such features and may not
have rights to use any such developed advanced features.

 On
March 15, 2017, we entered into a know-how license agreement with Mayo Foundation for Medical Education and Research ("Mayo Clinic"),
effective December 2, 2016, and as amended whereby we were granted an exclusive license, with the right to sublicense, certain know how
and patent applications in the fields of signal processing, physiologic recording, electrophysiology recording, electrophysiology software
and autonomics to develop, make and offer for sale. The agreement expires ten years from the effective date. In furtherance of this collaboration,
we subsequently entered into four additional agreements whereby we were granted exclusive licenses, with the right to sublicense additional
Mayo Clinic patents and know-how. Pursuant to these agreements, Mayo Clinic retains ownership of the licensed intellectual property and
any developed intellectual property. Mayo Clinic also retains the right to prosecute and enforce the developed intellectual property.
If our agreements with Mayo Clinic terminate, our access to technology and intellectual property licensed to us by Mayo Clinic may be
restricted or terminate entirely, which may delay our continued development of such advanced features utilizing the Mayo Clinic's
technology or intellectual property or require us to stop development of those product candidates completely. Additional risks posed
by this collaboration include:

 Mayo
 Clinic may not properly obtain, maintain, enforce, or defend intellectual property or proprietary
 rights relating to our advanced features or may use our proprietary information in such a
 way as to expose us to potential litigation or other intellectual property related proceedings,
 including proceedings challenging the scope, ownership, validity, and enforceability of our
 intellectual property;

 Mayo
 Clinic may own or co-own intellectual property covering our advanced features that results
 from our collaboration with them, and in such cases, we may not have the exclusive right
 or any right to commercialize such intellectual property or such product candidates or research
 programs; or

 We
 may be prevented from enforcing or defending any intellectual property that we contribute
 to or that arises out of the collaboration, if Mayo Clinic refuses to cooperate with such
 action.

 Our
collaboration with Mayo Clinic is made subject to the rights of the U.S. government to the extent that the technology covered by the
licensed intellectual property was developed under a funding agreement between Mayo Clinic and the U.S. government. Additionally, to
the extent there is any conflict between our agreements with Mayo Clinic and applicable laws or regulations, applicable laws and regulations
will prevail. Some, and possibly all, of the developed intellectual property rights relating to our advanced features may have been developed
in the course of research funded by the U.S. government. As a result, the U.S. government may have certain rights to intellectual property
embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. Government rights in certain inventions developed under
a government-funded program include a nonexclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental
purpose. In addition, the U.S. government has the right to require us, or an assignee or exclusive licensee to such inventions, to grant
licenses to any of these inventions to a third party if the U.S. government determines that adequate steps have not been taken to commercialize
the invention, that government action is necessary to meet public health or safety needs, that government action is necessary to meet
requirements for public use under federal regulations, or that the right to use or sell such inventions is exclusively licensed to an
entity within the U.S. and substantially manufactured outside the U.S. without the U.S. government's prior approval. Additionally,
we may be restricted from granting exclusive licenses for the right to use or sell our inventions created pursuant to such agreements
unless the licensee agrees to additional restrictions (e.g., manufacturing substantially all of the invention in the U.S.). The U.S.
government also has the right to take title to these inventions if we fail to disclose the invention to the government and fail to file
an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title
in any country in which a patent application is not filed within specified time limits. Additionally, certain inventions are subject
to transfer restrictions during the term of these agreements and for a period, thereafter, including sales of products or components,
transfers to foreign subsidiaries for the purpose of the relevant agreements, and transfers to certain foreign third parties. If any
of our intellectual property becomes subject to any of the rights or remedies available to the U.S. government or third parties pursuant
to the Bayh-Dole Act of 1980, this could impair the value of our intellectual property and could adversely affect our business. The U.S.
government has not exercised any of these rights or provided us with any notice of its intent to exercise any of these rights with respect
to any of the intellectual property licensed to us by Mayo Clinic. We are not aware of any instance in which the U.S. government has
ever exercised any such rights with respect to any technologies or other intellectual property developed under funding agreements with
the U.S. government.

 If
we fail to comply with our obligations under our license agreements, we could lose the rights to intellectual property that is important
to our business.

 Our
current license agreements impose on us various development obligations, payment of royalties and fees based on achieving certain milestones
as well as other obligations. If we fail to comply with our obligations under these agreements, the licensor may have the right to terminate
the license. In addition, if the licensor fails to enforce its intellectual property, the licensed rights may not be adequately maintained.
The termination of any license agreements or failure to adequately protect such license agreements could prevent us from commercializing
our products or possible future products covered by the licensed intellectual property. Any of these events could materially adversely
affect our business, prospects, financial condition and results of operation.

 We
may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their
former employers.

 Our
employees may have been previously employed at other companies in the industry, including our competitors or potential competitors. Although
we are not aware of any claims currently pending against us, we may be subject to claims that these employees or we have inadvertently
or otherwise used or disclosed trade secrets or other proprietary information of the former employers of our employees. Litigation may
be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in
substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may
lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability
to commercialize product(s), which would materially adversely affect our commercial development efforts.

 Obtaining
and maintaining patent protection depends on compliance with various procedures and other requirements, and our patent protection could
be reduced or eliminated in case of non-compliance with these requirements.

 Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the relevant
patent agencies in several stages over the lifetime of the patents and /or applications. The relevant patent agencies require compliance
with a number of procedural, documentary, fee payment and other provisions during the patent application process. In many cases, an inadvertent
lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations
in which the failure to comply with the relevant requirements can result in the abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able
to use our technologies and know-how which could have a material adverse effect on our business, prospects, financial condition and results
of operation.

 Risks
Related to our Common Stock

 The
market price for our common stock may fluctuate significantly, which could result in substantial losses by our investors.

 The
stock market in general, and Nasdaq in particular, as well as biotechnology companies, have experienced extreme price and volume fluctuations
that have often been unrelated or disproportionate to the operating performance of small companies. The market price of our common stock
may fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:

 announcements
 of technological innovations, new products or product enhancements by us or others;

 actual
 or anticipated quarterly increases or decreases in revenue, gross margin or earnings, and
 changes in our business, operations or prospects;

 announcements
 of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions
 or capital commitments by us or our competitors;

 conditions
 or trends in the biotechnology industry;

 in the economic performance or market valuations of other biotechnology companies;

 general
 market conditions or domestic or international macroeconomic and geopolitical factors unrelated
 to our performance or financial condition;

 purchase
 or sale of our common stock by stockholders, including executives and directors;

 volatility
 and limitations in trading volumes of our common stock;

 in our capital structure or dividend policy, future issuances of securities, sales or distributions
 of large blocks of our common stock by stockholders;

 our
 cash position;

 announcements
 and events surrounding financing efforts, including debt and equity securities;

 in earnings estimates or recommendations by security analysts, if our common stock is covered
 by analysts;

 the
 addition or departure of key personnel;

 disputes
 and litigation related to intellectual property rights, proprietary rights, and contractual
 obligations;

 in applicable laws, rules, regulations, or accounting practices and other dynamics; and

 other
 events or factors, many of which may be out of our control.

 These
factors and any corresponding price fluctuations may materially and adversely affect the market price of our common stock and result
in substantial losses by our investors.

 Further,
the stock market in general, and the market for technology companies in particular, has experienced extreme price and volume fluctuations
in the past. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline
in the value of our common stock.

 Moreover,
the COVID-19 pandemic has resulted in significant financial market volatility and uncertainty in recent months. A continuation or worsening
of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital,
on our business, results of operations and financial condition, and on the market price of our common stock.

 Price
volatility of our common stock might be worse if the trading volume of our common stock is low. In the past, following periods of market
volatility, stockholders have often instituted securities class action litigation. If we were involved in securities litigation, it could
have a substantial cost and divert resources and attention of management from our business, even if we are successful. Future sales of
our common stock could also reduce the market price of such stock.

 Moreover,
the liquidity of our common stock is limited, not only in terms of the number of shares that can be bought and sold at a given price,
but by delays in the timing of transactions and reduction in security analysts' and the media's coverage of us, if any. These
factors may result in lower prices for our common stock than might otherwise be obtained and could also result in a larger spread between
the bid and ask prices for our common stock. In addition, without a large float, our common stock is less liquid than the stock of companies
with broader public ownership and, as a result, the trading prices of our common stock may be more volatile. In the absence of an active
public trading market, an investor may be unable to liquidate its investment in our common stock. Trading of a relatively small volume
of our common stock may have a greater impact on the trading price of our stock than would be the case if our public float were larger.
We cannot predict the prices at which our common stock will trade in the future.

our shares of common stock are now listed on The Nasdaq Capital Market, we currently have a limited trading volume, which results in
higher price volatility for, and reduced liquidity of, our common stock.

our shares of common stock are now listed on The Nasdaq Capital Market under the symbol "BSGM," trading volume in our common
stock has been limited and an active trading market for our shares of common stock may never develop or be maintained. The absence of
an active trading market increases price volatility and reduces the liquidity of our common stock. As long as this condition continues,
the sale of a significant number of shares of common stock at any particular time could be difficult to achieve at the market prices
prevailing immediately before such shares are offered.

 Our
failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock, which could negatively
impact the market price and liquidity of our common stock and our ability to access the capital markets.

 Our
common stock is listed on the Nasdaq Capital Market. If we fail to satisfy the continued listing requirements of Nasdaq, such as minimum
bid price, shareholders' equity, public float and other requirements, Nasdaq may take steps to delist our common stock. Such a
delisting would have a negative effect on the price of our common stock, impair the ability to sell or purchase our common stock when
persons wish to do so, and any delisting materially adversely affect our ability to raise capital or pursue strategic restructuring,
refinancing or other transactions on acceptable terms, or at all. Delisting from the Nasdaq Capital Market could also have other negative
results, including the potential loss of institutional investor interest and fewer business development opportunities. In the event of
a delisting, we would attempt to take actions to restore our compliance with Nasdaq's listing requirements, but we can provide
no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve
the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future
non-compliance with Nasdaq's listing requirements.

 On
March 5, 2024, we received a letter from the Listing Qualifications Department of Nasdaq (the "Staff") stating that the Company
has not regained compliance with Listing Rule 5550(a)(2) because the Company's common stock did not meet the minimum bid price
of $1.00 per share required for continued listing on The Nasdaq Capital Market, and the Company is not eligible for a second 180 day
cure period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $5,000,000 minimum stockholders' equity initial
listing requirement for The Nasdaq Capital Market, and that accordingly, Nasdaq would delist the Company's common stock unless
the Company requested an appeal of this determination. On March 11, 2024, the Company submitted a request for a hearing before the Nasdaq
Hearings Panel to appeal the Staff's delisting determination.

 On
March 12, 2024, we received a letter from the Staff stating that based upon the Staff's review of the Company and pursuant to Listing
Rule 5101, the Staff believes that the Company no longer has an operating business and is a "public shell," and that the
continued listing of its securities is no longer warranted, in view of work force reductions and resignations of members of the board
of directors and officers (see below).

 The
letter further stated that the Company no longer meets the requirement of Rule 5550(b)(2) to maintain a minimum Market Value of Listed
Securities of $35 million, if none of the other standards set forth in Rule 5550(b) is met.

 The
Staff stated that the foregoing matters serve as an additional basis for delisting the Company's common stock from The Nasdaq Stock
Market, and that the Hearings Panel will consider this matter in rendering a determination regarding the Company's continued listing

 We
intend have appealed the foregoing determinations. The requested hearing before the Hearings Panel will be held on May 7, 2024.

 On
April 15, 2024, the closing price of our Common Shares reported on the Nasdaq Capital Market was $1.10. We may need to seek to effect
a reverse stock split of our common stock in order to attempt to comply with the Nasdaq minimum bid price requirements, which could occur
in the near term, but requires stockholder approval, of which there can be no assurance. We may be unable to complete a reverse stock
split, and even if we do, we may still be unable to meet the minimum bid price requirement, and we may be unable to meet other applicable
Nasdaq listing requirements, including maintaining minimum levels of stockholders' equity or market values of our common stock.

 If
our common stock is delisted and we are not able to list our common stock on another national securities exchange, we expect our securities
would be quoted on an over-the-counter market. There can be no assurance that an active trading market for our common stock will develop
or be sustained.

 Future
sales of our common stock in the public market or other financings could cause our stock price to fall.

 Sales
of a substantial number of shares of our common stock in the public market, the perception that these sales might occur or other financings,
could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity
securities. A substantial majority of the outstanding shares of our common stock are freely tradable without restriction or further registration
under the Securities Act unless these shares are owned or purchased by "affiliates" as that term is defined in Rule 144 under
the Securities Act. In addition, shares of common stock issuable upon exercise of outstanding options, restricted stock units and shares
reserved for future issuance under our incentive stock plan will be eligible for sale in the public market to the extent permitted by
applicable vesting requirements and, in some cases, subject to compliance with the requirements of Rule 144. As a result, these shares
can be freely sold in the public market upon issuance, subject to restrictions under the securities laws.

 If
we sell additional equity or debt securities to fund our operations, it may impose restrictions on our business.

 In
order to raise additional funds to support our operations, we may sell additional equity or debt securities, which may impose restrictive
covenants that adversely impact our business. The incurrence of indebtedness would result in increased fixed payment obligations and
could also result in restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to
acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct
our business. If we are unable to expand our operations or otherwise capitalize on our business opportunities due to such restrictions,
our business, financial condition and results of operations could be materially adversely affected.

 Our
stockholders may experience substantial dilution as a result of the exercise of outstanding options or warrants to purchase shares of
our common stock, or upon conversion of our Series C preferred stock into shares of our common stock.

 As
of April 15, 2024, we have outstanding options to purchase 543,479 shares of common stock, 763,333 restricted stock units and have reserved
259,968 shares of our common stock for further issuances pursuant to our 2023 Long-Term Incentive Plan. In addition, as of April 15,
2024, we may be required to issue 267,508 shares of our common stock for issuance upon conversion of outstanding convertible Series C
preferred stock which includes accrued dividends as of April 15, 2024, and 2,878,734 shares of our common stock for issuance upon exercise
of outstanding warrants. Should all of these shares be issued, you would experience dilution in ownership of our common stock and the
price of our common stock will decrease unless the value of our company increases by a corresponding amount.

 The
interests of our controlling stockholders may not coincide with yours and such controlling stockholders may make decisions with which
you may disagree.

 As
of April 15, 2024, two of our stockholders beneficially owned over 19.78% of our common stock. As a result, these stockholders may
be able to influence the outcome of matters requiring stockholder approval, including the election of directors and approval of significant
corporate transactions. In addition, this concentration of ownership may delay or prevent a change in control of our company and make
some future transactions more difficult or impossible without the support of our controlling stockholders. The interests of our controlling
stockholders may not coincide with our interests or the interests of other stockholders.

 Delaware
law and our Amended and Restated Certificate of Incorporation and By-laws contain anti-takeover provisions that could delay or discourage
takeover attempts that stockholders may consider favorable.

 Our
board of directors is authorized to issue shares of preferred stock in one or more series and to fix the voting powers, preferences and
other rights and limitations of the preferred stock. Accordingly, we may issue shares of preferred stock with a preference over our common
stock with respect to dividends or distributions on liquidation or dissolution, or that may otherwise adversely affect the voting or
other rights of the holders of common stock. Issuances of preferred stock, depending upon the rights, preferences and designations of
the preferred stock, may have the effect of delaying, deterring or preventing a change of control, even if that change of control might
benefit our stockholders. In addition, we are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits
a public Delaware corporation from engaging in a "business combination" with an "interested stockholder" for
a period of three years after the date of the transaction in which the person became an interested stockholder, unless (i) prior to the
date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which
resulted in the stockholder becoming an interested stockholder; (ii) the interested stockholder owned at least 85% of the voting stock
of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding
(a) shares owned by persons who are directors and also officers and (b) shares owned by employee stock plans in which employee participants
do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer;
or (iii) on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual
or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
stock which is not owned by the interested stockholder.

 Section
203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage
attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above
the prevailing market price.

 Risks
Related to our Series C Preferred Stock

 Our
Series C Preferred Stock contains covenants that could limit our financing options and liquidity position, which would limit our ability
to grow our business.

 Covenants
in the certificate of designation for our Series C Preferred Stock impose operating and financial restrictions on us. These restrictions
prohibit or limit our ability to, among other things:

 incur additional indebtedness;

 permit liens on assets;

 repay, repurchase or otherwise acquire more than a de minimis
number of shares of capital stock;

 pay cash dividends to our stockholders; and

 engage in transactions with affiliates.

 As
of April 16, 2024, we were in compliance with all covenants of the Series C Preferred Stock.

 These
restrictions may limit our ability to obtain financing, withstand downturns in our business or take advantage of business opportunities.
Moreover, debt financing we may seek may contain terms that include more restrictive covenants, may require repayment on an accelerated
schedule or may impose other obligations that limit our ability to grow our business, acquire needed assets, or take other actions we
might otherwise consider appropriate or desirable.

 In
addition, the certificate of designation for our Series C Preferred Stock requires us to redeem shares of our Series C Preferred Stock,
at each holder's option and for an amount greater than their stated value, upon the occurrence of certain events, including our
being subject to a judgment of greater than $100,000 or our initiation of bankruptcy proceedings.

 The
holders of our Series C Preferred Stock are entitled to receive a dividend, which may be increased if we do not comply with certain covenants.

 The
holders of the Series C Preferred Stock are entitled to a 9% annual dividend on the $1,000 per share stated value of our Series C Preferred
Stock, which is payable in cash or, subject to the satisfaction of certain conditions, in pay-in-kind shares. The dividend may be increased
to a 18% annual dividend if we fail to comply with certain covenants, including our being subject to a judgment of greater than $100,000
or our initiation of bankruptcy proceedings. As a result of the payment of dividends related to our Series C Preferred Stock, we may
be obligated to pay significant sums of money or issue a significant number of shares of our common stock, which could negatively affect
our operations or result in the dilution of the holders of our common stock, respectively.

 The
terms of our Series C Preferred Stock contain anti-dilution provisions that may result in the reduction of the conversion prices in the
future.

 The
terms of our Series C Preferred Stock contain anti-dilution provisions, which provisions require the lowering of the conversion price
to the purchase price of future offerings. If in the future we issue securities for less than the conversion of our Series C Preferred
Stock then in effect, we will be required to further reduce the relevant conversion prices.

 The
terms of our Series C Preferred Stock prohibit us from paying dividends in the future on our common stock. As a result, any return on
investment may be limited to the value of our common stock.

 The
terms of our Series C Preferred Stock prohibit us from paying dividends in the future on our common stock, absent consent from the holders
representing a super-majority of the outstanding shares of our Series C Preferred Stock and a certain investor. Because we will likely
not pay dividends, our common stock may be less valuable because a return on an investment in our common stock will only occur if our
stock price appreciates.

 General
Risk Factors

 The
liability of our directors and officers is limited.

 The
applicable provisions of the Delaware General Corporation Law and our Amended and Restated Certificate of Incorporation and By-laws limit
the liability of our directors to us and our stockholders for monetary damages for breaches of their fiduciary duties, with certain exceptions,
and for other specified acts or omissions of such persons. In addition, the applicable provisions of the Delaware General Corporation
Law and of our Amended and Restated Certificate of Incorporation and By-laws provide for indemnification of such persons under certain
circumstances. In the event we are required to indemnify any of our directors or any other person, our financial strength may be harmed.

 Negative
publicity or unfavorable media coverage could damage our reputation and harm our operations.

 In
the event that the marketplace perceives our products as not offering the benefits which we believe they offer, we may receive negative
publicity. This publicity may result in litigation and increased regulation and governmental review. If we were to receive such negative
publicity or unfavorable media attention, whether warranted or unwarranted, our ability to market our products would be adversely affected.
We may be required to change our products and services and become subject to increased regulatory burdens, and we may be required to
pay large judgments or fines and incur significant legal expenses. Any combination of these factors could further increase our cost of
doing business and adversely affect our financial position, results of operations and cash flows.

 If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price
and trading volume could decline.

 The
trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about
us or our business. We currently have new research coverage by securities and industry analysts. If one or more of the analysts who covers
us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If
one or more of these analysts cease coverage of us or fails to publish reports on us regularly, demand for our stock could decrease,
which could cause our stock price and trading volume to decline.

 We
are subject to financial reporting and other requirements that place significant demands on our resources.

 We
are subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended, including the requirements of Section
404 of the Sarbanes-Oxley Act of 2002. Section 404 requires us to conduct an annual management assessment of the effectiveness of our
internal controls over financial reporting. These reporting and other obligations place significant demands on our management, administrative,
operational, internal audit and accounting resources. Any failure to maintain effective internal controls could have a material adverse
effect on our business, operating results and stock price. Moreover, effective internal control is necessary for us to provide reliable
financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may not be able to manage our
business as effectively as we would if an effective control environment existed, and our business and reputation with investors may be
harmed.

 ITEM 1B – UNRESOLVED STAFF COMMENTS

 Not
applicable.

 ITEM
1C – CYBERSECURITY

 To
respond to the threat of security breaches and cyberattacks, we have developed a cybersecurity risk management program designed to identify,
assess, manage, mitigate, and respond to cybersecurity threats to all information and systems owned by us. We maintain certain risk management
processes intended to identify cybersecurity threats, determine their likelihood of occurring, and assess potential material impacts
to our business. Based on our assessment, we implement and maintain risk management processes designed to protect the confidentiality,
integrity, and availability of our information systems and the information residing therein.

 Cybersecurity
is reviewed as part of our overall enterprise risk management program, led by our Chief Administrative Officer, which assesses our significant enterprise
risks, provides a summary of those risks and primary mitigations, identifies control improvement projects for our significant risks,
and regularly reports on the progress of control improvement projects for those risks to our Board of Directors. Cybersecurity risks
are reviewed by the Board of Directors, at least annually, as part of the Company's corporate risk mapping exercise.

 The
Company's processes are designed to identify such threats by, among other things, monitoring the threat environment using manual
and automated tools, subscribing to services that identify cybersecurity threats, analyzing reports of threats, conducting scans of the
threat environment, evaluating threats reported to us and conducting vulnerability assessments to identify vulnerabilities.

 We
rely on a multidisciplinary team (including from management and third-party service providers) to assess how identified cybersecurity
threats could impact our business. These assessments may leverage, among other processes, industry tools and metrics designed to assist
in the assessment of risks from such cybersecurity threats. Management also conducts periodic and on-demand assessments of our cybersecurity
risks.

 Our
Chief Administrative Officer is responsible for developing and implementing the cybersecurity risk management program and reporting on
cybersecurity matters to the Board. Additionally, members of the third-party service providers have cybersecurity experience and/or certifications.
We view cybersecurity as a shared responsibility across our management team and periodically perform simulations and incorporate external
resources and advisors as needed. All employees are required to complete cybersecurity training at least annually and have access to
more frequent cybersecurity training through online events.

 The
Chief Administrative Officer is responsible for continuously monitoring and assessing the Company's cybersecurity risk management
program, informing senior management regarding the prevention, detection and mitigation and remediation of cybersecurity incidents and
supervising such efforts.

 To
operate our business, we utilize certain third-party service providers to perform a variety of functions, such as outsourced business
critical functions, clinical research, professional services, SaaS platforms, cloud-based infrastructure, encryption and other functions.
We have certain vendor management processes designed to help to manage cybersecurity risks associated with our use of these providers.
Depending on the nature of the services provided, and the sensitivity and quantity of information processed, our vendor management process
may include reviewing the cybersecurity practices of such provider, contractually imposing obligations on the provider related to the
services they provide and/or the information they process, conducting security assessments, conducting on-site inspections, requiring
their completion of written questionnaires regarding their services and data handling practices, and conducting periodic re-assessments
during their engagement.

 We
have not experienced any material cybersecurity incidents in the past, and we believe no cybersecurity events have occurred that have
materially affected the Company or its business strategy, results of operations or financial condition. We continue to invest in the
cybersecurity of our infrastructure and the enhancement of our internal controls and processes, which are designed to help protect our
systems and data, and the information they contain. We carry insurance in amounts that we believe are reasonable for our business that
provides protection against potential losses arising from a cybersecurity incident. However, there is no assurance that our insurance
coverage will cover or be sufficient to cover all losses or claims that may arise from a cybersecurity incident.

 ITEM
2 – PROPERTIES

 We
maintain our principal executive office at 55 Greens Farms Road, Westport, Connecticut, where we sublease approximately 6,590 square
feet of office space. This lease runs until December 31, 2024, with monthly payments of $14,828 from January 1, 2022 through December
31, 2022, $15,377 per month from January 1, 2023 through December 31, 2023 and $15,926 from January 1, 2024 through December 31, 2024
plus any additional utility expenses. We do not have an option to extend the lease. In connection with the lease, we paid a security
deposit of $14,828. There is no option to extend the lease past its initial term.

 In
addition, we maintain our engineering offices at 12424 Wilshire Boulevard, Los Angeles, California, where we lease approximately 4,000
square feet of office space. This lease runs until July 31, 2025, with monthly payments of $14,124 from September 1, 2022 through June
30, 2023, $14,618 from July 1, 2023 through June 30, 2024 and $15,130 from July 1, 2024 through July 31, 2025. In connection with the
lease, we paid a security deposit of $27,404. We have an option to extend past its lease term for three additional years.

 We
believe we do not believe we need to expand our current facilities to meet our future needs.

 ITEM
3 – LEGAL PROCEEDINGS

 On
December 4, 2023, the Company received a threat of litigation for the termination of employment with the Company alleging the termination
of employment was in retaliation for bringing to the attention of the Company's board of directors and executives a series of wrongful
and questionable practices by members of the Company's board of directors, Chief Executive Officer and Chief Financial Officer.
The claimant sought compensation of in the amount of $775,782. After an investigation conducted by the Board and guidance of legal counsel,
it was concluded that the claim was without merit.

 On
February 22, 2024, the Company received a threat of litigation seeking restitution for losses resulting from unlawful actions taken by
the Company's board of directors. The claimant contends that he and others have sustained losses totaling $1,440,000. On
March 22, 2024, the claimant sent another letter to the Company referencing the previous letter and requesting several documents. The
Company believes that these claims are without merit.

 On
March 22, 2024, plaintiff, Michael Gray Fleming (the "Plaintiff"), filed a lawsuit in Hennepin County, Minnesota District
Court naming the Company, its former Chief Executive Officer and former Chief Financial Officer as defendants. The Plaintiff contends
that the Company failed to meet its obligations in issuing the Plaintiff stock certificates at the end of the restricted period under
the terms of a restricted stock award agreement, and is seeking $144,000 in damages and compensation for damages reasonably believed
to exceed $50,000. The Company's intent is to contest the allegations vigorously and, as of the date of this report, is unable
to provide an evaluation of the outcome of the litigation within the probate or remote range or to provide an estimate of the amount
of or a range of potential loss that might be incurred by the Company.

 We
may be subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional
adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material
adverse effect on its financial position, results of operations or liquidity.

 There
are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more
than 5% of our common stock is an adverse party or has a material interest adverse to our interest.

 ITEM
4 – MINE SAFETY DISCLOSURES

 Not
applicable.

 PART
II

 ITEM
5 – MARKET FOR REGISTRANT ' S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 Market
for Common Stock

 On
October 29, 2014, our common stock commenced trading on OTCQB under the symbol "BSGM" and on September 21, 2018 we commenced
trading on the Nasdaq Capital Market exchange under the same ticker symbol. Prior to October 29, 2014, there was no established trading
price for our common stock. The last reported sales price of our common stock on the Nasdaq Capital Market on April 15, 2024, was $1.10
per share.

 Holders
of Record

 As
of April 15, 2024, there were approximately 392 holders of our common stock, as determined by counting our record holders and the number
of participants reflected in a security position listing provided to us by the Depository Trust Company. Because the "DTC participants"
are brokers and other institutions holding shares of our common stock on behalf of their customers, we do not know the actual number
of unique shareholders represented by these record holders.

 Dividends

 We
have never paid cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future but intend
to retain our capital resources for reinvestment in our business.

 ITEM
6 – RESERVED

 ITEM
7 – MANAGEMENT ' S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 Management ' s
Discussion and Analysis of Financial Condition and Results of Operations is intended to provide a reader of our financial statements
with a narrative from the perspective of our management on our financial condition, results of operations, liquidity, and certain other
factors that may affect our future results. You should read the following discussion and analysis of our financial condition and results
of operations in conjunction with our financial statements and the related notes thereto that are included in this Form 10-K. In addition
to historical information, the following discussion and analysis includes forward-looking statements that reflect our plans, estimates
and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause
or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in the section entitled
 " Risk Factors. " See " Note on Forward-Looking Statements. "

 Overview

 Business
Overview

Technologies is a medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment
of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology
(EP), we are committed to addressing healthcare's biggest priorities — saving time, saving costs, and saving lives.

 Our
first product, the PURE EP System, is an FDA 510(k) cleared non-invasive class II device consisting of a unique combination of
hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals
paving the way for personalized patient care. Integrating with existing systems in the EP lab, PURE EP is designed to accurately
pinpoint even the most complex signals to maximize procedural success and efficiency.

 By
capturing critical cardiac signals—even the most complex, the PURE EP System is designed to enhance clinical decision-making
and improve clinical workflow for all types of arrhythmias - even the most challenging procedures for cardiac arrhythmias, like ventricular
tachycardia (VT) and atrial fibrillation (AF).

 Our
owned patent portfolio now includes 36 (issued/allowed) issued utility patents (24 utility patents where BioSig is at least one of the
applicants). Twenty five additional U.S. and foreign utility patent applications are pending covering various aspects of our PURE EP
System for recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures (25 U.S. and foreign
utility patent applications where either BioSig, Mayo, or both is at least one of the applicants). We also have one U.S. patent and one
U.S. Pending application directed to artificial intelligence (AI). We also have 30 issued worldwide design patents, which cover various
features of our display screens and graphical user interface for enhanced visualization of biomedical signals (30 design patents where
BioSig is at least one of the applicants). Finally, we have licenses to 12 (issued/allowed) patents and 9 additional worldwide utility
patent applications from Mayo Foundation for Medical Education and Research that are pending (12 issued/allowed patents and 9 applications
where only Mayo is the applicant). These patents and applications are generally directed to electroporation and stimulation.

Developments

 PURE
EP Software Version 7 in late 2023 was launched by the Company's commercial and operations team and represents the most
advanced iteration of the Company's digital signal processing technology. Despite having a field team of 15 persons, PURE EP sales,
leasing and/or subscriptions to the software were mostly limited to our research partners at Mayo Clinic, Texas Cardiac Arrhythmia Institute,
Cleveland Clinic, and Kansas City Heart Rhythm Institute.

 Given
the very challenging hospital market post-COVID where capital budgets and purchasing has been restricted due to budget shortfalls, the
Company began to seek partners already in the EP field that have an established field force to increase the penetration of PURE EP into
the hospital systems. This approach would also increase the efficiency in the lab given that established companies already have clinical
support within the lab during the procedure and we feel that adding PURE EP would drive the partner's sales at no additional support
cost.

 Reverse
stock split

 On
December 18, 2023, the Company held its 2023 annual meeting of stockholders, at which meeting the Company's stockholders approved
an amendment (the "Reverse Stock Split Amendment") to the Company's Amended and Restated Certificate of Incorporation
(the "Certificate of Incorporation") to effect a reverse stock split of all of the issued and outstanding shares of the Company's
common stock, at a ratio in the range of 1-for-2 to 1-for-10, with the exact exchange ratio and timing to be determined by the Company's
board of directors in its discretion and included in a public announcement (the "Reverse Stock Split"). Following the annual
meeting, the Board determined to effect the Reverse Stock Split at a ratio of 1-for-10 and approved the corresponding final form of the
Reverse Stock Split Amendment. On January 31, 2024, the Company filed the Reverse Stock Split Amendment with the Secretary of State of
the State of Delaware to effect the Reverse Stock Split, effective as of 4:05 p.m. (New York time) on February 1, 2024.

 As
a result of the Reverse Stock Split, every ten (10) shares of issued and outstanding Common Stock was automatically combined into one
(1) issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares will be issued
as a result of the Reverse Stock Split. Any fractional shares that would otherwise have resulted from the Reverse Stock Split will be
rounded up to the next whole number. The Reverse Stock Split will reduce the number of shares of Common Stock outstanding from 93,344,435
shares to approximately 9,378,513 shares, subject to adjustment for the rounding up of fractional shares. The number of authorized shares
of Common Stock under the Certificate of Incorporation will not change as a result of the Reverse Stock Split.

 Proportionate
adjustments was made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of
outstanding stock options, restricted stock units, and warrants granted by the Company, the per share conversion price and the number
of shares of common stock that may be issued upon conversion of outstanding shares of convertible preferred stock issued by the Company
and the number of shares of Common Stock reserved for future issuance under the Company's 2023 Long-Term Incentive Plan.

 The
Common Stock began trading on a Reverse Stock Split-adjusted basis on The Nasdaq Capital Market on February 2, 2024. The trading symbol
for the Common Stock will remain "BSGM." The new CUSIP number for the Common Stock following the Reverse Stock Split is 09073N300.

 Notices
of Delisting

 On
March 5, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq (the "Staff") stating that
the Company has not regained compliance with Listing Rule 5550(a)(2) because the Company's common stock did not meet the minimum
bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market, and the Company is not eligible for a second
180 day cure period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $5,000,000 minimum stockholders' equity
initial listing requirement for The Nasdaq Capital Market, and that accordingly, Nasdaq would delist the Company's common stock
unless the Company requested an appeal of this determination. On March 11, 2024, the Company submitted a request for a hearing before
the Nasdaq Hearings Panel to appeal the Staff's delisting determination.

 On
March 12, 2024, the Company received a letter from the Staff stating that based upon the Staff's review of the Company and pursuant
to Listing Rule 5101, the Staff believes that the Company no longer has an operating business and is a "public shell," and
that the continued listing of its securities is no longer warranted, in view of work force reductions and resignations of members of
the board of directors and officers (see below).

 The
letter further stated that the Company no longer meets the requirement of Rule 5550(b)(2) to maintain a minimum Market Value of Listed
Securities of $35 million, if none of the other standards set forth in Rule 5550(b) is met.

 The
Staff stated that the foregoing matters serve as an additional basis for delisting the Company's common stock from The Nasdaq Stock
Market, and that the Hearings Panel will consider this matter in rendering a determination regarding the Company's continued listing

 The
Company intends also to appeal the foregoing determinations. The requested hearing before the Hearings Panel will be held on May 7, 2024.

 Delisting
from Nasdaq Stock Market could negatively impact the Company's ability to raise additional financing to fund future operations.

 Lack
of funding, workforce reductions, resignations of members of the Company's board of directors and certain officers

 On
January 28, 2024 and February 20, 2024, management of the Company commenced a workforce reduction intended to reduce significantly the
annual cash burn which was completed as of February 20, 2024. The workforce reduction consisted of the departure of sixteen employees,
effective as of January 31, 2024 and included the departure of John Sieckhaus, the Company's Chief Operating Officer, and Gray
Fleming, the Company's Chief Commercial Officer and twenty six employees effective February 20, 2024. The effect of the workforce
reductions had significantly reduce operations in the short-term.

 On
February 15, 2024, Steve Buhaly resigned from his position as the Chief Financial Officer of the Company effective as of the same date.

 On
February 19, 2024, David Weild IV, Donald E. Foley, Patrick J. Gallagher and James J. Barry, resigned from their positions as directors
of the Company, effective as of the same date.

 On
February 20, 2024, James L. Klein and Frederick D. Hrkac resigned from their positions as directors of the Company, effective as of the
same date.

 On
February 20, 2024 due to lack of funding, the company had laid off the entire workforce except for the CEO.

 On
February 27, 2024, the company re-appointed Frederick D. Hrkac as a director and the president and principal executive officer. Additionally,
on February 27, 2024, Kenneth L. Londoner resigned from his positions as director, executive chairman and chief executive officer of
the Company and from any and all committees, offices, appointments, designations, responsibilities or other capacities related to the
Company or any of its subsidiaries, effective as of the same date.

 Currently,
the Company has 4 employees and 4 key consultants. Dependent upon funding, Mr. Hrkac would plan on hiring a team of 4-6 persons to
execute the business development strategy of finding partners for the commercialization of PURE EP, develop new products in
the field of Pulse Field Ablation and to continue to integrate PURE EP into today's lab equipment.

 Pending
Legal Proceedings

 On
December 4, 2023, the Company received a threat of litigation for the termination of employment with the Company alleging the termination
of employment was in retaliation for bringing to the attention of the Company's board of directors and executives a series of wrongful
and questionable practices by members of the Company's board of directors, Chief Executive Officer and Chief Financial Officer.
The claimant sought compensation of in the amount of $775,782. After an investigation conducted by the Board and guidance of legal counsel,
it was concluded that the claim was without merit.

 On
February 22, 2024, the Company received a threat of litigation seeking restitution for losses resulting from unlawful actions taken by
the Company's board of directors. The claimant contends that he and others have sustained losses totaling $1,440,000. On
March 22, 2024, the claimant sent another letter to the Company referencing the previous letter and requesting several documents. The
Company believes that these claims are without merit.

 On
March 22, 2024, plaintiff, Michael Gray Fleming (the "Plaintiff"), filed a lawsuit in Hennepin County, Minnesota District
Court naming the Company, its former Chief Executive Officer and former Chief Financial Officer as defendants. The Plaintiff contends
that the Company failed to meet its obligations in issuing the Plaintiff stock certificates at the end of the restricted period under
the terms of a restricted stock award agreement, and is seeking $144,000 in damages and compensation for damages reasonably believed
to exceed $50,000. The Company's intent is to contest the allegations vigorously and, as of the date of this report, is unable
to provide an evaluation of the outcome of the litigation within the probate or remote range or to provide an estimate of the amount
of or a range of potential loss that might be incurred by the Company.

Equity transaction

 On
January 12, 2024, the Company entered into a securities purchase agreement with certain accredited and institutional investors, pursuant
to which the Company sold to the investors an aggregate of 260,720 shares of the Company's common stock and warrants to purchase
up to 130,363 shares of common stock, at a purchase price of $3.989 per share and a warrant to purchase one-half of a share. The warrants
have an exercise price of $3.364 per share, will become exercisable six months after the date of issuance and will expire five and one-half
years following the date of issuance. The gross proceeds from this offering were $1,040,000.

 Issuance
of debt

 On
March 7, 2024, the Company issued a promissory note to an investor and related party (10% plus shareholder) for $500,000. The Company
designated its 12% note due 2026, in accordance with exemptions from registration under the Securities Act of 1933, as amended (the "Securities
Act").

 The
note is due March 7, 2026. The Company promises to pay interest in cash on the unpaid principal amount of this note at a rate per annum
equal to twelve percent (12%), commencing to accrue on the date hereof and payable on the maturity date or earlier prepayment as provided
therein. The Note contains customary events of default.

 The
Company may prepay all or any portion of the principal amount of the Note at any time or from time to time without penalty.

 Critical
Accounting Estimates

 The
following discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements,
which have been prepared in accordance with generally accepted accounting principles in the U.S. The preparation of consolidated financial
statements in accordance with generally accepted accounting principles in the U.S. requires us to make estimates and assumptions that
affect the amounts reported in our consolidated financial statements. The consolidated financial statements include estimates based on
currently available information and our judgment as to the outcome of future conditions and circumstances.

 We
believe the following critical accounting estimates affect our more significant judgments and estimates used in the preparation of our
financial statements. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on our historical experience
and on various other assumptions that we believe to be reasonable under the circumstances. Among the significant judgments made by management
in the preparation of our financial statements are the following:

 Stock
Based Compensation

 We
estimate the fair value of options and stock warrants granted using the Black Scholes Merton model. We estimate when and if performance-based
awards will be earned. If an award is not considered probable of being earned, no amount of equity-based compensation expense is recognized.
If the award is deemed probable of being earned, related equity-based compensation expense is recorded. The fair value of an award ultimately
expected to vest is recognized as an expense, net of forfeitures, over the requisite service periods in our statements of operations,
which is generally the vesting period of the award.

 The
Black Scholes Merton model requires the input of certain subjective assumptions and the application of judgment in determining the fair
value of the awards. The most significant assumptions and judgments include the expected volatility, risk-free interest rate, the expected
dividend yield, and the expected term of the awards. In addition, the recognition of equity-based compensation expense is impacted by
our forfeitures, which are accounted for as they occur.

 The
assumptions used in our option pricing model represent management's best estimates. If factors change and different assumptions
are used, our equity-based compensation expense could be materially different in the future. The assumptions used in our option pricing
model represent management's best estimates. If factors change and different assumptions are used, our equity-based compensation
expense could be materially different in the future.

 All
stock-based payments to employees and to nonemployee directors for their services as directors consisted of grants of restricted stock
and stock options, which are measured at fair value on the grant date and recognized in the statements of operations as compensation
expense over the relevant vesting period. Restricted stock payments and stock-based payments to nonemployees are recognized as an expense
over the period of performance.

 Such
payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed.
In addition, for awards that vest immediately and are non-forfeitable, the measurement date is the date the award is issued.

 Results
of Operations (000 ' s)

 We
anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, such as financing needs,
the progress of our research and development efforts and the timing and outcome of regulatory submissions. Due to these uncertainties,
accurate predictions of future operations are difficult or impossible to make.

 Twelve
Months Ended December 31, 2023, Compared to Twelve Months Ended December 31, 2022

 Revenues
and Cost of Goods Sold. Revenue for the year ended December 31, 2023, totaled $18 comprised recognized service revenue as compared
to $286 comprised of product sales of $254 and recognized service revenue of $32 for the year ended December 31, 2022.

 We
derive our revenue primarily from the sale or lease of our medical device, PURE EP system, as well as related support and maintenance
services and software upgrades in connection with the system.

 Cost
of sales for the year ended December 31, 2023, was Nil as compared to $57 for the year ended December 31, 2022 comprised of cost of products
sold.

 Gross
profit from the year ended December 31, 2023, was $18 or 100.0% as compared to $229 or 80.0% for the year ended December 31, 2022. In
2023, our revenue was comprised of service revenue only.

and Development Expenses. Research and development expenses for the twelve months ended December 31, 2023, were $5,092, a decrease
of $729 or 12.5%, from $5,821 for the twelve months ended December 31, 2022. This decrease is primarily due to decrease in the BioSig
segment research and development in 2023 as compared to 2022.

and development expenses were comprised of the following:

 2023

 2022

 Salaries and equity compensation

 $
 3,885

 $
 3,770

 Consulting expenses

 Research, clinical studies, and design work

 Regulatory

 Data/AI development

 Product development and formulation

 -

 Travel, supplies, other

 Total

 $
 5,092

 $
 5,821

 Stock-based
compensation for research and development personnel was $1,224 and $951 for the twelve months ended December 31, 2023, and 2022, respectively.

 General
and Administrative Expenses. General and administrative expenses for the twelve months ended December 31, 2023, were $23,077, an
increase of $1,697, or 7.9%, from $21,380 incurred in the twelve months ended December 31, 2022. This increase is primarily due to increases
in equity-based and other compensation, professional services, consulting fees and travel, meals and entertainment costs.

 Payroll
related expenses (including equity compensation) increased to $14,144 in the twelve months ended December 31, 2023, from $12,001 for
the twelve months ended December 31, 2022, an increase of $2,143, or 17.9%. This increase is due to the value of the stock-based compensation
increasing to $6,754 in 2023, as a result of the vesting of stock and stock options issued to board members, officers, and employees,
as compared to $3,582 stock-based compensation in 2022.

 Professional
services for the twelve months ended December 31, 2023, totaled $953, a decrease of $221, or 18.8%, over the $1,174 recognized for the
twelve months ended December 31, 2022. Of professional services, legal fees totaled $734 for the twelve months ended December 31, 2023,
a decrease of $48, or 6.1%, from $782 incurred for the twelve months ended December 31, 2022. The decrease in legal fees in 2023 is due
to reduction in legal work in asset acquisitions, financing and in developing and registering patents. Accounting fees incurred in the
twelve months ended December 31, 2023, amounted to $217, a decrease of $8 or 3.6%, from $225 incurred for the same period in 2022.

 Consulting
fees and marketing totaled $3,067 for the twelve months ended December 31, 2023, a decrease of $888 or 22.5%, from $3,955 for the twelve
months ended December 31, 2022. The decrease primarily relates to reductions in fund raising and investor relations to support our efforts
in market research and potential investor identification and key consultants in connection with our commercialization efforts, net increases
in marketing activities.

 Travel,
meals and entertainment costs for the twelve months ended December 31, 2023, were $710, a decrease of $400, or 36.0%, from $1,110 incurred
during the twelve months ended December 31, 2022. The decrease in 2022 was due to reductions in travel in both corporate and commercialization
as compared to 2022.

 Rent
for the twelve months ended December 31, 2023, totaled $378, a decrease of $48, or 11.3%, from $426 incurred during the same period in
2022. In 2022, we incurred a rent reduction with our lease extension in our Los Angeles facility and closed our Minnesota office reflecting
the savings in 2023.

 Depreciation
and Amortization Expense. Depreciation and amortization expense for the twelve months ended 2023 totaled $361 as compared to $293
incurred during the same period in 2022. The increase is due primarily to additional manufacturing and testing equipment purchased in
2022.

 Interest
Income. Interest income for the twelve months ended December 31, 2023, totaled $9 as compared to $3 earned during the twelve months
ended December 31, 2022. The increase in 2023 was due interest received under our lease agreements in 2022.

 Other
Income (expense). Other income (expense) for the twelve months ended December 31, 2023, totaled $(187) as compared to nil in 2022.
The net expense was comprised of dispute settlement of $240, net of gain on accounts payable of $38 and other income of $15.

 Preferred
Stock Dividend. Preferred stock dividend for the twelve months ended December 31, 2023 and 2022, totaling $9 Preferred stock dividends
are related to the issuance of our Series C Preferred Stock from 2013 through 2015. In addition, the Series C Preferred stock conversion
rate reset from $0.63 to $0.25 in 2022, therefore we recorded a noncash deemed preferred stock dividend of $210 during the year ended
December 31, 2022.

 Noncontrolling
Interest. In 2023, BioSig AI Sciences sold shares of its common stock to fund initial and ongoing operations. As of December 31,
2023, we had a majority interest in BioSig AI Sciences of 84.5%

 In
2019 and 2020, ViralClear sold shares of its common stock to fund its initial and ongoing operations. As of December 31, 2022 and 2023,
we had a majority interest in ViralClear of 69.08%.

 The
proportionate income (loss) attributed to noncontrolling interests for the twelve months ended December 31, 2023, was $351 as compared
to $(210) for 2022.

 Net
Loss Available to BioSig Technologies, Inc. Net loss available to common stockholders for the twelve months ended December 31, 2023,
was $29,050 compared to a net loss of $27,271 for the twelve months ended December 31, 2022, an increase of $1,779 or 6.5%. The primary
reasons for the increase, as described above, are the increases in general and administrative expenses from 2023 to 2022.

 Segment
Results

 The
Company reports segment information based on the "management" approach. The management approach designates the internal reporting
used by management for making decisions and assessing performance as the source of the Company's reportable segments.

 Summary
Statement of Operations for the year ended December 31, 2023, as compared to the year ended December 31, 2022, are detailed in Note 13
of the accompanying consolidated financial statements.

 Liquidity
and Capital Resources

 We
had an accumulated deficit as of December 31, 2023, of approximately $245 million, as well as a net loss of approximately $29 million
and negative operating cash flows. We expect to continue incurring losses and negative cash flows from operations until our products
(primarily PURE EP System) reach commercial profitability.

 We
have incurred net losses and negative cash flows from operations since inception and our expectation is that these conditions will continue
for the foreseeable future. In addition, we will require additional financing to fund future operations. Although we have commercial
products available for sale, we have not generated significant revenues to date, and there is no assurance that we will be able to generate
cash flow to fund operations. In addition, there can be no assurance that our research and development will be successfully completed
or that any additional products will be approved or commercially viable. Our ability to continue as a going concern is subject to our
ability to obtain necessary funding from outside sources, including obtaining additional funding from the sale of our securities, obtaining
loans from various financial institutions or being awarded grants from government agencies, where possible. Our continued net operating
losses increase the difficulty in meeting such goals and there can be no assurances that such methods will prove successful. Additionally,
with our reduction in staff, our planned commercialization may be further delayed.

 Our
plans include the continued commercialization of the PURE EP System and other applications of our core technology and raising capital
through the sale of additional equity securities, debt or capital inflows from strategic partnerships. Our shift from a focus on technology
development to commercialization has allowed us to reduce our annual expenses in a meaningful way. As a result of this transition, we
have been able to achieve savings through reductions in executive and management compensation and a reduction of our utilization of external
consultants and professional service providers. We believe these cost-saving measures combined with our expectations of positive trends
in commercial activity create the potential for us to achieve a lower cash flow breakeven rate. There are no assurances, however, that
we will be successful in obtaining the level of financing needed for our operations. The ongoing COVID-19 pandemic has resulted and continues
to result in significant financial market volatility and uncertainty in recent months. In addition, U.S. and global markets are experiencing
volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and
Ukraine.

 A
continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our
ability to access capital and on the market price of our common stock, and we may not be able to successfully raise capital through the
sale of our securities.

 Our
Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of
(a) 120% of the stated value of $1 or (b) the product of (I) the variable weighted average price of our common stock on the trading day
immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in shares
of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%. As of December 31, 2023,
the aggregate stated value of our Series C Preferred Stock was $105. The triggering events include our being subject to a judgment of
greater than $100 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred Stock
occur, the holders of our Series C Preferred Stock may demand redemption, an obligation we may not have the ability to meet at the time
of such demand. We will be required to pay interest on any amounts remaining unpaid after the required redemption of our Series C Preferred
Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable law.

 We
expect to incur losses from operations for the near future. We expect to incur additional marketing and commercialization expenses related
to our PURE EP system in addition to additional research and development costs relating to the PURE EP and other product candidates,
including expenses related to clinical trials. We expect that our general and administrative expenses will increase in the future as
we expand our business development, add infrastructure and incur additional costs related to being a public company, including incremental
audit fees, investor relations programs and increased professional services.

 Our
future capital requirements will depend on a number of factors, including the progress of our research and development of product candidates,
the timing and outcome of regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing
patent claims and other intellectual property rights, the status of competitive products, the availability of financing and our success
in developing markets for our product candidates.

 Future
financing may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. Even if
we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash
requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, existing
holders of our securities may experience additional dilution or the new equity securities may have rights, preferences or privileges
senior to those of existing holders of our securities.

 If
additional financing is not available or is not available on acceptable terms, we may be required to delay, reduce the scope of or eliminate
our research and development programs, reduce our commercialization efforts or obtain funds through arrangements with collaborative partners
or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize
independently.

Financing

 In
2023, the Company entered into multiple Securities Purchase Agreements with certain institutional and accredited investors, pursuant
to which the Company sold to the investors an aggregate of 1,613,906 shares of common stock at an average purchase price of $8.7571
per share, and warrants to purchase up to an aggregate of 806,981 shares of common stock at an average exercise price of $8.1324 per
share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date
of issuance, in exchange for aggregate consideration of $13,140,441, net of transactional expenses of $727,333.44 (the "2023 PIPEs").

to certain engagement agreements, dated October 11, 2022, February 24, 2023 and July 26, 2023, we had entered into with Laidlaw &
Company (UK) Ltd. ("Laidlaw"), we issued to Laidlaw in connection with the 2023 PIPEs, warrants to purchase an aggregate
of 77,405 shares of common stock at an average exercise price of $7.85 per share. The Laidlaw warrants become exercisable six months
after the date of issuance and will expire five and one-half years following the date of issuance.

 On
November 8, 2023, the Company entered into a Securities Purchase Agreement with an institutional investor, pursuant to which the Company
sold in a registered direct offering (the "Offering"), (i) 699,693 shares (the "Shares") of the Company's
common stock, $0.001 par value per share (the "Common Stock"), (ii) Series A warrants (the "Series A Warrants")
to purchase up to 699,693 shares of Common Stock, and (iii) Series B Warrants (the "Series B Warrants", and together with
the Series A Warrants, the "Series Warrants") to purchase up to 699,693 shares of Common Stock, at a purchase price of $3.573
per Share and associated Series Warrants. The Series Warrants have an exercise price of $3.573 per share and will become exercisable
on the effective date of stockholder approval for the issuance of the shares upon exercise of the Series Warrants (or, if permitted by
the applicable rules and regulations of the Nasdaq Stock Market, upon payment by the holder of $1.25 per share in addition to the applicable
exercise price). The Series A Warrants will expire five years from the date of issuance and the Series B Warrants will expire eighteen
months from the date of issuance.

 H.C.
Wainwright & Co., LLC (the "Placement Agent") acted as the Company's exclusive placement agent in the Offering.
In connection with the Offering, the Company paid the Placement Agent a cash fee equal to seven percent (7.0%) of the aggregate gross
proceeds raised in the Offering and a management fee equal to one percent (1.0%) of the aggregate gross proceeds raised in the Offering.
The Company had also paid the Placement Agent $50,000 for non-accountable expenses and $15,950 for clearing fees. In addition, the Company
issued the Placement Agent or its designees, warrants to purchase up to 48,979 shares of Common Stock (equal to 7.0% of the aggregate
number of Shares sold in the Offering), which warrants have the same terms and conditions as the Series A Warrants, except that such
warrants have an exercise price of $4.466 per share, which represents 125% of the offering price per Share and accompanying Series Warrants
(the "Placement Agent Warrants", and together with Series Warrants, the "Warrants").

 The
Shares and the Warrants (and shares issuable upon exercise of the Warrants) were offered and sold by the Company pursuant to a shelf
registration statement on Form S-3 (File No. 333-251859) (the "Shelf Registration Statement"), previously filed with the
Securities and Exchange Commission (the "SEC") on December 31, 2020, and declared effective by the SEC on January 12, 2021,
and the base prospectus included therein. A final prospectus supplement relating to the Offering, dated November 8, 2023, and the accompanying
prospectus, has been filed with the SEC. The closing of the Offering occurred on November 13, 2023. The net proceeds to the Company from
the Offering, after deducting fees and expenses, were approximately $2.2 million.

 On
January 12, 2024, we entered into a securities purchase agreement with certain accredited and institutional investors, pursuant to which
we sold to the investors an aggregate of 260,720 shares of the Company's common stock and warrants to purchase up to 130,363 shares
of common stock, at a purchase price of $3.989 per share and a warrant to purchase one-half of a share. The warrants have an exercise
price of $3.364 per share, will become exercisable six months after the date of issuance and will expire five and one-half years following
the date of issuance. The gross proceeds from this offering were $1,040,000.

 ATM
Sales Agreements

 On
August 18, 2023, we entered into a Controlled Equity Offering Sales Agreement (the "Cantor Sales Agreement") with
Cantor Fitzgerald & Co. to act as our sales agent or principal ("Cantor"), with respect to the issuance and sale of up
to $30.0 million of our shares of common stock, from time to time in an at-the-market public offering.

 We
agreed to pay Cantor a commission of equal to 3.0% of the gross proceeds from the sale of the shares of common stock pursuant to the
Cantor Sales Agreement.

 From
August 22, 2023 through September 6, 2023, we sold 21,881 shares of its common stock through the Cantor Sales Agreement for net deficit
of $(899), after transactional costs of $120,430.

 We
terminated the Cantor Sales Agreement with Cantor, effective as of September 15, 2023.

 On
September 15, 2023, we entered into an At-The-Market Issuance Sales Agreement (the "Ascendiant Sales Agreement") with Ascendiant
Capital Markets, LLC, to act as our sales agent or principal ("Ascendiant"), with respect to the issuance and sale of up
to $30.0 million of the Company's shares of common stock, from time to time in an at-the-market public offering.

 We
agreed to pay Ascendiant a commission of equal to 3.0% of the gross proceeds from the sale of the shares of common stock pursuant to
the Ascendiant Sales Agreement.

 From
September 21, 2023 through September 25, 2023, we sold 28,911 shares of its common stock through the Ascendiant Sales Agreement for $60,876,
after transactional costs of $70,806.

 We
terminated the Ascendiant Sales Agreement with Ascendiant, effective as of November 6, 2023.

 Issuance
of debt

 On
March 7, 2024, we issued a promissory note to an investor and an affiliate (10% or more shareholder) for $500,000. We designated its
12% note due 2026, in accordance with exemptions from registration under the Securities Act of 1933, as amended (the "Securities
Act").

 The
note is due March 7, 2026. We promise to pay interest in cash on the unpaid principal amount of this note at a rate per annum equal to
twelve percent (12%), commencing to accrue on the date hereof and payable on the maturity date or earlier prepayment as provided therein.
The Note contains customary events of default.

 We
may prepay all or any portion of the principal amount of the Note at any time or from time to time without penalty.

 Twelve
Months Ended December 31, 2023, Compared to Twelve Months Ended December 31, 2022

 As
of December 31, 2023, we had a working capital deficit of $(4,054), comprised of cash of $190, accounts receivable of $24, employee advance
of $5, net investments in leases of $103 and prepaid expenses of $206, which was offset by $4,116 of accounts payable and accrued expenses,
customer deposits of $16, accrued dividends on preferred stock issuances of $101 and short-term lease liabilities of $349. For the twelve
months ended December 31, 2023, cash provided by financing activities totaled $17,332, comprised of proceeds from the sale of our common
stock of $15,301, proceeds from At-the-market sale of our common stock of $60 and proceeds from sale of subsidiary stock of $1,971. In
the comparable period in 2022, $8,283 was raised through the sale of our common stock, proceeds from At-the-market sale of our common
stock of $2,070 and proceeds of $218 from the exercise of warrants. At December 31, 2023, we had cash of $190 compared to $357 at December
31, 2022. Our cash is held in bank deposit accounts. At December 31, 2023 and 2022, we had no convertible debentures outstanding.

 Cash
used in operations for the twelve months ended December 31, 2023, and 2022 was $17,313 and $21,705, respectively, which represent cash
outlays for research and development and general and administrative expenses in such periods. The decrease in cash outlays principally
resulted reduction in cash operating expenditures in 2023 as compared with 2022.

 Cash
used in investing activities for the twelve months ended December 31, 2023, was $186, compared to $168 for the twelve months ended December
31, 2022. During the twelve months ended December 31, 2023, we purchased office furniture, manufacturing and testing equipment, computer
equipment and leasehold improvements. For the twelve months ended December 31, 2022, we incurred $168 on purchases of office furniture,
manufacturing equipment, computer equipment and leasehold improvements.

 Our
Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of
(a) 120% of the stated value of $1,000 or (b) the product of (I) the variable weighted average price of our common stock on the trading
day immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in
shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%. As of December 31,
2023, the aggregate stated value of our Series C Preferred Stock was $105,000. The triggering events include our being subject to a judgment
of greater than $100,000 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred
Stock occur, the holders of our Series C Preferred Stock may demand redemption, an obligation we may not have the ability to meet at
the time of such demand. We will be required to pay interest on any amounts remaining unpaid after the required redemption of our Series
C Preferred Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable law.

Accounting Pronouncements

 In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments ("ASU 2016-13"), which requires the measurement and recognition of expected credit losses for financial assets
held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the
use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment
and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as
a reduction in the amortized cost basis of the securities. ASU 2016-13 was effective for annual periods, and interim periods within those
annual periods, beginning after December 15, 2019. Early adoption was permitted, including adoption in any interim period.

 In
February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments
to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting
Standards Update No. 2016-02, Leases (Topic 842), which amended the effective date of the original pronouncement for smaller reporting
companies. ASC 2016-13 and its amendments were effective for annual and interim periods beginning after December 15, 2022 for smaller
reporting companies. The Company did not have a material impact on the Company's financial position, results of operations or cash
flows upon adoption of this new standard.

 In
December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about
our effective tax rate reconciliation as well as information on income taxes paid. The guidance will first be effective in our annual
disclosures for the year ending December 31, 2025, and should be applied on a prospective basis with the option to apply retrospectively.
Early adoption is permitted. The Company is in the process of assessing the impact of ASU 2023-09 on our disclosures.

 There
were other various updates recently issued, most of which represented technical corrections to the accounting literature or application
to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations
or cash flows.

 Other
Potential Risks

 The
Company takes some tax positions, including the reporting of stock-based compensation, that may not be accepted by the Internal Revenue
Service upon an examination, and we may be subject to penalties for underreporting of recipient's income. The result of any
such examination is uncertain, and any such penalties could be material to our financial position and results of operations given our
current limited cash and revenues.

 ITEM
7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 Not
applicable.

 ITEM
8 – FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 BIOSIG
TECHNOLOGIES, INC.

 CONSOLIDATED
FINANCIAL STATEMENTS

 TABLE
OF CONTENTS

 Report of Independent Registered Public Accounting Firm (PCAOB ID 688)

 Consolidated Balance Sheets as of December 31, 2023 and 2022

 Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022

 Consolidated Statement of Changes in Equity (Deficit) for the Years Ended December 31, 2023 and 2022

 Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022

 Notes to Consolidated Financial Statements

 F- 1

 REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 To
the Stockholders and Board of Directors of

Technologies, Inc.

 Opinion
on the Consolidated Financial Statements

 We
have audited the accompanying consolidated balance sheets of BioSig Technologies, Inc. (the "Company") as of December 31,
2023 and 2022, the related consolidated statements of operations, changes in equity (deficit) and cash flows for each of the two years
in the period ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In
our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023,
in conformity with accounting principles generally accepted in the United States of America.

 Explanatory
Paragraph – Going Concern

 The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more
fully described in Note 2, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and
sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's
plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.

 Basis
for Opinion

 These
financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.

 Critical
Audit Matters

 Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 /s/
Marcum LLP

 Marcum
LLP

 We
have served as the Company's auditor since 2020.

 Marlton,
New Jersey
April 16, 2024

 F- 2

 BIOSIG TECHNOLOGIES, INC.

 CONSOLIDATED BALANCE SHEETS

 (In Thousands, Except Par Value and Share Amounts)

 2023

 2022

 2023

 2022

 ASSETS

 Current assets:

 Cash

 $

 $

 Accounts receivable

 Employee advance

 -

 Inventory, short term

 -

 Net investment in leases, short term

 Prepaid expenses and vendor deposits

 Total current assets

 1,128

 Property and equipment, net

 Right-to-use assets, net

 Other assets:

 Inventory, long term

 -

 1,141

 Net investment in leases, long term

 Patents, net

 Other assets

 Total assets

 $
 1,798

 $
 4,110

 LIABILITIES AND EQUITY (DEFICIT)

 Current liabilities:

 Accounts payable and accrued expenses, including $ 30 and $ 120 to related parties as of December 31, 2023 and 2022, respectively

 $
 4,116

 $
 2,852

 Customer deposits

 -

 Deferred revenue, short term

 -

 Dividends payable

 Lease liability, short term

 Total current liabilities

 4,582

 3,261

 Lease liability, long term

 Total long-term liabilities

 Total liabilities

 4,685

 3,713

 Commitments and contingencies (Note 12)

 -

 -

 Series C 9% Convertible Preferred Stock, $ 0.001 par value, $ 1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $ 105 as of December 31, 2023 and 2022

 Equity (Deficit):

 Preferred stock, $ 0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. 105 shares of Series C outstanding as of December 31, 2023 and 2022 (see above)

 -

 -

 Common stock, $ 0.001 par value, authorized 200,000,000 shares, 9,040,043 and 5,505,068 issued and outstanding as of December 31, 2023 and 2022, respectively

 Additional paid in capital

 241,988

 216,282

 Accumulated deficit

 ( 245,015
)

 ( 215,974
)

 Total stockholders' equity (deficit) attributable to BioSig Technologies, Inc.

 ( 3,018
)

 Non-controlling interest

 ( 21
)

 Total equity (deficit)

 ( 2,992
)

 Total liabilities and equity (deficit)

 $
 1,798

 $
 4,110

 The
accompanying notes are an integral part of these Consolidated Financial Statements

 F- 3

 BIOSIG TECHNOLOGIES, INC.

 CONSOLIDATED STATEMENTS OF OPERATIONS

 (In Thousands, Except Par Value and Share Amounts)

 2023

 2022

 Year ended December 31,

 2023

 2022

 Revenue:

 $
 -

 $

 Service

 Total revenue

 Cost of revenue

 -

 Gross profit

 Operating expenses:

 Research and development

 5,092

 5,821

 General and administrative

 23,077

 21,380

 Depreciation and amortization

 Total operating expenses

 28,530

 27,494

 Loss from operations

 ( 28,512
)

 ( 27,265
)

 Other income (expense):

 Interest income, net

 Other income (expense), net:

 ( 187
)

 -

 Loss before income taxes

 ( 28,690
)

 ( 27,262
)

 Income taxes (benefit)

 -

 -

 Net loss

 ( 28,690
)

 ( 27,262
)

 Non-controlling interest

 ( 351
)

 Net loss attributable to BioSig Technologies, Inc.

 ( 29,041
)

 ( 27,052
)

 Preferred stock dividend

 ( 9
)

 ( 9
)

 Preferred stock deemed dividend

 -

 ( 210
)

 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 $
 ( 29,050
)

 $
 ( 27,271
)

 Net loss per common share, basic and diluted

 $
 ( 3.95
)

 $
 ( 6.33
)

 Weighted average number of common shares outstanding, basic and diluted

 7,351,794

 4,307,244

 The
accompanying notes are an integral part of these Consolidated Financial Statements

 F- 4

 BIOSIG TECHNOLOGIES, INC.

 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

 YEARS ENDED DECEMBER 31, 2023 AND 2022

 (In Thousands, Except Par Value and Share Amounts)

 Additional

 Common stock

 Paid in

 Accumulated

 Non-controlling

 Amount

 Capital

 Deficit

 Interest

 Total

 Balance, December 31, 2021

 3,600,701

 $

 $
 201,159

 $
 ( 188,922
)

 $

 $
 12,460

 Common stock issued for services

 193,000

 - *

 2,109

 -

 -

 2,109

 Sale of common stock and warrants, net transactional costs of $ 528

 1,265,795

 8,282

 -

 -

 8,283

 Sale of common stock under At-the-market offering, net of transaction expenses of $ 96

 308,491

 - *

 2,070

 -

 -

 2,070

 Common stock issued upon exercise of warrants at $ 2.50 per share

 87,300

 - *

 -

 -

 Common stock issued in settlement of accounts payable

 23,864

 - *

 -

 -

 Change in fair value of modified options

 -

 -

 -

 -

 Issuance of subsidiary stock in settlement of debt to parent

 -

 -

 ( 292
)

 -

 Stock based compensation

 25,917

 - *

 2,625

 -

 ( 322
)

 2,303

 Accretion of deemed preferred stock dividend

 -

 -

 -

 -

 Deemed preferred stock dividend

 -

 -

 ( 210
)

 -

 -

 ( 210
)

 Preferred stock dividend

 -

 -

 ( 9
)

 -

 -

 ( 9
)

 Net loss

 -

 -

 -

 ( 27,052
)

 ( 210
)

 ( 27,262
)

 Balance, December 31, 2022

 5,505,068

 216,282

 ( 215,974
)

 ( 21
)

 Balance

 5,505,068

 216,282

 ( 215,974
)

 ( 21
)

 Common stock for services

 882,463

 7,616

 -

 -

 7,617

 Common stock issued for services

 882,463

 7,616

 -

 -

 7,617

 Sale of common stock and warrants, net transactional costs of $ 1,067

 2,313,599

 15,298

 -

 -

 15,301

 Sale of common stock under At-the-market offering, net of transactional expenses of $ 192

 50,792

 - *

 -

 -

 Common stock issued in settlement of accounts payable

 8,800

 - *

 -

 -

 Common stock issued for exercise of warrants cashlessly

 4,360

 - *

 - *

 -

 -

 -

 Sale of subsidiary stock

 -

 -

 1,675

 -

 1,971

 Stock based compensation

 274,961

 - *

 -

 ( 600
)

 Common stock issued upon exercise of warrants

 87,300

 - *

 -

 -

 Sale of common stock under At-the-market offering

 50,792

 - *

 -

 -

 Sale of common stock and warrants

 2,313,599

 15,298

 -

 -

 15,301

 Preferred stock dividend

 -

 -

 ( 9
)

 -

 -

 ( 9
)

 Net loss

 -

 -

 -

 ( 29,041
)

 ( 28,690
)

 Balance, December 31, 2023

 9,040,043

 $

 $
 241,988

 $
 ( 245,015
)

 $

 $
 ( 2,992
)

 Balance

 9,040,043

 $

 $
 241,988

 $
 ( 245,015
)

 $

 $
 ( 2,992
)

 See the accompanying notes to the Consolidated Financial Statements

 *
 Less than $1

 F- 5

 BIOSIG TECHNOLOGIES, INC.

 CONSOLIDATED STATEMENTS OF CASH FLOWS

 (In Thousands, Except Par Value and Share Amounts)

 2023

 2022

 Year ended December 31,

 2023

 2022

 CASH FLOWS FROM OPERATING ACTIVITIES:

 Net loss

 $
 ( 28,690
)

 $
 ( 27,262
)

 Adjustments to reconcile net loss to cash used in operating activities:

 Depreciation and amortization

 Non-cash lease expense

 Non-cash inventory write-down

 1,976

 -

 Equity based compensation

 7,978

 4,412

 Change in fair value of modified options

 -

 Changes in operating assets and liabilities:

 Accounts receivable

 ( 15
)

 ( 9
)

 Lease receivables

 ( 220
)

 Employee advances

 ( 5
)

 -

 Inventory

 ( 498
)

 Prepaid expenses and other

 Deferred revenue

 ( 5
)

 ( 32
)

 Customer deposits

 -

 Accounts payable and accrued expenses

 1,370

 Operating lease liabilities

 ( 313
)

 ( 365
)

 Net cash used in operating activities

 ( 17,313
)

 ( 21,705
)

 CASH FLOWS FROM INVESTING ACTIVITIES:

 Purchase of property and equipment

 ( 186
)

 ( 168
)

 Net cash used in investing activity

 ( 186
)

 ( 168
)

 CASH FLOWS FROM FINANCING ACTIVITIES:

 Proceeds from sale of common stock and warrants, net of issuance costs

 15,301

 8,283

 Proceeds from sale of common stock under a At-the-market offering, net of issuance costs

 2,070

 Proceeds from sale of subsidiary stock to non-controlling interest, net of issuance costs

 1,971

 Proceeds from exercise of warrants

 -

 Net cash provided by financing activities

 17,332

 10,571

 Net decrease in cash and cash equivalents

 ( 167
)

 ( 11,302
)

 Cash, beginning of the period

 11,659

 Cash, end of the period

 $

 $

 Supplemental disclosures of cash flow information:

 Cash paid during the period for interest

 $

 $
 -

 Cash paid during the period for income taxes

 $
 -

 $
 -

 Noncash investing and financing activities:

 Common stock issued in settlement of debt

 $

 $

 Dividend payable on preferred stock charged to additional paid in capital

 $

 $

 Series C convertible preferred stock deemed dividend

 $
 -

 $

 Record right-to-use assets and related lease liability

 $
 -

 $

 The accompanying notes are an integral part of these Consolidated Financial Statements

 F- 6

 NOTE
1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

 Business
and organization

Technologies, Inc. was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated
in the state of Delaware in 2011. The Company is principally devoted to improving the standard care in electrophysiology with our PURE
EP System's enhanced signal acquisition, digital signal processing, and analysis during ablation of cardiac arrhythmias. The Company
has generated minimal revenue to date and consequently its operations are subject to all risks inherent in business enterprises in early
commercialization stage.

 On
November 7, 2018, the Company formed a subsidiary under the laws of the State of Delaware originally under the name of NeuroClear Technologies,
Inc. which was renamed to ViralClear Pharmaceuticals, Inc. ("ViralClear") in March 2020. The subsidiary was established to
pursue additional applications of the PURE EP signal processing technology outside of cardiac electrophysiology, and subsequently
in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that showed potential for the treatment of COVID-19.
Since late 2020, ViralClear has been realigned with its original objective of pursuing additional applications of the PURE EP
signal processing technology outside of cardiac electrophysiology.

 In
2019 and 2020, ViralClear sold an aggregate of 1,965,240 shares of its common stock to investors for net proceeds of $ 15.6 million and
issued an aggregate of 894,869 shares of its common stock in connection with acquiring assets and with know-how agreements. As of December
31, 2023 and 2022, the Company had a majority interest in ViralClear of 69.08 %.

 On
July 2, 2020, the Company formed an additional subsidiary, NeuroClear Technologies, Inc., a Delaware corporation, which was renamed to
BioSig AI Sciences, Inc. ("BioSig AI") on May 31, 2023. The subsidiary was established to pursue clinical needs of cardiac
and neurological disorders through recordings and analyses of action potentials. BioSig AI aims to contribute to the advancements of
AI-based diagnoses and therapies. In June and July 2023, BioSig AI sold an aggregate of 2,205,000 shares of its common stock for net
proceeds of $ 1,971,277 to fund initial operations. At December 31, 2023, the Company had a majority interest in BioSig AI of 84.5 % (see
Notes 9 and 11).

 On
January 28, 2024 and February 20, 2024, management of the Company commenced a workforce reduction intended to reduce significantly the
annual cash burn which was completed as of February 20, 2024. The workforce reduction consisted of the departure of sixteen employees,
effective as of January 31, 2024 and included the departure of John Sieckhaus, the Company's Chief Operating Officer, and Gray
Fleming, the Company's Chief Commercial Officer and twenty six employees effective February 20, 2024. The effect of the workforce
reductions has significantly reduced operations in the short-term.

 On
March 5, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq (the "Staff") stating that
the Company has not regained compliance with Listing Rule 5550(a)(2) because the Company's common stock did not meet the minimum
bid price of $ 1.00 per share required for continued listing on The Nasdaq Capital Market, and the Company is not eligible for a second
180 day cure period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $ 5,000,000 minimum stockholders' equity
initial listing requirement for The Nasdaq Capital Market, and that accordingly, Nasdaq would delist the Company's common stock
unless the Company requested an appeal of this determination. On March 11, 2024, the Company submitted a request for a hearing before
the Nasdaq Hearings Panel to appeal the Staff's delisting determination.

 On
March 12, 2024, the Company received a letter from the Staff stating that based upon the Staff's review of the Company and pursuant
to Listing Rule 5101, the Staff believes that the Company no longer has an operating business and is a "public shell," and
that the continued listing of its securities is no longer warranted, in view of work force reductions and resignations of members of
the board of directors and officers (see below).

 The
letter further stated that the Company no longer meets the requirement of Rule 5550(b)(2) to maintain a minimum Market Value of Listed
Securities of $ 35 million, if none of the other standards set forth in Rule 5550(b) is met.

 F- 7

 The
Staff stated that the foregoing matters serve as an additional basis for delisting the Company's common stock from The Nasdaq Stock
Market, and that the Hearings Panel will consider this matter in rendering a determination regarding the Company's continued listing

 The
Company intends also to appeal the foregoing determinations. The requested hearing before the Hearings Panel will be held on May 7, 2024.

 Delisting
from Nasdaq Stock Market could negatively impact the Company's ability to raise additional financing to fund future operations.

 NOTE
2 – GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS

 As
of December 31, 2023, the Company had cash of $ 0.2 million and working capital deficit of $ 4.1 million. During the year ended December
31, 2023, the Company used net cash in operating activities of $ 17.3 million. These balances create a liquidity concern, which in turn raises substantial
doubt about the Company's ability to continue as a going concern.

 The
Company's primary source of operating funds since inception has been cash proceeds from sale of common and preferred stock. The
Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for
the foreseeable future.

 The
Company's plans include the continued commercialization of the PURE EP System and other applications of our core technology
and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. The
Company's strategic shift to potentially hiring a team of an additional 4-6 persons to execute a business development strategy of finding
partners for the commercialization of PURE EP, develop new products in the field of Pulse Field Ablation and to continue to
integrate PURE EP into today's lab equipment will allow the Company to significantly reduce operating expenses.

 The
Company will require additional financing to fund future operations. Further, although the Company began commercial operations, there
is no assurance that the Company will be able to generate sufficient cash flow to fund operations. In addition, there can be no assurance
that the Company's continuing research and development will be successfully completed or that any additional products will be commercially
viable.

 Accordingly,
the accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of
the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying
amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable
or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this
uncertainty.

 NOTE
3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 A
summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows.

 Reverse
Stock Split

 On
January 31, 2024, the Company filed a Reverse Stock Split Amendment with the Secretary of State of the State of Delaware, effective February
2, 2024. Pursuant to the Reverse Stock Split Amendment, the Company effected a 1-for-10 reverse stock split of its issued and outstanding
shares of common stock. The Company accounted for the reverse stock split on a retrospective basis pursuant to ASC 260, Earnings Per
Share. All authorized, issued and outstanding common stock, common stock warrants, stock option awards, exercise prices and per share
data have been adjusted in these consolidated financial statements, on a retroactive basis, to reflect the reverse stock split for all
periods presented. Authorized common and preferred stock was not adjusted because of the reverse stock split.

 Principals
of consolidation

 The
accompanying consolidated financial statements include the accounts of BioSig Technologies, Inc. and its majority owned subsidiary, ViralClear
Pharmaceuticals, Inc., and wholly owned subsidiary, NeuroClear Technologies, Inc. herein collectively referred to as the "Company"
or "BioSig". All significant intercompany accounts and transactions have been eliminated in consolidation.

 F- 8

 Use
of Estimates

 The
preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the
recoverability and useful lives of long-lived assets, stock-based compensation and the valuation allowance related to deferred tax assets.
Actual results may differ from these estimates.

 Revenue
Recognition

 The
Company derives its revenue primarily from the sale of its medical device, the PURE EP System, and well as related support and
maintenance services and software upgrades in connection with the system.

 The
Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 842, Leases ("ASC 842") for
lease components and ASC 606, Revenue from Contracts with Customers ("ASC 606") for non-lease components. For medical
device sales, the Company recognize revenue under ASC 606.

 The
core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an
amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

 Under
ASC 606, the Company determines revenue recognition through the following five steps:

 Identify
 the contract with the customer;

 Identify
 the performance obligations in the contract;

 Determine
 the transaction price;

 Allocate
 the transaction price to the performance obligation in the contract; and

 Recognize
 revenue when, or as, the performance obligations are satisfied.

 Performance
obligations are the units of accounting for revenue recognition and generally represent the distinct goods or services that are promised
to the customer. If the Company determines that it has not satisfied a performance obligation, it will defer recognition of the revenue
until the performance obligation is deemed to be satisfied. Once the PURE EP Platform is delivered, installed, and accepted by the customer,
our performance obligation is recognized. Support, maintenance, and software upgrades are performance obligations over a defined period
and are recognized ratably over the contractual service period. Customers typically purchase these services with the initial sale of
the PURE EP Platform and do not have the right to terminate their contracts unless we fail to perform material obligations.

 The
Company may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a
package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance
of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions
reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related
to those arrangements.

 The
Company records accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration
as provided under the contractual arrangement. Unbilled receivables, if any, include amounts related to the Company's contractual
right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance
of performance under the contract. Our unbilled receivables and deferred revenue are reported on an individual contract basis at the
end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill
the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue.

 F- 9

 The
Company's unconditional right to consideration for goods and services transferred to the customer is included in accounts receivable,
net (if any) in the Company's consolidated balance sheet.

 In
2022, the Company entered two leases for our PURE EP Platform at a rate of $ 4,333 per month each. The term of the leases is for 30 months
with an option provided to extend for an additional one year. The leases also have an option to purchase at the end of the lease at the
fair market value. The Company accounts for the leases in accordance with ASC 842 and ASC 606.

 The
Company determined the leases meet the criteria of a sales-type lease whereby the present value of the future expected revenue (less
the present value of the estimated unguaranteed residual value), cost of sales and profit and loss are recognized at the lease inception.
Non-lease components are recognized under ASC 606. The discount rate utilized was the contract explicit rate of 2 % per annum. (See Note
6 – Lease Receivables).

 A
reconciliation of contract liabilities with customers for the year ended December 31, 2023 and 2022, are presented below:

OF RECONCILIATION OF CONTRACT LIABILITIES WITH CUSTOMERS

 Year
ended December 31, 2023:

 2022

 Consideration Received

 Recognized in Revenue

 2023

 Service revenue

 $

 $

 $
 ( 18
)

 $
 -

 Year
ended December 31, 2022:

 2021

 Consideration Received

 Recognized in Revenue

 2022

 Product revenue

 $
 -

 $

 $
 ( 254
)

 $
 -

 Service revenue

 -

 ( 32
)

 Total

 $

 $

 $
 ( 286
)

 $

 The
table below summarizes our deferred revenue as of December 31, 2023 and 2022:

OF DEFERRED REVENUE

 2023

 2022

 Deferred revenue-current

 $
 -

 $

 Deferred revenue-noncurrent

 -

 -

 Total deferred revenue

 $
 -

 $

 The
Company had three customers which accounts for 48.1 %, 29.7 % and 22.2 % of our revenue in the year ended December 31, 2023 and three customers
which accounts for approximately 44.4 %, 44.4 % and 11.2 % of our revenue in the year ended December 31, 2022.

 The
Company had three customers which accounts for approximately 62.3 %, 19.6 % and 18.0 % of our outstanding accounts receivable at December
31, 2023 and at December 31, 2022, the Company had two customers representing 52.2 % and 47.8 % of the outstanding accounts receivable.

 F- 10

 The
Company utilized one contract manufacturer for the manufacture and supply of the PURE EP Platform for the year ended December 31, 2023
and 2022.

 Deferred
Costs (Contract acquisition costs)

 The
Company capitalizes initial and renewal sales commissions in the period the commission is earned, which generally occurs when a customer
contract is obtained, and amortize deferred commission costs on a straight-line basis over the expected period of benefit, which we have
deemed to be the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period
of related deferred commission costs would have been one year or less.

 Cost
of Revenue

 Cost
of revenue consists primarily of the delivered cost of our medical device(s) sold or leased under a sales-type lease.

 Allowance
for Doubtful Accounts

 The
Company adjusts accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for doubtful
accounts for estimated losses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based
upon historical collection experience, financial condition of the customer and the status of any open or unresolved issues with the customer
preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables.
The allowance for doubtful accounts was $ 0 at December 31, 2023 and 2022. The Company believes that its reserve is adequate, however
results may differ in future periods. For the year ended December 31, 2023 and 2022, bad debt expense totaled $ 0.

 Concentrations
of Credit Risk

 Financial
instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and
cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts
may be in excess of the FDIC insurance limit. At December 31, 2023 and 2022, deposits in excess of FDIC limits were nil and $ 0.05 million,
respectively.

 Fair
Value of Financial Instruments

 Accounting
Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10") requires disclosure of the fair value of certain
financial instruments. The carrying value of cash, accounts payable and accrued liabilities as reflected in the balance sheets, approximate
fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and
equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant
for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial
assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has
been disclosed.

 The
Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures ("ASC 820-10")
and ASC 825-10, which permits entities to choose to measure many financial instruments and certain other items at fair value.

 Inventory

 The
inventory is comprised of finished goods available for sale and are stated at the lower of cost or net realizable value using specific
identification method for serial numbered inventory and first-in, first-out method for all other inventory for valuation. The inventory
at December 31, 2023 and 2022 was comprised of the following:

OF INVENTORY

 2023

 2022

 Finished goods

 $
 1,976

 $
 1,477

 Less: Inventory reserve

 ( 1,976
)

 -

 Finished goods, net

 -

 1,477

 Finished goods-short term

 -

 Finished goods-long term

 $
 -

 $
 1,141

 F- 11

the year ended December 31, 2023, the Company recorded an allowance for inventory for $ 1,976 due to age of underlying product.

 Prepaid
Expenses and Vendor Deposits

 Prepaid
expenses and vendor deposits are comprised of prepaid insurance, operating expenses and other prepayments.

 Leases
(lessee)

 The
Company determines if a contractual arrangement is a lease at inception. Operating leases are included in operating lease right-of-use
("ROU") assets, current operating lease liabilities, and noncurrent operating lease liabilities on the Company's consolidated
balance sheet. The Company evaluates and classifies leases as operating or finance leases for financial reporting purposes. The classification
evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the
Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonably
certain and failure to exercise such option which result in an economic penalty. All the Company's real estate leases are classified
as operating leases. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities
represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are
recognized at the commencement date of the lease based on the present value of lease payments over the lease term.

 The
lease payments included in the present value are fixed lease payments. As most of the Company's leases do not provide an implicit
rate, the Company estimates its collateralized incremental borrowing rate, based on information available at the commencement date, in
determining the present value of lease payments. The Company applies the portfolio approach in applying discount rates to its classes
of leases. The operating lease ROU assets include any payments made before the commencement date. Lease expense for lease payments is
recognized on a straight-line basis over the lease term. The Company does not currently have subleases. The Company does not currently
have residual value guarantees or restrictive covenants in its leases.

 Leases
(lessor)

 The
Company classifies contractual lease arrangements entered as a lessor as a sales-type, direct financing or operating lease as described
in ASC 842-Leases. For sales-type leases, the Company derecognizes the leased asset and recognizes the lease investment on the balance
sheet.

and Equipment

and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When
retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the
net difference less any amount realized from disposition is reflected in earnings.

 F- 12

 Other
Assets:

 Other
assets are comprised of the following:

OF OTHER ASSETS

 2023

 2022

 Security deposits

 Trademarks

 Total other assets

 $

 $

 Impairment
of Long-lived Assets

 The
Company recognizes an impairment of long-lived assets used in operations, other than goodwill, when events or circumstances indicate
that the asset might be impaired and the estimated undiscounted cash flows to be generated by those assets over their remaining lives
are less than the carrying amount of those items. The net carrying value of assets not recoverable is reduced to fair value, which is
typically calculated using the discounted cash flow method. The Company did not recognize and record any impairments of long-lived assets
used in operations during the year ended December 31, 2023 and 2022.

and Development Costs

 The
Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research
and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred.
Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed
when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs
related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses
of $ 5.1 million and $ 5.8 million for the year ended December 31, 2023 and 2022, respectively.

 Net
Income (loss) Per Common Share

 The
Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share ("ASC 260-10").
Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the period. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of
all potentially dilutive securities into common stock using the "treasury stock" and/or "if converted" methods
as applicable.

 The
computation of basic and diluted loss per share as of December 31, 2023 and 2022 excludes potentially dilutive securities when their
inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the
period.

 Potentially
dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

 2023

 2022

 Series C convertible preferred stock

 65,711

 65,562

 Options to purchase common stock

 603,229

 455,548

 Warrants to purchase common stock

 2,748,371

 421,711

 Restricted stock units to acquire common stock

 163,250

 23,958

 Totals

 3,580,561

 966,779

 Stock
Based Compensation

 The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as
measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided
in exchange for the award, usually the vesting period.

 F- 13

 Income
Taxes

 The
Company follows Accounting Standards Codification subtopic 740-10, Income Taxes ("ASC 740-10") for recording the provision
for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income
tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to
be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period.
If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized,
a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future
changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income
taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes
in different periods.

 Patents,
Net

 The
Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other
professional fees associated with the application. Patent costs incurred prior to the Company's U.S. Food and Drug Administration
("FDA") 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon
first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser
of the legal patent term or the estimated life of the product of 20 years. During the years ended December 31, 2023 and 2022, the Company
recorded amortization of $ 19,106 and $ 19,006 to current period operations, respectively.

 Warranty

 The
Company generally warrants its products to be free from material defects and to conform to material specifications for a period of up
to two (2) years. Warranty expense is estimated based primarily on historical experience and is reflected in the consolidated financial
statements.

 Segment
Information

 Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance.
The information disclosed herein represents all of the material financial information related to the Company's principal operating
segments. (See Note 13 – Segment Reporting).

 Non-controlling
Interest

 The
Company's non-controlling interest represents the non-controlling shareholders ownership interests related to the
Company's subsidiaries, ViralClear and BioSig AI. The Company reports its non-controlling interest in subsidiaries as a
separate component of equity in the unaudited condensed consolidated balance sheets and reports both net loss attributable to the
non-controlling interest and net loss attributable to the Company's common shareholders on the face of the unaudited condensed
consolidated statements of operations. The Company's equity interest in ViralClear and BioSig AI is 69.08 %
and 84.48 %;
and the non-controlling stockholders' interest is 30.92 %
and 15.52 %,
respectively as of December 31, 2023 and December 31, 2022. This is reflected in the consolidated statements of changes in equity.

 Warrants

 The
Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480,
Distinguishing Liabilities from Equity (ASC 480), and ASC 815, Derivatives and Hedging (ASC 815), depending on the specific terms of
the warrant agreement.

 F- 14

Accounting Pronouncements

 In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments ("ASU 2016-13"), which requires the measurement and recognition of expected credit losses for financial assets
held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the
use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment
and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as
a reduction in the amortized cost basis of the securities. ASU 2016-13 was effective for annual periods, and interim periods within those
annual periods, beginning after December 15, 2019. On January 1, 2023, the Company adopted ASU 2016-13. The adoption did not have a material
impact on the Company's financial position, results of operations or cash flows.

 In
December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about
our effective tax rate reconciliation as well as information on income taxes paid. The guidance will first be effective in our annual
disclosures for the year ending December 31, 2025, and should be applied on a prospective basis with the option to apply retrospectively.
Early adoption is permitted. The Company is in the process of assessing the impact of ASU 2023-09 on our disclosures.

 There
were various updates recently issued, most of which represented technical corrections to the accounting literature or application to
specific industries and are not expected to a have a material impact on the Company's financial position, results of operations
or cash flows.

 NOTE
4 – PROPERTY AND EQUIPMENT

and equipment as of December 31, 2023 and 2022 is summarized as follows:

OF PROPERTY AND EQUIPMENT

 2023

 2022

 Computer equipment

 $

 $

 Furniture and fixtures

 Manufacturing equipment

 Testing/Demo equipment

 Leasehold improvements

 Total

 1,452

 1,266

 Less accumulated depreciation

 ( 943
)

 ( 601
)

 Property and equipment, net

 $

 $

and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. Leasehold
improvements are depreciated over the related expected lease term. When retired or otherwise disposed, the related carrying value and
accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is
reflected in earnings.

 Depreciation
expenses were $ 342,028 and $ 273,915 for the year ended December 31, 2023 and 2022, respectively.

 NOTE
5 – RIGHT TO USE ASSETS AND LEASE LIABILITY

 As
of December 31, 2023 and 2022, the Company had outstanding two leases with aggregate payments of $ 29,995 and $ 28,951 per month, respectively,
expiring through July 31, 2025.

 Right
to use assets is summarized below:

 SCHEDULE OF RIGHT TO USE ASSETS

 2023

 2022

 Right to use asset

 $

 $

 Less accumulated amortization

 ( 583
)

 ( 290
)

 Right to use assets, net

 $

 $

 F- 15

the years ended December 31, 2023 and 2022, the Company recorded $ 378,263 and $ 438,129 as lease expense to current period operations,
respectively.

 Lease
liability is summarized below:

 SCHEDULE OF LEASE LIABILITY

 2023

 2022

 Total lease liability

 $

 $

 Less: short term portion

 ( 349
)

 ( 313
)

 Long term portion

 $

 $

 Maturity
analysis under these lease agreements are as follows (000's):

 SCHEDULE OF MATURITY ANALYSIS UNDER LEASE AGREEMENTS

 Year ended December 31, 2024

 Year ended December 31, 2025

 Total

 Less: Present value discount

 ( 24
)

 Lease liability

 $

 Lease
expense for the year ended December 31, 2023 and 2022 was comprised of the following:

 SCHEDULE OF LEASE LIABILITY

 2023

 2022

 Operating lease expense

 $

 $

 Short-term lease expense

 Variable lease expense

 Total

 $

 $

 NOTE
6 – LEASE RECEIVABLES

 In
2022, the Company entered into two leases for our PURE EP Platform at a rate of $ 4,333 per month each. The term of the leases is for
 30 months with an option provided to extend for an additional one year. The leases also have an option to purchase at the end of the
lease at the fair market value.

 The
Company determined the leases meet the criteria of a sales-type lease whereby the present value of the future expected revenue (less
the present value of the estimated unguaranteed residual value), cost of sales and profit and loss are recognized at the lease inception.
The discount rate utilized was the contract explicit rate of 2 % per annum. The present value of the unguaranteed residual assets of $ 4
are included in net investment in leases in the balance sheet.

 A
reconciliation of lease receivables with customers for the year ended December 31, 2023 and 2022 are presented below:

OF RECONCILIATION OF LEASE RECEIVABLES WITH CUSTOMERS

 Year
ended December 31, 2023:

 Recognized in Revenue

 Invoiced to Customer

 Interest Earned

 Unguaranteed
 Residual
 Assets

 2023

 Contract asset

 $

 $
 -

 $
 ( 100
)

 $

 $

 $

 Less current portion

 ( 101
)

 -

 ( 2
)

 -

 -

 ( 103
)

 Noncurrent portion

 $

 $
 -

 $
 ( 102
)

 $

 $

 F- 16

 Year
ended December 31, 2022:

 Balance
 at

 December
 31, 2021

 Recognized
 in Revenue

 Invoiced
 to Customer

 Interest
 Earned

 Unguaranteed

 Residual

 Assets

 Balance
 at

 December
 31,

 2022

 Contract
 asset

 $

 -

 $

 $

 ( 39

)

 $

 $

 $

 Less
 current portion

 -

 -

 -

 -

 -

 ( 120

)

 Noncurrent
 portion

 $

 -

 $

 $

 ( 39

)

 $

 $

 Future
cash flows under this lease agreement are as follows (000's):

 SCHEDULE OF FUTURE CASH FLOWS UNDER LEASE AGREEMENT

 Year ended December 31, 2024

 Year ended December 31, 2025

 Present value of unguaranteed residual assets

 Total

 Less: Present value discount

 ( 1
)

 Net investment in leases

 $

 NOTE
7 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 Accounts
payable and accrued expenses at December 31, 2023 and 2022 consist of the following:

 SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE

 2023

 2022

 Accrued accounting and legal

 $
 1,277

 $

 Accrued reimbursements and travel

 Accrued consulting

 Accrued research and development expenses

 Accrued marketing

 Accrued office and other

 Accrued payroll

 Accrued settlement related to arbitration

 -

 Accounts
 payable and accrued expenses

 $
 4,116

 $
 2,852

 NOTE
8 – SERIES C 9% CONVERTIBLE PREFERRED STOCK

 Series
C 9% Convertible Preferred Stock

 On
January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the
"Series C Preferred Stock").

 The
Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $ 1,000 plus any accrued
and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9 % per annum of the stated value
of $ 1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of the Series C Preferred Stock
vote together with the holders of our common stock on an as-converted basis but may not vote the Series C Preferred Stock in excess of
the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99 % of our then outstanding
shares of common stock following such conversion or exercise, which may be increased to up to 9.99 % of our then outstanding shares of
common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined
on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when
calculating the limitation for a different holder.

 F- 17

 As
a result of an amendment to the conversion price of our Series C Preferred Stock, the conversion price effective as of December 31, 2020
was $ 3.75 per share, subject to certain reset provisions. In 2021, the conversion price was reset from $ 3.75 per share to $ 2.27 per share
and in 2022 reset to $ 0.25 per share. As such, the Company recorded a noncash deemed dividend of $ 209,682 during the year ended December
31, 2022.

 The
Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of
(a) 120% of the stated value of $1,000 or (b) the product of (I) the variable weighted average price of our common stock on the trading
day immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in
shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%. As of December 31,
2023 and 2022, the aggregate stated value of our Series C Preferred Stock was $ 105,000. The triggering events include our being subject
to a judgment of greater than $ 100,000 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our
Series C Preferred Stock occur, the holders of our Series C Preferred Stock may demand redemption, an obligation the Company may not
have the ability to meet at the time of such demand. The Company will be required to pay interest on any amounts remaining unpaid after
the required redemption of our Series C Preferred Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted
by applicable law. Accordingly, the Company has classified the Series C Preferred Stock as a mezzanine obligation in the accompanying
consolidated balance sheets.

 Series
C Preferred Stock issued and outstanding totaled 105 as of December 31, 2023 and 2022. As of December 31, 2023 and 2022, the Company
has accrued $ 100,567 and $ 91,117 dividends payable on the Series C Preferred Stock.

 NOTE
9 – STOCKHOLDER EQUITY

 Preferred
stock

 The
Company is authorized to issue 1,000,000 shares of $ 0.001 par value preferred stock. As of December 31, 2023 and 2022, the Company has
designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock,
 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E Preferred Stock and 200,000 shares of Series F Preferred Stock. As
of December 31, 2023, and 2022, there were no outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock.

 Common
stock

 On
January 31, 2024, the Company filed a Reverse Stock Split Amendment with the Secretary of State of the State of Delaware, effective February
2, 2024. Pursuant to the Reverse Stock Split Amendment, the Company effected a 1-for-10 reverse stock split of its issued and outstanding
shares of common stock. The Company accounted for the reverse stock split on a retrospective basis pursuant to ASC 260, Earnings Per
Share. All authorized, issued and outstanding common stock, common stock warrants, stock option awards, exercise prices and per share
data have been adjusted in these consolidated financial statements, on a retroactive basis, to reflect the reverse stock split for all
periods presented. Authorized common and preferred stock was not adjusted because of the reverse stock split.

 The
Company is authorized to issue 200,000,000 shares of $ 0.001 par value common stock. As of December 31, 2023 and 2022, the Company had
 9,040,043 and 5,505,068 shares issued and outstanding, respectively.

 2022:

the year ended December 31, 2022, the Company issued 193,000 shares of common stock for services at a fair value of $ 2,108,500.

the year ended December 31, 2022, the Company issued an aggregate of 25,917 shares of its common stock for vested restricted stock units.

 F- 18

the year ended December 31, 2022, the Company issued an aggregate of 23,864 shares of its common stock in settlement of outstanding accounts
payable of $ 105,000.

 On
November 3, 2022, the Company reduced the exercise price of the March 21, 2022 issued warrants (see below) from an exercise price of
$ 14.00 per share to $ 2.50 per share from November 4, 2022 through November 10, 2022. The Company issued an aggregate of 87,300 shares
of Common Stock for warrants exercised for a total of $ 218,250.

 At
December 31, 2022, the Company accrued 237,000 obligated, but unissued shares of common stock for services at a fair value of $ 1,060,740.

 Sale
of common stock

 On
March 21, 2022, the Company entered into a securities purchase agreement with several institutional and accredited investors, pursuant
to which the Company sold in a registered direct offering an aggregate of 261,313 shares of the Company's common stock, at an offering
price of $ 11.50 per share and warrants to purchase up to 261,313 shares of common stock at an exercise price of $ 14.00 per share, that
are exercisable six months after the date of issuance and will expire three and one-half years following the date of issuance, for gross
proceeds of approximately $ 3,005,000, net of expenses of approximately $ 5,000.

 On
June 24, 2022, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Laidlaw & Company
(UK) Ltd. (the "Underwriter"), which was amended and restated on June 28, 2022 (the "Amended and Restated Underwriting
Agreement"), relating to a best-efforts public offering (the "June 2022 Offering") of 434,168 shares of the Company's
common stock. The public offering price of the common stock was $ 7.50 per share. After the underwriting discounts, which includes a reduced
discount with respect to certain Company-introduced investors, and offering expenses, the Company received net proceeds from the offering
of approximately $ 2,818,000.

to the Amended and Restated Underwriting Agreement, the Company issued to the Underwriter, or its designees warrants to purchase up to
 an aggregate 21,709 shares of common stock, or 5% of the number of common stock sold in the offering.

 On
November 18, 2022, the Company entered into a Securities Purchase Agreement with certain accredited investors pursuant to which the Company
sold to the investors an aggregate of 354,152 shares (the "Shares") of the Company's common stock at a purchase price
of $ 4.10 per share, in exchange for aggregate consideration of $ 1,411,775, net of expenses of $ 40,225.

 On
December 21, 2022, the Company entered into a Securities Purchase Agreement with certain institutional and accredited investors pursuant
to which the Company sold to the investors an aggregate of 216,162 shares of the Company's common stock at a purchase price of
$ 5.10 per share, and warrants to purchase up to 108,081 shares of common stock at an exercise price of $ 4.50 per share, that are exercisable
 six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate
consideration of $ 1,050,960, net of expenses of $ 47,132.

 ATM
Sales Agreement

 On
May 17, 2022, the Company entered into an ATM Sales Agreement (the "Sales Agreement") with Virtu Americas LLC to act as the
Company's sales agent or principal ("Agent"), with respect to the issuance and sale of up to $ 10.0 million of the Company's
shares of common stock, from time to time in an at-the-market public offering.

 The
Company will pay Agent a commission of up to 2.5 % of the gross proceeds from the sale of the common stock pursuant to the Sales Agreement.

 From
May 18, 2022 through November 29, 2022, the Company sold 308,491 shares of its common stock through the Sales Agreement for net proceeds
of $ 2,069,582, after transactional costs of $ 121,926.

 F- 19

 On
November 30, 2022, the Company delivered written notice to the Agent to terminate the Sales Agreement, effective December 1, 2022 pursuant
to Section 13(b) of the Sales Agreement. The Company is not subject to any termination penalties related to the termination of the Sales
Agreement.

 2023:

the year ended December 31, 2023, the Company issued an aggregate of 882,463 shares of common stock for services at a fair value of $ 7,617,242,
of which 237,000 common shares at a fair value of $ 1,060,740 was recognized as stock based compensation during the year ended December
31, 2022.

the year ended December 31, 2023, the Company issued an aggregate of 8,800 shares of common stock in settlement of 2022 board fees at
a fair value of $ 104,720.

the year ended December 31, 2023, the Company issued an aggregate of 37,961 shares of common stock for vested restricted stock units.

 At
December 31, 2023, the Company accrued board fees of $ 230,000 as stock based compensation.

sales:

Technologies, Inc.:

 In
2023, the Company entered into multiple Securities Purchase Agreements with certain institutional and accredited investors, pursuant
to which the Company sold to the investors an aggregate of 1,613,906 shares of common stock at an average purchase price of $ 8.7571
per share, and warrants to purchase up to an aggregate of 806,981 shares of common stock at an average exercise price of $ 8.1324 per
share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date
of issuance, in exchange for aggregate consideration of $ 13,140,441, net of transactional expenses of $ 727,333.44 (the "2023 PIPEs").

to certain engagement agreements, dated October 11, 2022, February 24, 2023 and July 26, 2023, the Company had entered into with Laidlaw
& Company (UK) Ltd. ("Laidlaw"), the Company issued to Laidlaw in connection with the 2023 PIPEs, warrants to purchase
an aggregate of 77,405 shares of common stock at an average exercise price of $ 7.85 per share. The Laidlaw warrants become exercisable
 six months after the date of issuance and will expire five and one-half years following the date of issuance.

 On
November 8, 2023, the Company entered into a Securities Purchase Agreement with an institutional investor, pursuant to which the Company
sold in a registered direct offering (the "Offering"), (i) 699,693 shares (the "Shares") of the Company's
common stock, $ 0.001 par value per share (the "Common Stock"), (ii) Series A warrants (the "Series A Warrants")
to purchase up to 699,693 shares of Common Stock, and (iii) Series B Warrants (the "Series B Warrants", and together with
the Series A Warrants, the "Series Warrants") to purchase up to 699,693 shares of Common Stock, at a purchase price of $ 3.573
per Share and associated Series Warrants. The Series Warrants have an exercise price of $ 3.573 per share and will become exercisable
on the effective date of stockholder approval for the issuance of the shares upon exercise of the Series Warrants (or, if permitted by
the applicable rules and regulations of the Nasdaq Stock Market, upon payment by the holder of $ 1.25 per share in addition to the applicable
exercise price). The Series A Warrants will expire five years from the date of issuance and the Series B Warrants will expire eighteen
months from the date of issuance.

 H.C.
Wainwright & Co., LLC (the "Placement Agent") acted as the Company's exclusive placement agent in the Offering.
In connection with the Offering, the Company paid the Placement Agent a cash fee equal to seven percent ( 7.0 %) of the aggregate gross
proceeds raised in the Offering and a management fee equal to one percent ( 1.0 %) of the aggregate gross proceeds raised in the Offering.
The Company had also paid the Placement Agent $ 50,000 for non-accountable expenses and $ 15,950 for clearing fees. In addition, the Company
issued the Placement Agent or its designees, warrants to purchase up to 48,979 shares of Common Stock (equal to 7.0 % of the aggregate
number of Shares sold in the Offering), which warrants have the same terms and conditions as the Series A Warrants, except that such
warrants have an exercise price of $ 4.466 per share, which represents 125 % of the offering price per Share and accompanying Series Warrants
(the "Placement Agent Warrants", and together with Series Warrants, the "Warrants").

 The
Shares and the Warrants (and shares issuable upon exercise of the Warrants) were offered and sold by the Company pursuant to a shelf
registration statement on Form S-3 (File No. 333-251859) (the "Shelf Registration Statement"), previously filed with the
Securities and Exchange Commission (the "SEC") on December 31, 2020, and declared effective by the SEC on January 12, 2021,
and the base prospectus included therein. A final prospectus supplement relating to the Offering, dated November 8, 2023, and the accompanying
prospectus, has been filed with the SEC. The closing of the Offering occurred on November 13, 2023. The net proceeds to the Company from
the Offering, after deducting fees and expenses, were approximately $ 2.2 million.

 F- 20

 ATM
Sales Agreements

 On
August 18, 2023, the Company entered into a Controlled Equity Offering Sales Agreement (the "Cantor Sales Agreement")
with Cantor Fitzgerald & Co. to act as the Company's sales agent or principal ("Cantor"), with respect to the issuance
and sale of up to $ 30.0 million of the Company's shares of common stock, from time to time in an at-the-market public offering.

 The
Company agreed to pay Cantor a commission of equal to 3.0 % of the gross proceeds from the sale of the shares of common stock pursuant
to the Cantor Sales Agreement.

 From
August 22, 2023 through September 6, 2023, the Company sold 21,881 shares of its common stock through the Cantor Sales Agreement for
net deficit of $( 899), after transactional costs of $ 120,430.

 The
Company terminated the Cantor Sales Agreement with Cantor, effective as of September 15, 2023.

 On
September 15, 2023, the Company entered into an At-The-Market Issuance Sales Agreement (the "Ascendiant Sales Agreement")
with Ascendiant Capital Markets, LLC, to act as the Company's sales agent or principal ("Ascendiant"), with respect
to the issuance and sale of up to $ 30.0 million of the Company's shares of common stock, from time to time in an at-the-market
public offering.

 The
Company agreed to pay Ascendiant a commission of equal to 3.0 % of the gross proceeds from the sale of the shares of common stock pursuant
to the Ascendiant Sales Agreement.

 From
September 21, 2023 through September 25, 2023, the Company sold 28,911 shares of its common stock through the Ascendiant Sales Agreement
for $ 60,876, after transactional costs of $ 70,806.

 The
Company terminated the Ascendiant Sales Agreement with Ascendiant, effective as of November 6, 2023.

AI Sciences, Inc.:

 In
June and July 2023, BioSig AI sold an aggregate of 2,205,000 shares of its common stock for net proceeds of $ 1,971,277 ($ 1.00 per share).
Prior to such sale, BioSig AI was a wholly owned subsidiary. At December 31, 2023, BioSig had a majority interest in BioSig AI of 84.5 %.

to an engagement agreement, dated June 13, 2023, as amended on July 19, 2023, BioSig AI entered into with Laidlaw, BioSig AI issued to
Laidlaw warrants to purchase an aggregate of 130,500 shares of its common stock at an exercise price of $ 1.00 per share. The Laidlaw
warrants become exercisable immediately and will expire five years following the date of issuance.

 NOTE
10 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

Technologies, Inc.

 2012
Equity Incentive Plan

 On
October 19, 2012, the Board of Directors of BioSig Technologies, Inc. approved the 2012 Equity Incentive Plan (the "Plan")
and terminated the Long-Term Incentive Plan (the "2011 Plan"). The Plan (as amended) provides for the issuance of options,
stock appreciation rights, restricted stock and restricted stock units to purchase up to 1,447,445 shares of the Company's
common stock to officers, directors, employees and consultants of the Company. Under the terms of the Plan the Company may issue Incentive
Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors
of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants
under the Plan.

 F- 21

 However,
 the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant
for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is
determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.

 Additionally,
the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period
of not more than ten years. On October 19, 2022, the 2012 Equity Incentive Plan expired.

 2023
Long-Term Incentive Plan

 On
December 27, 2022, the Board of Directors of BioSig Technologies, Inc. approved the 2023 Long-Term Incentive Plan (the "2023 Plan").
The 2023 Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase
up to 876,595 shares, plus any prior plan awards of the Company's common stock to officers, directors, employees and consultants
of the Company. Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to
employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the
Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.

 However,
 the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant
for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is
determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.

 Additionally,
the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period
of not more than ten
years. At December 31, 2023, there were 216,718
 shares available under the 2023 Long-Term Incentive
Plan.

 Option
valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using
the Black-Scholes option model with a volatility figure derived from historical stock prices of the Company. The Company accounts for
the expected life of options using the based on the contractual life of options for non-employees.

 For
employees, the Company accounts for the expected life of options in accordance with the "simplified" method, which is used
for "plain-vanilla" options, as defined in the accounting standards codification. The risk-free interest rate was determined
from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.

the years ended December 31, 2023 and 2022, the Company granted an aggregate of 195,710 and 142,800 options to officers, directors and
key consultants, respectively.

 The
following table presents information related to stock options at December 31, 2023:

OF STOCK OPTIONS

 Exercisable

 Weighted

 Average

 Exercisable

 Remaining
 Life

 Price

 In
 Years

 $

 Under 9.99

 108,110

 9.2

 41,172

 10.00 - 19.99

 215,150

 7.1

 78,995

 20.00 - 29.99

 85,538

 7.9

 73,833

 30.00 - 39.99

 36,748

 2.8

 36,748

 40.00 - 49.99

 90,092

 4.2

 88,168

 50.00 - 59.99

 14,414

 5.6

 14,414

 60.00 - 69.99

 33,405

 3.7

 33,405

 70.00 - 79.99

 15,772

 4.7

 15,772

 Over
 79.99

 4,000

 6.4

 4,000

 603,229

 6.7

 386,507

 F- 22

 A
summary of the stock option activity and related information for the Plan for the two years ended December 31, 2023 is as follows:

OF STOCK OPTION ACTIVITY

 Weighted-Average Exercise Price

 Weighted-Average Remaining Contractual Term

 Aggregate Intrinsic Value

 Outstanding at January 1, 2022

 456,852

 $
 45.70

 6.9

 $
 -

 Grants

 142,800

 $
 11.20

 10.0

 -

 Forfeited/expired

 ( 144,100
)

 $
 45.40

 Outstanding at December 31, 2022

 455,552

 $
 45.70

 6.9

 $
 -

 Grants

 195,710

 $
 10.00

 10.0

 $
 -

 Forfeited/expired

 ( 48,033
)

 $
 44.69

 -

 Outstanding at December 31, 2023

 603,229

 $
 25.67

 6.7

 $
 37,671

 Exercisable at December 31, 2023

 386,507

 $
 33.53

 5.9

 $
 35,425

 The
aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price
less than the stock price of BioSig Technologies, Inc. of $ 4.75 as of December 31, 2023, which would have been received by the option
holders had those option holders exercised their options as of that date.

the year ended December 31, 2022, the Company granted an aggregate of 142,800 options to purchase the Company's common stock in
connection with services rendered at exercise prices from $ 4.00 to $ 17.20 per share for a term of ten years and with vesting from immediate
to three years from the date of issuance.

the year ended December 31, 2023, the Company granted an aggregate of 195,710 options to purchase the Company's common stock at
a weighted average exercise prices from of $ 2.60 to $ 13.60 per share for a term of ten years, with vesting from six months to three years
from the date of grant.

 The
following assumptions were used in determining the fair value of options during the years ended December 31, 2023 and 2022:

OF FAIR VALUE OF OPTIONS

 2023

 2022

 Risk-free interest rate

 3.32 % - 4.54
 %

 1.17 % to 4.06
 %

 Dividend yield

 %

 %

 Stock price volatility

 94.44 %
to 102.70
 %

 83.83 % to 99.29
 %

 Expected life

 5 – 6 years

 5 - 10 years

 Weighted average grant date fair value

 $
 7.72

 $
 8.00

 On
March 16, 2022, in connection with the termination of a Company executive, the Company extended the life of 10,000 previously issued
options from the contractual 90 days from termination of service to the earlier of the initial life or March 16, 2024. The change in
estimated fair value of the modified options of $ 15,181 was charged to current period operations.

 F- 23

 The
following assumptions were used in determining the change in fair value of the modified options at March 16, 2022:

 Risk-free interest rate

 0.44 % - 1.95
 %

 Dividend yield

 %

 Stock price volatility

 83.86
 %

 Expected life

 0.25 – 2 years

 The
fair value of all options vesting during the year ended December 31, 2023 and 2022 of $ 1,445,915 and $ 1,829,233, respectively, was charged
to current period operations. Unrecognized compensation expense of $ 997,894 at December 31, 2023 which the Company expects to recognize
over a weighted average period of 0.52 years.

 Warrants

 The
following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at
December 31, 2023:

OF OUTSTANDING WARRANTS

 Expiration

 Price

 Date

 $
 3.573

 1,399,386

 May 2025-November 2028

 $
 4.066

 November 2032

 $
 4.455

 113,005

 June 2028

 $
 4.466

 48,980

 November 2028

 $
 4.6626

 64,982

 April 2029

 $
 4.9252

 56,307

 March 2029

 $
 4.929

 76,997

 March 2029

 $
 5.1358

 116,045

 July 2028

 $
 7.181

 95,761

 July 2028

 $
 7.502

 9,846

 July 2028

 $
 7.963

 88,324

 August 2028

 $
 9.000

 21,709

 June 2027

 $
 9.596

 84,390

 January 2029

 $
 10.0992

 19,118

 August 2028

 $
 10.26

 51,705

 September 2028

 $
 10.4678

 84,296

 September 2028

 $
 11.30

 40,417

 October 2028

 $
 13.28

 96,198

 November 2028

 $
 14.00

 174,013

 September 2025

 $
 48.00

 February 2025 to July 2026

 $
 61.60

 56,892

 November 2027

 2,748,371

the year ended December 31, 2022, the Company issued warrants to purchase an aggregate of 369,393 shares of its common stock to investors
and warrants to purchase 32,727 shares of its common stock for engagement services at an average exercise price of $ 10.90 per share that
are exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance.

 On
November 18, 2022, the Company issued warrants to purchase 25,000 shares of common stock at an exercise price of $ 4.066 for services.
The warrants expire ten years following the date of issuance The fair value of $ 90,865, determined using the Black-Scholes Option method
was charged to current period operations. The assumptions issued in the fair value determination was volatility: 96.26 %, estimated life:
 10 years and risk-free rate of 3.82 %.

 F- 24

the year ended December 31, 2023, the Company issued warrants to purchase an aggregate of 2,206,367 shares of its common stock to investors
and warrants to purchase 126,385 shares of its common stock for engagement services at an average exercise price of $ 5.31 per share that
are exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance.

the year ended December 31, 2023, the Company issued 4,361 shares of its common stock upon cashless exercise of warrants to purchase
an aggregate of 6,098 shares of common stock, pursuant to the formula set forth in such warrants.

 A
summary of the warrant activity for the two years ended December 31, 2023 is as follows:

OF WARRANT ACTIVITY

 Weighted-Average Exercise Price

 Weighted-Average Remaining Contractual Term

 Aggregate Intrinsic Value

 Outstanding at January 1, 2022

 81,897

 $
 57.40

 5.3

 $
 -

 Issued

 427,120

 $
 10.50

 4.0

 -

 Expired

 ( 87,300
)

 $
 2.50

 Outstanding at December 31, 2022

 421,717

 $
 18.90

 4.3

 $
 3,960

 Issued

 2,332,752

 $
 5.31

 3.8

 Exercised

 ( 6,098
)

 $
 4.10

 -

 -

 Outstanding at December 31, 2023

 2,748,371

 $
 7.40

 3.7

 $
 -

 Vested and expected to vest at December 31, 2023

 2,748,371

 $
 7.40

 3.7

 $
 1,717,104

 Exercisable at December 31, 2023

 2,465,695

 $
 7.53

 3.6

 $
 1,711,424

 The
aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price
less than the company's stock price of $ 4.75 of December 31, 2023, which would have been received by the warrant holders had those
warrants holders exercised their options as of that date.

 The
fair value of warrants issued for services during the year ended December 31, 2023 and 2022 of $ 0 and $ 90,865 respectively, was charged
to current period operations. Unrecognized compensation expense of $ 0 at December 31, 2023.

Stock Units

 The
following table summarizes the restricted stock activity for the two years ended December 31, 2023:

OF RESTRICTED STOCK ACTIVITY

 Restricted shares issued as of January 1, 2022

 14,128

 Granted

 38,750

 Vested and issued

 ( 25,917
)

 Forfeited

 ( 3,000
)

 Restricted shares issued as of December 31, 2022

 23,961

 Granted

 177,250

 Vested and issued

 ( 37,961
)

 Forfeited

 -

 Vested restricted shares as of December 31, 2023

 -

 Unvested restricted shares as of December 31, 2023

 163,250

 In
2022, the Company granted an aggregate of 38,750 restricted stock units for services with 37,750 vesting from four months to one year
and 1,250 upon achievement of certain performance conditions.

 F- 25

 On
January 29, 2023, in connection with a separation agreement, the Company granted 12,500 restricted stock units vesting at separation
date at a fair value of $ 92,500.

 On
March 27, 2023, the Company granted an aggregate of 18,750 restricted stock units vesting on March 27, 2024 for services at a fair value
of $ 223,125.

 On
June 26, 2023, the Company granted an aggregate of 26,000 restricted stock units vesting quarterly over one year for services at a fair
value of $ 301,600.

 On
August 15, 2023, the Company granted an aggregate of 30,000 restricted stock units, with 5,000 vesting quarterly over one year, and 25,000
vesting on the one-year anniversary, for services at a fair value of $ 190,920.

 On
December 28, 2023, the Company granted an aggregate of 90,000 restricted stock units to a member of the Company's board of directors,
based on certain market conditions for services at a fair value of $ 426,780.

 Stock
based compensation expense related to restricted stock grants was $ 601,272 and $ 358,931 for the year ended December 31, 2023 and 2022,
respectively. As of December 31, 2023, the stock-based compensation relating to restricted stock of $ 741,308 remains unamortized.

Pharmaceuticals, Inc.

 2019
Long-Term Incentive Plan

 On
September 24, 2019, ViralClear's Board of Directors approved the 2019 Long-Term Incentive Plan (as subsequently amended, the "ViralClear
Plan"). The ViralClear Plan was approved by BioSig as ViralClear's majority stockholder. The ViralClear Plan provides for
the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 4,000,000 shares of
ViralClear's common stock to officers, directors, employees and consultants of the ViralClear. Under the terms of the ViralClear
Plan, ViralClear may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of ViralClear only and nonqualified
options. The Board of Directors of ViralClear or a committee thereof (the "Administrator") administers the ViralClear Plan
and determines the exercise price, vesting and expiration period of the grants under the ViralClear Plan.

 However,
 the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of
the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder. The fair market value
of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the Administrator in
good faith.

 Additionally,
the vesting period of the grants under the ViralClear Plan will be determined by the Administrator, in its sole discretion, with an expiration
period of not more than ten years. There are 2,650,071 shares remaining available for future issuance of awards under the terms of the
ViralClear Plan.

 A
summary of the stock option activity and related information for the ViralClear Plan for the two years ended December 31, 2023 is as
follows:

OF STOCK OPTION ACTIVITY

 Weighted-Average Exercise Price

 Weighted-Average Remaining Contractual Term

 Outstanding at January 1, 2021

 125,000

 $
 5.00

 7.2

 Forfeited/expired

 ( 100,000
)

 $
 5.00

 Outstanding at December 31, 2022

 $
 5.00

 1.5

 Forfeited/expired

 -

 Outstanding at December 31, 2023

 $
 5.00

 0.5

 Exercisable at December 31, 2023

 $
 5.00

 0.5

 F- 26

 The
following table presents information related to stock options at December 31, 2023:

 Options Outstanding

Exercisable

 Weighted

 Average

 Exercisable

 Remaining Life

 Price

 In Years

 $
 5.00

 0.5

 The
fair value of the stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from
an index of historical stock prices of comparable entities with the market value of stock price based on recent sales. The Company accounts
for the expected life of options in accordance with the "simplified" method, which is used for "plain-vanilla"
options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S.
Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.

 Warrants
(ViralClear)

 The
following table presents information related to warrants (ViralClear) at December 31, 2023:

OF INFORMATION RELATED TO WARRANTS

 Expiration

 Price

 Date

 $
 5.00

 473,772

 November 2027

 10.00

 6,575

 May 2025

 480,347

stock units (ViralClear)

 The
following table summarizes the restricted stock activity for the two years ended December 31, 2023:

OF RESTRICTED STOCK ACTIVITY

 Restricted shares outstanding at January 1, 2022:

 1,318,679

 Forfeited

 ( 240,000
)

 Restricted shares outstanding at December 31, 2022

 1,078,679

 Forfeited

 -

 Total restricted shares outstanding at December 31, 2023:

 1,078,679

 Comprised of:

 Vested restricted shares as of December 31, 2022

 678,679

 Unvested restricted shares as of December 31, 2022

 400,000

 Total

 1,078,679

 Stock
based compensation expense related to restricted stock unit grants of ViralClear was $( 1,941,861) and $( 1,072,094) for the years ended
December 31, 2023 and 2022, respectively. As of December 31, 2023, the stock-based compensation relating to restricted stock of $ 0 remains
unamortized.

 F- 27

AI Sciences, Inc.

 Warrants
(BioSig AI)

 The
following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at December 31, 2023:

OF INFORMATION RELATED TO WARRANTS

 Expiration

 Price

 Date

 $
 1.00

 June-July 2028

 In
June and July 2023, the BioSig AI issued warrants to purchase an aggregate of 130,500 shares of its common stock for investment banking
services at an exercise price of $ 1.00 per share that are exercisable immediately and will expire five years following the date of issuance.

 A
summary of the warrant activity for the year ended December 31, 2023 is as follows:

OF WARRANT ACTIVITY

 Weighted-
 Average
 Exercise Price

 Weighted-
 Average
 Remaining
 Contractual Term

 Outstanding at December 31, 2022

 -

 -

 -

 Issued

 $
 1.00

 5.0

 Outstanding at December 31, 2023

 $
 1.00

 5.0

 Vested and expected to vest at December 31, 2023

 $
 1.00

 4.5

 Exercisable at December 31, 2023

 $
 1.00

 4.5

 NOTE
11 – NON-CONTROLLING INTEREST

 On
November 7, 2018, the Company formed a subsidiary, now known as ViralClear, to pursue additional applications of the PURE EP signal
processing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum
anti-viral agent that showed potential for the treatment of COVID-19. Since late 2020, ViralClear has been realigned with its original
objective of pursuing additional applications of the PURE EP signal processing technology outside of cardiac electrophysiology.

 As
of December 31, 2023 and 2022, the Company had a majority interest in ViralClear of 69.08 %.

 On
July 2, 2020, the Company formed an additional subsidiary, now known as BioSig AI Sciences, Inc., to pursue clinical needs of cardiac
and neurological disorders through recordings and analyses of action potential. BioSig AI aims to contribute to the advancements of AI-based
diagnoses therapies. In June and July 2023, BioSig AI sold 2,205,000 shares of its common stock for net proceeds of $ 1,971,277 to fund
initial operations.

 As
of December 31, 2023 and 2022, the Company had a majority interest in BioSig AI of 84.5 % and 100.0 %, respectively.

 A
reconciliation of ViralClear Pharmaceuticals, Inc. and BioSig AI Sciences, Inc. non-controlling loss attributable to the Company:

 Net
income (loss) attributable to the non-controlling interest for the year ended December 31, 2023 (000's):

 SCHEDULE OF NON-CONTROLLING INTEREST

 ViralClear Pharmaceuticals,
 Inc.

 BioSig AI Sciences, Inc.

 Total

 Net income (loss)

 $
 1,498

 $
 ( 745
)

 $

 Average Non-Controlling interest percentage of profit/losses

 %

 %

 %

 Net income (loss) attributable to non-controlling interest

 $

 $
 ( 112
)

 $

 F- 28

 Net
loss attributable to the non-controlling interest for the year ended December 31, 2022 (000's):

 ViralClear Pharmaceuticals,
 Inc.

 BioSig AI Sciences, Inc.

 Total

 Net Loss

 $
 ( 671
)

 $
 ( 3
)

 $
 ( 674
)

 Net income (loss)

 $
 ( 671
)

 $
 ( 3
)

 $
 ( 674
)

 Average Non-Controlling interest percentage of profit/losses

 %

 %

 %

 Net loss attributable to non-controlling interest

 $
 ( 210
)

 $

 $
 ( 210
)

 The
following table summarizes the changes in non-controlling interest for the two years ended December 31, 2023 (000's):

 SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST

 ViralClear Pharmaceuticals,
 Inc.

 BioSig AI Sciences, Inc.

 Total

 Balance, January 1, 2022

 $

 $
 -

 $

 Allocation of equity to non-controlling interest for settlement of shares issued to settle debt to parent

 -

 Allocation of equity to non-controlling interest to equity-based compensation issued

 ( 322
)

 -

 ( 322
)

 Net loss attributable to non-controlling interest

 ( 210
)

 -

 ( 210
)

 Balance, January 1, 2023

 $
 ( 21
)

 $
 -

 $
 ( 21
)

 Allocation of equity to non-controlling interest due to sale of subsidiary stock

 -

 Allocation of equity to non-controlling interest due to equity-based compensation issued

 ( 600
)

 -

 ( 600
)

 Net income (loss) attributable to non-controlling interest

 ( 112
)

 Balance, December 31, 2023

 $
 ( 158
)

 $

 $

 NOTE
12 — COMMITMENTS AND CONTINGENCIES

 Operating
leases

 See
Note 5 for operating lease discussion.

 Licensing
agreements

 Master
Services Agreement

 On
January 1, 2022, the Company entered into a master services agreement with Access Strategy Partners Incorporated ("ASPI")
whereby ASPI will provide commercial executives assigned with specific customer targets and develop sales and marketing plans that are
mutually agreed to between ASPI and the Company and assist in their execution. The agreement expires two years from the effective date,
with an additional one year extension option.

 The
Company is obligated to pay ASPI: i) a monthly service fee of $ 40,000, subsequently reduced to $ 20,000 October 1, 2023 and ii) 10 % commission
on all New Account revenue, as defined, on a quarterly basis. At December 31, 2023 and 2022, accounts payable due under the contract
was $ 180 and $ 80, respectively. At December 31, 2023 the contract expired.

 F- 29

 2017
Know-How License Agreement

 On
March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby
the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of
signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and
offer for sale. The agreement expires in ten years from the effective date.

 The
Company is obligated to pay to Mayo Foundation a 1 % or 2 % royalty payment on net sales of licensed products, as defined. At December
31, 2023 and 2022, accounts payable due under the contract was $ 4.

 Patent
and Know-How License Agreement – EP Software Agreement

 On
November 20, 2019, the Company entered into a patent and know-how license agreement (the "EP Software Agreement") with Mayo
Foundation for Medical Education and Research ("Mayo"). The EP Software Agreement grants to the Company an exclusive worldwide
license, with the right to sublicense, within the field of electrophysiology software and under certain patent rights as described in
the EP Software Agreement (the "Patent Rights"), to make, have made, use, offer for sale, sell and import licensed products
and a non-exclusive license to the Company to use the research and development information, materials, technical data, unpatented inventions,
trade secrets, know-how and supportive information of Mayo to develop, make, have made, use, offer for sale, sell, and import licensed
products. The EP Software Agreement will expire upon the later of either (a) the expiration of the Patent Rights or (b) the 10th anniversary
of the date of the first commercial sale of a licensed product, unless earlier terminated by Mayo for the Company's failure to
cure a material breach of the EP Software Agreement, the Company's or a sublicensee's commencement of any action or proceedings
against Mayo or its affiliates other than for an uncured material breach of the EP Software Agreement by Mayo, or insolvency of the Company.

 In
connection with the EP Software Agreement, the Company agreed to make earned royalty payments to Mayo in connection with the Company's
sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to
$ 625,000 in aggregate. At December 31, 2023 and 2022, accounts payable due under the contract was $ 0.

 Amended
and Restated Patent and Know-How License Agreement – Tools Agreement

 On
November 20, 2019, the Company entered into an amended and restated patent and know-how license agreement (the "Tools Agreement")
with Mayo. The Tools Agreement contains terms of license grant substantially identical to the EP Software Agreement, although it is for
different patent rights and covers the field of electrophysiology systems. In June 2021, patent rights were issued ("Valid Claim")
as defined whereby the Company paid milestone one of $ 75,000 during the 2021 year.

 In
connection with the Tools Agreement, the Company agreed to pay Mayo an upfront consideration of $ 100,000. The Company also agreed to
make earned royalty payments to Mayo in connection with the Company's sales of the licensed products to third parties and sublicense
income received by the Company and to make milestone payments of up to $ 550,000 in aggregate. At December 31, 2023 and 2022, accounts
payable due under the contract was $ 0.

Patent and Know-How License Agreement

 On
November 20, 2019, the Company's majority-owned subsidiary, ViralClear, entered into a patent and know-how license agreement (the
"ViralClear Agreement") with Mayo. The ViralClear Agreement contains terms of license grant substantially identical to the
EP Software Agreement and the Tools Agreement, although it is for different patent rights and covers the field of stimulation and electroporation
for hypotension/syncope management, renal and non-renal denervation for hypertension treatment, and for use in treatment of arrhythmias
in the autonomic nervous system.

 In
connection with the ViralClear Agreement, ViralClear agreed to make earned royalty payments to Mayo in connection with ViralClear's
sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to
$ 700,000 in aggregate. In June 2021, patent rights were issued ("Valid Claim") as defined whereby the Company paid milestone
one of $ 75,000 during the 2021 year. At December 31, 2023 and 2022, accounts payable due under the contract was $ 0.

 F- 30

 Trek
Therapeutics, PBC

 In
the event of sublicensing, sale, transfer, assignment or similar transaction, ViralClear agreed to pay Trek 10 % of the consideration
received.

 As
part of the acquired assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding
certain formulas and compounds usage. The agreement calls for milestone payments upon marketing authorization (as amended and defined
with respect of product in a particular jurisdiction in the territory, the receipt of all approvals from the relevant regulatory authority
necessary to market and sell such product in any such jurisdiction, excluding any pricing approval or reimbursement authorization) in
any first and second country of $ 10 million and $ 5 million, respectively, in addition to 6 % royalty payments. At December 31, 2023 and
2022, accounts payable due under the contract was $ 0.

AI Sciences, Inc. – Consulting Agreement

 On
June 17, 2023, BioSig AI entered into an agreement with Reified Labs LLC ("Reified") whereby Reified will work with the BioSig
AI to develop datasets for the purpose of creating a foundational artificial intelligence platform. The agreement has a one-year term
from the effective date and automatically renews for successive one year terms, unless terminated.

AI is obligated to pay Reified a monthly consulting fee of $ 30,000. At December 31, 2023, accounts payable due under the contract was
$ 90,000.

 Defined
Contribution Plan

 Effective
January 1, 2019, the Company established a qualified defined contribution plan (the "401(k) Plan") pursuant to Section 401(k)
of the Code, whereby all eligible employees may participate. Participants may elect to defer a percentage of their annual pretax compensation
to the 401(k) plan, subject to defined limitations. The Company is required to make contributions to the 401(k) Plan equal to 3 percent
of each participant's eligible compensation, subject to limitations under the Code. For the year end December 31, 2023 and 2022,
the Company charged operations $ 229,744 and $ 247,622, respectively, for contributions under the 401(k) Plan.

 Purchase
commitments

 As
of December 31, 2023, the Company had aggregate purchase commitments of approximately $ 1,563,203 for future services or products, some
of which are subject to modification or cancellations.

 Litigation

 Threatened
litigation

 On
December 4, 2023, the Company received a threat of litigation for the termination of employment with the Company alleging the termination
of employment was in retaliation for bringing to the attention of the Company's board of directors and executives a series of wrongful
and questionable practices by members of the Company's board of directors, Chief Executive Officer and Chief Financial Officer.
The claimant sought compensation of in the amount of $ 775,782. After an investigation conducted by the Board and guidance of legal counsel,
it was concluded that the claim was without merit.

 On
February 22, 2024, the Company received a threat of litigation seeking restitution for losses resulting from unlawful actions taken by
the Company's board of directors. The claimant contends that he and others have sustained losses totaling $ 1,440,000. On
March 22, 2024, the claimant sent another letter to the Company referencing the previous letter and requesting several documents. The
Company believes that these claims are without merit.

 On
March 22, 2024, plaintiff, Michael Gray Fleming (the "Plaintiff"), filed a lawsuit in Hennepin County, Minnesota District
Court naming the Company, its former Chief Executive Officer and former Chief Financial Officer as defendants. The Plaintiff contends
that the Company failed to meet its obligations in issuing the Plaintiff stock certificates at the end of the restricted period under
the terms of a restricted stock award agreement, and is seeking $ 144,000 in damages and compensation for damages reasonably believed
to exceed $ 50,000. The Company's intent is to contest the allegations vigorously and, as of the date of this report, is unable
to provide an evaluation of the outcome of the litigation within the probate or remote range or to provide an estimate of the amount
of or a range of potential loss that might be incurred by the Company.

 F- 31

 We
may be subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional
adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material
adverse effect on its financial position, results of operations or liquidity.

 There
are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more
than 5% of our common stock is an adverse party or has a material interest adverse to our interest.

 Stock-based compensation

 The Company takes some tax positions, including the reporting of stock-based
compensation, that may not be accepted by the Internal Revenue Service upon an examination, and we may be subject to penalties for underreporting
of recipient's income. The result of any such examination is uncertain, and any such penalties could be material to our financial
position and results of operations given our current limited cash and revenues.

 NOTE
13 – SEGMENT REPORTING

 In
accordance with ASC 280-10, the Company reports segment information based on the "management" approach. The management approach
designates the internal reporting used by management for making decisions and assessing performance as the source of the Company's
reportable segments. The Company has three reportable segments: BioSig Technologies, Inc. (parent), NeuroClear Technologies, Inc. and
ViralClear Pharmaceuticals, Inc.

 Information
concerning the operations of the Company's reportable segments is as follows:

 SCHEDULE OF SEGMENT REPORTING

 December 31, 2023

 Revenues (from external customers)

 $

 $

 -

 -

 BioSig AI Sciences

 -

 -

 Revenues

 $

 $

 December 31, 2023

 Operating Expenses:

 $
 29,238

 $
 26,819

 ( 1,498
)

 BioSig AI Sciences

 Operating Expenses

 $
 28,530

 $
 27,494

 December 31, 2023

 (Loss) Income from Operations

 $
 ( 29,265
)

 $
 ( 26,590
)

 1,498

 ( 672
)

 BioSig AI Sciences

 ( 745
)

 ( 3
)

 (Loss)
 Income from Operations

 $
 ( 28,512
)

 $
 ( 27,265
)

 December 31, 2023

 Total Assets

 $

 $
 4,051

 -

 BioSig AI Sciences

 1,313

 Total Assets

 $
 1,798

 $
 4,110

 F- 32

 NOTE
14 – RELATED PARTY TRANSACTIONS

 Accounts
payable and accrued expenses include due to related parties comprised primarily director fees and travel reimbursements. Due to related
parties as of December 31, 2023 and 2022 was $ 30,000 and $ 120,000, respectively.

the year ended December 31, 2023, the Company's former Chief Financial Officer participated in the Company's 2023 PIPES,
acquiring 23,289 shares of the Company's common stock and 11,645 warrants to acquire the Company's common stock at an exercise
price of $ 7.963, expiring August 8, 2028 for an investment of $ 200,000.

 On
November 2, 2023, the Company appointed an independent board member as the new role of Executive Vice President. In connection with the
appointment, the Company entered into a consulting agreement at a rate of $ 12,500 per month. In addition, on December 28, 2023, the Company
granted an aggregate of 90,000 restricted stock units to the new Executive Vice President, vesting based on certain market conditions
for services at a fair value of $ 426,780 and options to purchase 60,000 shares our common stock at an exercise price of $ 4.472 per share,
vesting over six months at a fair value of $ 222,422.

the year ended December 31, 2023 and 2022, the Company's Chief former Financial Officer guaranteed issued corporate credit cards
for no consideration.

 NOTE
15 – INCOME TAXES

 At
December 31, 2023, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $ 160,926,000,
expiring in the year 2030, that may be used to offset future taxable income. The Company has provided a valuation reserve against the
full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it
is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company's ownership,
the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced
in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits. During the year ended December
31, 2023, the Company has increased the valuation allowance by $ 7,739,000
from $ 47,679,000
to $ 55,418,000.
We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax
positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in
a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination
by tax authorities.

 Tax
position that meet the more likely than not threshold is then measured using a probability weighted approach recognizing the largest
amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company had no tax positions relating
to open income tax returns that were considered to be uncertain.

 The
Company is required to file income tax returns in the U.S. Federal various State jurisdictions. The Company is no longer subject to income
tax examinations by tax authorities for tax years ending before December 31, 2017.

 The
effective rate differs from the statutory rate of 26.9 % as of December 31, 2023 and 2022 due to the following:

 SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION

 2023

 2022

 Statutory rate on pre-tax book loss

 26.9
 %

 26.9
 %

 Other

 33.6
 %

 Valuation allowance

 ( 26.9
)%

 ( 60.5
)%

 0.00
 %

 0.00
 %

 F- 33

 The
Company's deferred taxes as of December 31, 2023 and 2022 consist of the following:

 SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES

 2023

 2022

 Non-Current deferred tax asset:

 Net operating loss carry-forwards

 $
 43,329,000

 $
 36,977,000

 Stock based compensation

 9,680,000

 9,291,000

 Research and development costs

 2,409,000

 1,411,000

 Valuation allowance

 ( 55,418,000
)

 ( 47,679,000
)

 Net non-current deferred tax asset

 $
 -

 $
 -

 NOTE
16 – FAIR VALUE MEASUREMENT

 The
Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10").
ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities
required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would
transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer
restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of
observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs
that may be used to measure fair value:

 Level
1 – Quoted prices in active markets for identical assets or liabilities.

 Level
2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets
with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs
are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets
or liabilities.

 Level
3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

 All
items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

 To
the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair
value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value
hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed
and is determined based on the lowest level input that is significant to the fair value measurement.

 The
carrying value of the Company's cash and cash equivalents, accounts payable and other current assets and liabilities approximate
fair value because of their short-term maturity.

 As
of December 31, 2023, and 2022, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures.

 As
of December 31, 2023, and 2022, the Company did not have any derivative instruments that were designated as hedges.

 There
were no derivative and warrant liabilities as of December 31, 2023 and 2022.

 F- 34

 NOTE
17 – SUBSEQUENT EVENTS

 Notices
of Delisting

 On
March 5, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq (the "Staff") stating that
the Company has not regained compliance with Listing Rule 5550(a)(2) because the Company's common stock did not meet the minimum
bid price of $ 1.00 per share required for continued listing on The Nasdaq Capital Market, and the Company is not eligible for a second
180 day cure period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $ 5,000,000 minimum stockholders' equity
initial listing requirement for The Nasdaq Capital Market, and that accordingly, Nasdaq would delist the Company's common stock
unless the Company requested an appeal of this determination. On March 11, 2024, the Company submitted a request for a hearing before
the Nasdaq Hearings Panel to appeal the Staff's delisting determination.

 On
March 12, 2024, the Company received a letter from the Staff stating that based upon the Staff's review of the Company and pursuant
to Listing Rule 5101, the Staff believes that the Company no longer has an operating business and is a "public shell," and
that the continued listing of its securities is no longer warranted, in view of work force reductions and resignations of members of
the board of directors and officers (see below).

 The
letter further stated that the Company no longer meets the requirement of Rule 5550(b)(2) to maintain a minimum Market Value of Listed
Securities of $ 35 million, if none of the other standards set forth in Rule 5550(b) is met.

 The
Staff stated that the foregoing matters serve as an additional basis for delisting the Company's common stock from The Nasdaq Stock
Market, and that the Hearings Panel will consider this matter in rendering a determination regarding the Company's continued listing

 The
Company intends also to appeal the foregoing determinations. The requested hearing before the Hearings Panel will be held on May 7, 2024.

 Lack
of funding, workforce reductions, resignations of members of the Company's board of directors and certain officers

 On
January 28, 2024 and February 20, 2024, management of the Company commenced a workforce reduction intended to reduce significantly the
annual cash burn which was completed as of February 20, 2024. The workforce reduction consisted of the departure of sixteen employees,
effective as of January 31, 2024 and included the departure of John Sieckhaus, the Company's Chief Operating Officer, and Gray
Fleming, the Company's Chief Commercial Officer and twenty six employees effective February 20, 2024. The effect of the workforce
reductions had significantly reduce operations in the short-term.

 On
February 15, 2024, Steve Buhaly resigned from his position as the Chief Financial Officer of the Company effective as of the same date.

 On
February 19, 2024, David Weild IV, Donald E. Foley, Patrick J. Gallagher and James J. Barry, resigned from their positions as directors
of the Company, effective as of the same date.

 On
February 20, 2024, James L. Klein and Frederick D. Hrkac resigned from their positions as directors of the Company, effective as of the
same date.

 On
February 20, 2024 due to lack of funding, the company had laid off the entire workforce except for the CEO.

 On
February 27, 2024, the company re-appointed Frederick D. Hrkac as a director and the president and principal executive officer. Additionally,
on February 27, 2024, Kenneth L. Londoner resigned from his positions as director, executive chairman and chief executive officer of
the Company and from any and all committees, offices, appointments, designations, responsibilities or other capacities related to the
Company or any of its subsidiaries, effective as of the same date.

 F- 35

 Currently,
the Company has 4 employees and 4 key consultants. Dependent upon funding, Mr. Hrkac would plan on hiring a team of 4-6 persons to
execute the business development strategy of finding partners for the commercialization of PURE EP, develop new products in
the field of Pulse Field Ablation and to continue to integrate PURE EP into today's lab equipment.

 Issuance
of debt

 On
March 7, 2024, the Company issued a promissory note to an investor and related party (10% plus shareholder) for $ 500,000. The Company
designated its 12 % note due 2026, in accordance with exemptions from registration under the Securities Act of 1933, as amended (the "Securities
Act").

 The
note is due March 7, 2026. The Company promises to pay interest in cash on the unpaid principal amount of this note at a rate per annum
equal to twelve percent ( 12 %), commencing to accrue on the date hereof and payable on the maturity date or earlier prepayment as provided
therein. The Note contains customary events of default.

 The
Company may prepay all or any portion of the principal amount of the Note at any time or from time to time without penalty.

transactions

 On
January 12, 2024, the Company entered into a securities purchase agreement with certain accredited and institutional investors, pursuant
to which the Company sold to the investors an aggregate of 260,720 shares of the Company's common stock and warrants to purchase
up to 130,363 shares of common stock, at a purchase price of $ 3.989 per share and a warrant to purchase one-half of a share. The warrants
have an exercise price of $ 3.364 per share, will become exercisable six months after the date of issuance and will expire five and one-half
years following the date of issuance. The gross proceeds from this offering were $ 1,040,000.

 On
January 4, 2024, the Company issued 250 shares of its common stock for vested restricted stock units.

 On
February 5, 2024, the Company issued 76,744 shares of its common stock to former employees for services rendered, valued at $ 64,879.

 In
January 2024, the Company issued 77,500 shares of its common stock to consultants for services rendered, valued at $ 227,150.

 In
February 2024, the Company issued 1,250 shares of its common stock for vested restricted stock units.

 On
March 1, 2024, the Company issued 1,600,000 shares of its common stock to an officer, an employee and key consultants for services rendered, valued at $ 1,093,810.

 On March 1, 2024, the Company granted 500,000 shares of its common stock to a key consultant, vesting in substantially
equal monthly installments over one year, for services rendered, valued at $ 352,550.

 On
March 1, 2024, the Company entered into three business development consulting agreements with an officer and key consultants, each for
$ 10,000 per month and a three-month term. The Company may terminate upon giving consultant ten (10) days prior written notice. The Company
may terminate immediately and without prior notice if consultant refuses to or is unable to perform the services or is in breach of any
material provision of the agreement.

 On
March 1, 2024, the Company entered into a one-year consulting agreement with a consultant to provide clinical development services for
$ 16,667 per month. The Company may terminate upon giving consultant thirty (30) days prior written notice. The Company may terminate
immediately and without prior notice if consultant refuses to or is unable to perform the services or is in breach of any material provision
of the agreement.

 On
March 15, 2024, the Company issued 100,000 shares of its common stock to a consultant for services rendered, valued at
$ 53,020.

 On
April 1, 2024, the Company granted 200,000 shares of its common stock to employees, vesting in substantially equal monthly installments
over one year.

 On April 1, 2024, the Company issued 41,667 shares of its common stock for vested restricted stock units.

 F- 36

 ITEM
9 – CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 None.

 ITEM
9A – CONTROLS AND PROCEDURES

 Management ' s
evaluation of disclosure controls and procedures.

 Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure
controls and procedures pursuant to Rule 13a-15(e) under the Exchange Act. In designing and evaluating the disclosure controls and procedures,
management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance
of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that
there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls
and procedures relative to their costs.

 Based
on management's evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and
procedures are not designed at a reasonable assurance level and are not effective in providing reasonable assurance that information
we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported
within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management,
including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 Management ' s
report on internal control over financial reporting.

 Our
management is responsible for establishing and maintaining adequate internal control over financial reporting for our company. Internal
control over financial reporting is defined in Rule 13a-15(f) and 15d-15(f) promulgated under the Exchange Act, as a process designed
by, or under the supervision of, a company's principal executive and principal financial officer and effected by the our board
of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those
policies and procedures that:

 (1)

 pertain
 to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
 assets of the company;

 (2)

 provide
 reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
 generally accepted accounting principles, and that receipts and expenditures of the company are being made in accordance with authorizations
 of management and directors of the company; and

 (3)

 provide
 reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's
 assets that could have a material effect on the financial statements.

of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate. Management recognizes that any controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily
applies its judgment in evaluating the cost-benefit relationship of possible enhancements to controls and procedures.

 Management,
including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control
over financial reporting as of December 31, 2023, based on the criteria in a framework developed by the Company's management pursuant
to and in compliance with the criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of
Sponsoring Organizations ("COSO") of the Treadway Commission. This evaluation included review of the documentation of controls,
evaluation of the design effectiveness of controls, walkthroughs of the operating effectiveness of controls and a conclusion on this
evaluation. Based on this evaluation, management has concluded that our internal control over financial reporting was not effective as
of December 31, 2023, because management identified that i) inadequate identification, recording and reporting of stock based compensation,
ii) ineffective review processes over period end financial disclosure and reporting, and (iii) inadequate segregation of duties for transaction
posting and processing, amounted to a material weakness in the Company's internal control over financial reporting.

 The
material weaknesses did not result in any identified misstatements to the consolidated financial statements and there were no changes
to previously released financial results.

 Management ' s
Remediation Plan

 In
2024, we have intents to add sufficient staff and oversight supervision controls to provide adequate accounting segregation. We believe
these changes will remediate the underlying deficiencies as identified by us. The remediation efforts will include an ongoing review
of the implementation of additional controls to ensure all risks have been addressed.

 As
a result of the material weaknesses discussed above or of others, we may experience negative impacts on our ability to accurately report
our results of operation and financial condition in a timely manner. If we do identify a material weakness in our internal control over
financial reporting and are unsuccessful in implementing or following a remediation plan, or fail to update our internal control over
financial reporting as our business evolves or to integrate acquired businesses into our controls system, if additional material weaknesses
are found in our internal controls in the future, or if our external auditors cannot attest to the effectiveness of our internal control
over financial review, if applicable, we may not be able to timely or accurately report our financial condition, results of operations
or cash flows or to maintain effective disclosure controls and procedures. If we are unable to report financial information in a timely
and accurate manner or to maintain effective disclosure controls and procedures, we could be subject to, among other things, regulatory
or enforcement actions by the SEC, an inability for us to be accepted for listing on any national securities exchange in the near future,
securities litigation and a general loss of investor confidence, any one of which could adversely affect our business prospects and the
market value of our common stock. Further, there are inherent limitations to the effectiveness of any system of controls and procedures,
including the possibility of human error and the circumvention or overriding of the controls and procedures. We could face additional
litigation exposure and a greater likelihood of an SEC enforcement or other regulatory action if further restatements were to occur or
other accounting-related problems emerge.

 The
weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has
concluded, through testing, that these controls are operating effectively.

 Changes
in Internal Control over Financial Reporting

 There
has been no change in our internal control over financial reporting identified in connection with the evaluation referred to above that
occurred during our last completed fiscal quarter that has materially negatively affected, or is reasonably likely to materially affect,
our internal control over financial reporting. As discussed above, management has remediation plans that will be implemented in 2024.

 ITEM
9B – OTHER INFORMATION

 None.

 ITEM
9C – DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 Not
applicable.

 PART
III

 ITEM
10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 The
following table sets forth information regarding our executive officers and the members of our board of directors.

 Name

 Age

 Position
 with the Company

 Frederick
 D Hrkac

 Principal
 Executive Officer, President, and Director

 Directors
are elected at each annual meeting of our stockholders and hold office until their successors are elected and qualified or until their
earlier resignation or removal. Officers are appointed by our board of directors and serve at the discretion of the board of directors.

 On
February 15, 2024, Mr. Steve Buhaly resigned as Chief Financial Officer, on February 19, 2024, Mr. David Weild IV, Mr. Donald E. Foley,
Mr. Patrick J. Gallagher and Mr. James J. Barry resigned as members of the Company's board of directors, on February 20, 2024,
Mr. James L. Klein and Mr. Frederick D. Hrkac resigned as members of the board of directors and on February 27, 2024, Mr. Kenneth L.
Londoner resigned his positions as director, executive chairman and chief executive officer of the Company and subsidiaries.

 On
February 27, 2024, Mr. Frederick D. Hrkac, former director, was appointed as a director, president and principal executive officer of
the Company, to serve for a term expiring at the next annual meeting of the Company's shareholders.

 Biographical
Information

 Frederick
D. Hrkac. Mr. Hrkac has served as our director and principal executive officer since February 27, 2024. Previously, Mr. Hrkac had
served as our director from April 2022 until his resignation on February 20, 2024. Mr. Hrkac has more than 30 years of experience in
the medical device industry as an executive and corporate board director. He is currently serves on the board of Serres in Helsinki,
Finland since September 2018, and Spineart in Geneva, Switzerland as chairman of the board since August 2017. In 2017, he served as senior
vice president corporate development and from 2014-2016 served a senior vice president of global commercial operations of Biosensors
International. From 2009-2011, Mr. Hrkac served as Europe, Middle East & Africa president of Boston Scientific where he was responsible
for close to $2 billion of sales. From 2005-2009, Mr. Hrkac was an executive of Sorin Group CRM, Paris, France. And, from November 1990-April
2005 he lived in 6 different countries working as an executive for Johnson & Johnson including Biosense Webster, a Johnson &
Johnson company having laid the groundwork strategically for the most successful J&J division of the last 20 years with sales growing
from a few hundred million dollars to several billion dollars. Mr. Hrkac holds an Honors Bachelor of Business Administration from the
Wilfrid Laurier University, Waterloo, Ontario Canada and currently resides in Zagreb, Croatia. Mr. Hrkac brings extensive expertise in
global marketing and strategic business development, making him a valuable resource for our Board.

 Family
Relationships

 There
are no family relationships amongst our directors and executive officers.

 Delinquent
Section 16(a) Reports

 Section
16(a) of the Securities Exchange Act of 1934, as amended, requires our directors and officers, and persons who own more than ten percent
of our common stock, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock. To our
knowledge, based solely on a review of the copies of such reports furnished to us, during the fiscal year ended December 31, 2023, we
believe that all filing requirements applicable to our officers, directors and greater than ten percent stockholders were complied with
for the fiscal year ended December 31, 2023 except for one ten percent stockholder failed to file initial report in 2023, six directors'
Form 4s were delinquent in August 2023, and one director's Form 4 was delinquent in June 2023.

 Committees
of the Board of Directors

 Our
director intents to appoint additional interim directors until the next annual meeting of the Company's shareholders and to establish
an audit committee, a nominating and corporate governance committee, and a compensation committee.

 Code
of Ethics

 We
have adopted a code of business conduct and ethics that applies to our officers, directors and employees, including our principal executive
officer, principal financial officer and principal accounting officer. The full text of our Code of Business Conduct and Ethics is published
on the Investors section of our website at www.biosig.com. We intend to disclose any future amendments to certain provisions of the Code
of Business Conduct and Ethics, or waivers of such provisions granted to executive officers and directors, on this website within four
business days following the date of any such amendment or waiver.

 ITEM
11 – EXECUTIVE COMPENSATION

 Compensation
Philosophy and Practices

 We
believe that the performance of our executive officers significantly impacts our ability to achieve our corporate goals. We, therefore,
place considerable importance on the design and administration of our executive officer compensation program. This program is intended
to enhance stockholder value by attracting, motivating and retaining qualified individuals to perform at the highest levels and to contribute
to our growth and success. Our executive officer compensation program is designed to provide compensation opportunities that are tied
to individual and corporate performance.

 Our
compensation packages are also designed to be competitive in our industry. The Compensation Committee from time-to-time consults with
other advisors in designing our compensation program, including in evaluating the competitiveness of individual compensation packages
and in relation to our corporate goals.

 Our
overall compensation philosophy has been to pay our executive officers an annual base salary and to provide opportunities, through cash
and equity incentives, to provide higher compensation if certain key performance goals are satisfied.

 The
main principles of our fiscal year 2023 compensation strategy included the following:

 An
 emphasis on pay for performance. A significant portion of our executive officers' total compensation is variable and at
 risk and tied directly to measurable performance, which aligns the interests of our executives with those of our stockholders;

 Performance
 results are linked to Company and individual performance. When looking at performance over the year, we equally weigh individual
 performance as well as that of the Company as a whole. Target annual compensation is positioned to allow for above-median compensation
 to be earned through an executive officer's and the Company's extraordinary performance; and

 as a key component to align the interests of our executives with those of our stockholders. Our Compensation Committee continues
 to believe that keeping executives interests aligned with those of our stockholders is critical to driving toward achievement of
 long-term goals of both our stockholders and the Company.

 On
February 2, 2023, we entered into a General Release and Severance Agreement with Steve Chaussy, former Chief Financial Officer of the
Company, pursuant to which Mr. Chaussy's employment with the Company will terminate at such point when his services are no longer
required. On February 2, 2023, the Board appointed Mr. Steve Buhaly as the new Chief Financial Officer of the Company, whose employment
commenced on February 6, 2023.

 Summary
Compensation Table

 The
following table sets forth the names and positions of: (i) each person who served as our principal executive officer during the year
ended December 31, 2023; (ii) our most highly compensated executive officers, other than our principal executive officer, who was serving
as an executive officer, as determined in accordance with the rules and regulations promulgated by the SEC, as of December 31, 2023,
with compensation of $100,000 or more, and (iii) an additional individual for whom disclosure would have been provided pursuant to clause
(ii) but for the fact that the individual was not serving as our executive officer at December 31, 2023 (collectively our "Named
Executive Officers"):

 Name
 and principal position

 Year

 Salary
 ($)

 Bonus
 ($)

 Stock
 Awards
 ($)
 (1)

 Option
 Awards
 ($)(1)

 All
 Other
 Compensation
 ($)

 Total
 ($)

 Kenneth
 L. Londoner, Former Chief Executive Officer, Executive Chairman and Director (21)

 2023

 854,902
 (2)

 -

 831,908
 (3)

 -

 122,000
 (4)

 1,808,810

 2022

 865,667
 (5)

 125,000
 (6)

 504,000
 (7)

 -

 177,030
 (8)

 1,671,697

 Steven
 Chaussy, Former Chief Financial Officer (22)

 2023

 499,550
 (9)

 -

 652,745
 (10)

 -

 13,506
 (11)

 1,165,801

 2022

 498,333
 (12)

 85,000
 (13)

 252,000
 (14)

 -

 6,000
 (15)

 841,333

 Steven
 Buhaly, Former Chief Financial Officer (23)

 2023

 69,744

 -

 -

 240,130
 (16)

 -

 309,874

 John
 R Sieckhaus, Former Chief Operating Officer (24)

 2022

 277,480

 -

 421,635
 (17)

 -

 -

 699,115

 2022

 219,693

 -

 70,000
 (18)

 315,862
 (19)

 605,555

 Gray
 Fleming, Former Chief Commercial Officer (25)

 2023

 396,400

 -

 431,943
 (20)

 -

 -

 828,343

 2022

 400,000

 -

 -

 -

 -

 400,000

 (1)

 In
 accordance with SEC rules, this column reflects the aggregate fair value of the stock awards or option awards, as applicable, granted
 during the respective fiscal year computed as of their respective grant dates in accordance with Financial Accounting Standard Board
 Accounting Standards Codification Topic 718 for share-based compensation transactions. The assumptions made in the valuation of the
 share-based payments are contained in Notes 9 and 10 to our financial statements for the fiscal year ended December 31, 2023 in this
 annual report.

 (2)

 (i) salary of $679,902 from Company and (ii) salary of $175,000 from ViralClear.

 (3)

 (i) a common stock award of 57,600 fully vested shares granted on May 8, 2023 and (ii) a common stock award of 21,970 fully vested
 shares granted November 30, 2023.

 (4)

 (i) director fees of $80,000 from company; (ii) director fees of $30,000 from ViralClear, (iii) $12,000 auto allowance in lieu for
 reimbursement of mileage.

 (5)

 (i) salary of $690,667 from Company and (ii) salary of $175,000 from ViralClear.

 (6)

 bonus of $125,000 from ViralClear.

 (7)

 a common stock award of 40,000 fully vested shares granted on April 5, 2022.

 (8)

 (i) director fees of $60,000 from company; (ii) director fees of $105,030 from ViralClear, (iii) $12,000 auto allowance in lieu for
 reimbursement of mileage.

 (9)

 (i) salary of $399,550 from Company and (ii) salary of $100,000 from ViralClear.

 (10)

 (i) a common stock award of 20,000 fully vested shares granted February 10, 2023 (ii) a common stock award of 35,000 fully vested
 shares granted on May 8, 2023 and (iii) a common stock award of 13,060 fully vested shares granted November 30, 2023.

 (11)

 (i) $6,000 auto allowance in lieu for reimbursement of mileage and (ii) $7,506 medical insurance reimbursement in lieu of Company
 provided plan.

 (12)

 (i) salary of $398,333 from Company and (ii) salary of $100,000 from ViralClear.

 (13)

 bonus of $85,000 from ViralClear

 (14)

 a common stock award of 20,000 fully vested shares granted April 5, 2022.

 (15)

 an auto allowance in lieu of reimbursement for mileage.

 (16)

 a stock option granted February 16, 2023 for the purchase of 25,000 shares of common stock, vesting quarterly over one year at an
 exercise price of $12.50 and termination date of February 16, 2033.

 (17)

 (i) a common stock award of 29,562 fully vested shares granted on May 8, 2023 and (ii) a common stock award of 9,230 fully vested
 shares granted November 30, 2023.

 (18)

 a common stock award of 5,000 fully vested shares granted March 21, 2022

 (19)

 a stock option granted March 30, 2022 for the purchase of 35,000 shares of common stock, vesting 1/3 on one year anniversary and
 remainder quarterly over the next two years at an exercise price of $1.30 and termination date of March 30, 2032

 (20)

 (i) a common stock award of 29,562 fully vested shares granted on May 8, 2023 and (ii) a common stock award of 13,190 fully vested
 shares granted November 30, 2023.

 (21)

 Mr.
 Londoner served as our Executive Chairman and Director through the entirety of our last two fiscal years. Mr. Londoner has served
 as our Chief Executive Officer since July 31, 2017. On February 27, 2024, Mr. Londoner resigned his positions as director, executive
 chairman and chief executive officer of the Company and subsidiaries.

 (22)

 Mr.
 Chaussy served as served as our Chief Financial Officer since January 1, 2018 until his retirement as Chief Financial Officer on
 February 6, 2023.

 (23)

 Mr.
 Buhaly served as our Chief Financial Officer since February 6, 2023. On February 15, 2024, Mr. Buhaly resigned his position as Chief
 Financial Officer.

 (24)

 Mr.
 Sieckhaus served as our Chief Operating Officer from March 21, 2022, date of hire. On January 31, 2024, Mr. Sieckhaus was discharged
 as part of the Company's reduction in force.

 (25)

 Mr.
 Fleming served as of Chief Commercial Officer from December 6, 2021, date of hire. On January 31, 2024, Mr. Fleming was discharged
 as part of the Company's reduction in force.

 Narrative
Disclosure to Summary Compensation Table

 Executive
Employment Agreements

 Messrs.
Londoner, Chaussy, Buhaly, Sieckhaus and Fleming were at-will employees, and do not have employment agreements with us. Additionally,
we do not have any agreements that would provide for payment to any of Messrs. Londoner, Chaussy, Sieckhaus or Fleming following, or
in connection with the resignation, retirement, or other termination of any of them, a change of control of us, or a change in either
of their responsibilities following a change of control of us.

 On
February 2, 2023, we entered into a General Release and Severance Agreement (the "Release Agreement") with Mr. Chaussy, pursuant
to which Mr. Chaussy's employment with the Company will terminate at such point when his services are no longer required (the "Separation
Date"). For more detailed discussion of the Release Agreement, please see below under "Executive Employment Agreements –
Steve Chaussy" in this Form 10-K.

 Kenneth
L. Londoner

 Mr.
Londoner's salary, bonus and stock awards were determined by the Compensation Committee with consultation from members of the board
of directors.

 Mr.
Londoner also serves as the director of ViralClear, and from September 24, 2019 to April 28, 2020 and again since October 30, 2020, Mr.
Londoner served as the chairman of the board of directors and chief executive officer of ViralClear. Mr. Londoner received $175,000 annually
from ViralClear for his services (which was partially paid in 2020). Mr. Londoner has received and may be granted awards under the ViralClear
Plan.

 Steve
Chaussy

 Mr.
Chaussy's salary, bonus and stock awards were determined by the chairman of the board with consultation from members of the board
of directors.

 Steve
Chaussy also served as the chief financial officer of ViralClear and, commencing on September 24, 2019, received an annual salary of
$100,000 from ViralClear (which was partially paid in 2020). Mr. Chaussy has received and may be granted awards under the ViralClear
Plan.

 On
February 2, 2023, we entered into the Release Agreement with Mr. Chaussy, pursuant to which Mr. Chaussy's employment with the Company
will terminate at the Separation Date. Pursuant to the Release Agreement, we agreed, among other things, to: (i) continue to pay Mr.
Chaussy's base salary through the Separation Date, less applicable taxes and other withholdings, payable in equal installments
in accordance with our normal payroll policies; (ii) continued participation through the Separation Date in our current employee benefit
plans in which Mr. Chaussy has elected to participate and in accordance with the terms and conditions of such benefit plans; (iii) to
grant Mr. Chaussy 200,000 restricted shares (the "Tranche A Awarded Shares") of our common stock, pursuant to the terms and
conditions of the 2023 Long-Term Incentive Plan and our standard Restricted Stock Award Agreement (the "RSA Agreement");
and (iv) upon the successful filing of this Annual Report on Form 10-K with the U.S. Securities and Exchange Commission on or before
April 14, 2023, pay a cash bonus of $200,000 to Mr. Chaussy as severance pay over six months, beginning on the Separation Date. Pursuant
to the Release Agreement and provided that Mr. Chaussy executes and does not revoke the Supplemental Release Agreement (as defined in
the Release Agreement) before the expiration of the consideration period set forth therein, we also agreed to grant Mr. Chaussy an additional
125,000 restricted shares of our common stock (the "Tranche B Awarded Shares", and together with the Tranche A Awarded Shares,
the "Awarded Shares"), pursuant to the terms and conditions of the 2023 Long-Term Incentive Plan and the RSA Agreement. The
Awarded Shares will be fully vested on the date of grant. In consideration of the foregoing, Mr. Chaussy agreed to a release of claims
against the Company including all of its affiliates, parent companies, subsidiary companies, employees, owners, directors, officers,
principals, agents, insurers, and attorneys regarding, among other things, claims arising out of (i) his hiring, compensation, benefits,
and employment with the Company, and (ii) his separation from employment with the Company. Mr. Chaussy also agreed to a customary covenant
not to sue and a nondisclosure and confidentiality covenant. Please see our Current Report on 8-K filed with the SEC on February 7, 2023,
as amended on February 7, 2023 for a copy of the full Release Agreement.

 Retirement
Plans

 As
part of our overall compensation program, we provided all full-time employees, including our named executive officers, with the opportunity
to participate in a defined contribution 401(k) plan. Our 401(k) plan is intended to qualify under Section 401 of the Internal Revenue
Code so that employee pre-tax contributions and income earned on such contributions are not taxable to employees until withdrawn. Employees
may elect to defer up to 100 percent of their eligible compensation (not to exceed the statutorily prescribed annual limit) in the form
of elective deferral contributions to our 401(k) plan. Our 401(k) plan also has a "catch-up contribution" feature for employees
aged 50 or older (including those who qualify as "highly compensated" employees) who can defer amounts over the statutory
limit that applies to all other employees. As of February 29, 2024 this benefit was terminated.

 Employee
Benefits and Perquisites

 Along
with all other full-time employees, Messrs. Londoner, Chaussy, Sieckhaus and Fleming were eligible to participate in our health and welfare
plans which were comprised of medical, vision, life, and dental insurance benefits and an FSA and HSA plan. As of February 29, 2024 these
benefits were terminated.

to the Release Agreement described above, Mr. Chaussy had continued participation through the Separation Date in our previous employee
benefit plans in which Mr. Chaussy had elected to participate and in accordance with the terms and conditions of such benefit plans.

 No
Tax Gross-Ups

 We
do not make gross-up payments to cover our executives' personal income taxes that may pertain to any of the compensation paid by
us.

Equity Awards at Fiscal Year-End

 The
following table sets forth information regarding equity awards that have been previously awarded to each of the named executive officers
and which remained outstanding as of December 31, 2023.

 Name

 Number of Securities underlying Unexercised Options (#) Exercisable

 Number of Securities underlying Unexercised Options (#) Unexercisable

 Option Exercise Price ($/Sh)

 Option Expiration Date

 Number of Shares or Units of Stock that have not Vested (#)

 Market Value of Shares of Units That Have Not Vested ($)

 Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have Not Vested (#)

 Equity Incentive Plan Awards: Market of Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested ($)

 Kenneth

 10,000
 (1)

 -

 $
 46.60

 4/14/2030

 -

 $
 -

 -

 $
 -

 Londoner

 7,500
 (1)

 -

 $
 24.40

 12/28/2031

 -

 $
 -

 -

 $
 -

 Steve

 (2)

 -

 $
 12.50

 2/16/2033

 -

 $
 -

 -

 $
 -

 Buhaly

 John

 17,498
 (3)

 17,502
 (3)

 $
 13.00

 3/30/2032

 -

 $
 -

 -

 $
 -

 Sieckhaus

 Gray

 23,330
 (4)

 11,670

 $
 25.80

 12/15/2031

 -

 $
 -

 -

 $
 -

 Fleming

 (1)
Each of these options vested immediately

 (2)
Each of these options vested quarterly over on year.

 (3)
Each of these options vest 1/3 on first anniversary and remainder quarterly over the next two years

 (4)
Each of these options vest 1/3 on first anniversary and remainder quarterly over the next two years

 Director
Compensation

 The
following table presents the total compensation for each person who served as a non-employee director of our Board during the fiscal
year ended December 31, 2023. Other than as set forth in the table and described more fully below, we did not pay any compensation, reimburse
any expense of, make any equity awards or non-equity awards to, or pay any other compensation to any of the other members of our Board
in such period.

 Name

 Fees Earned
 or Paid in
 Cash ($)

 Stock
 Awards ($)
 (1)

 Option
 Awards ($)
 (1)

 All Other
 Compensation ($) (1)(2)

 Total ($)

 Donald E. Foley

 $
 -

 $

 (2)

 $
 -

 $
 -

 $

 Patrick J Gallagher

 $
 -

 $
 39,274

 (3)

 $
 -

 $
 -

 $
 39,274

 David Weild, IV

 $
 -

 $

 (4)

 $
 -

 $
 -

 $

 James J. Barry PhD

 $
 -

 $
 39,274

 (5)

 $
 -

 $
 -

 $
 39,274

 Frederick Hrkac

 $
 -

 $

 (6)

 $
 649,202

 (7)

 $
 -

 $
 701,588

 James Klein

 $
 -

 $
 46,591

 (8)

 $
 -

 $
 -

 $
 46,591

 Total:

 $
 -

 $
 282,279

 $
 649,202

 $
 -

 $
 931,481

 (1)

 In
 accordance with SEC rules, this column reflects the aggregate fair value of stock or option awards granted during the fiscal year
 ended December 31, 2023, computed as of their respective grant dates in accordance with Financial Accounting Standard Board Accounting
 Standards Codification Topic 718 for share-based compensation transactions.

 (2)

 (i) a common stock award of 1,600 fully vested shares granted March 1, 2023, (ii) a common stock award of 1,754 fully vested shares
 granted on April 27, 2023 and (iii) a common stock award of 1,600 fully vested shares on August 18, 2023. Mr. Foley resigned as a
 member of the Company's board of directors on February 19, 2024.

 (3)

 (i) a common stock award of 1,200 fully vested shares granted March 1, 2023, (ii) a common stock award of 1,316 fully vested shares
 granted on May 4, 2023 and (iii) a common stock award of 1,200 fully vested shares on August 31, 2023. Mr. Gallagher resigned as
 a member of the Company's board of directors on February 19, 2024.

 (4)

 (i) a common stock award of 1,600 fully vested shares granted March 1, 2023, (ii) a common stock award of 1,755 fully vested shares
 granted on April 27, 2023 and (iii) a common stock award of 1,600 fully vested shares on August 18, 2023. Mr. Weild resigned as a
 member of the Company's board of directors on February 19, 2024.

 (5)

 (i) a common stock award of 1,200 fully vested shares granted March 1, 2023, (ii) a common stock award of 1,316 fully vested shares
 granted on April 27, 2023 and (iii) a common stock award of 1,200 fully vested shares on August 21, 2023. Mr. Gallaher resigned as
 a member of the Company's board of directors on February 19, 2024.

 (6)

 (i) a common stock award of 1,600 fully vested shares granted March 1, 2023, (ii) a common stock award of 1,755 fully vested shares
 granted on April 27, 2023 and (iii) a common stock award of 1,600 fully vested shares on August 18, 2023. Mr. Hrkac resigned as a
 member of the Company's board of directors on February 20, 2024 and rejoined the Company on February 27, 2024 as a director,
 president and principal executive officer.

 (7)

 (i) a stock option granted December 28, 2023 for the purchase of 60,000 shares of common stock, vesting monthly over six months at
 an exercise price of $4.742 per share and termination date of December 28, 2032 and (ii) a restricted stock award for 90,000 shares
 of common stock with vesting based on market conditions granted December 28, 2023.

 (8)

 (i) a common stock award of 1,600 fully vested shares granted March 1, 2023, (ii) a common stock award of 1,316 fully vested shares
 granted on April 27, 2023 and (iii) a common stock award of 1,600 fully vested shares on August 21, 2023. Mr. Klein resigned as a
 member of the Company's board of directors on February 20, 2024.

 ITEM
12 – SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Compensation Plan Information

 The
following table provides certain information as of December 31, 2023, with respect to our equity compensation plans under which our equity
securities are authorized for issuance:

 Plan category

 securities to
 be issued
 upon
 exercise of
 outstanding
 options
 (a)

 Weighted-
 average
 exercise
 price of
 outstanding
 options
 (b)

 Securities remaining
 available for future
 issuance under equity
 compensation plans
 (excluding securities
 reflected in column (a))
 (c)

 Equity compensation plans approved by security holders(1)

 405,019

 $
 33.16

 -

 Equity compensation plans approved by security holders(2)

 198,210

 $
 10.00

 216,718

 Equity compensation plans not approved by security holders(3)

 $
 5.00

 2,650,071

 Total

 628,229

 $
 24.73

 2,866,789

 (1)
Represents shares available for issuance under the 2012 Plan.

 (2)
Represents shares available for issuance under the 2023 Plan.

 (3)
Represents shares available for issuance under the ViralClear Plan

Technologies, Inc. 2012 Equity Incentive Plan (expired October 2022)

 On
October 19, 2012, our board of directors adopted the BioSig Technologies, Inc. 2012 Equity Incentive Plan (the "2012 Plan"),
which provided for the grant of stock options, stock appreciation rights, restricted stock and restricted stock units to employees, directors
and consultants, to be granted from time to time as determined by our board of directors or its designees. The 2012 Plan was amended
at various times to, among other things, increase the number of shares of our Common Stock authorized under the plan. The 2012 Plan expired
by its terms on October 17, 2022. As of December 28, 2022, the number of shares issuable upon exercise of outstanding options and underlying
restricted stock awards granted under the 2012 Plan was 410,799. The material features of the 2012 Plan are described below:

 Administration
and Eligibility. The 2012 Plan was administered by our Board or the Compensation Committee of the Board (the "Administrator").
Employees (including any employee who was also a director or an officer), consultants, and non-employee directors of the Company who
rendered services to the Company were eligible to participate in the 2012 Plan.

 Stock
Options. The Administrator could grant either incentive stock options ("ISOs") qualifying under Code Section 422, or
nonstatutory stock options, provided that only employees of the Company and its subsidiaries (excluding subsidiaries that are not corporations)
were eligible to receive ISOs. The Administrator determined the terms of each stock option at the time of grant, including, without limitation,
the method of delivery of shares and provisions governing the term, exercise, and forfeiture of each option.

Stock and Restricted Stock Units. The Administrator was authorized to grant restricted stock and restricted stock units. The Administrator
determined the eligible participants to whom, and the time or times at which, grants of restricted stock or restricted stock units were
made; the number of shares or units to be granted; the price to be paid, if any; the time or times within which the shares covered by
such grants would be subject to forfeiture; the time or times at which the restrictions would terminate; and all other terms and conditions
of the grants.

 Vesting,
Forfeiture, Assignment. The Administrator, in its sole discretion, could determine that an award will be immediately vested in whole
or in part, or that all or any portion could not be vested until a date, or dates, subsequent to its date of grant, or until the occurrence
of one or more specified events, subject in any case to the terms of the 2012 Plan. If the Administrator imposed conditions upon vesting,
then the Administrator may, in its sole discretion, accelerate the date on which all or any portion of the award may be vested.

Technologies, Inc. 2023 Long-Term Incentive Plan

 Purpose.
The purpose of the 2023 Plan is to enable us to remain competitive and innovative in our ability to attract and retain the services of
key employees, key contractors, and outside directors of the Company and our subsidiaries. The 2023 Plan provides for the granting of
incentive stock options, nonqualified stock options, stock appreciation rights ("SARs"), restricted stock, restricted stock
units, performance awards, dividend equivalent rights, other awards, performance goals, and tandem awards which may be granted singly
or in combination, or in tandem, and that may be paid in cash, shares of our Common Stock, or other consideration, or any combination
thereof. The 2023 Plan is expected to provide flexibility to our compensation methods in order to adapt the compensation of our key employees,
key contractors, and outside directors to a changing business environment, after giving due consideration to competitive conditions and
the impact of applicable tax laws.

 Effective
Date and Expiration. The 2023 Plan was approved by our Board on December 27, 2022 (the "Effective Date") and approved
by our stockholders at a special meeting held on February 7, 2023. The 2023 Plan will terminate on the tenth anniversary of the Effective
Date, unless earlier terminated by our Board. No award may be granted under the 2023 Plan after its termination date, but awards made
prior to the termination date may extend beyond that date in accordance with their terms.

 Share
Authorization. Subject to certain adjustments, the maximum aggregate number of shares of our Common Stock that may be delivered pursuant
to awards under the 2023 Plan is currently 216,718 shares, plus any Prior Plan Awards (as defined below), subject to adjustment in
certain circumstances to prevent dilution or enlargement as described below. All of the shares available for issuance as an award under
the 2023 Plan may be delivered pursuant to incentive stock options. "Prior Plan Awards" means (i) any awards granted pursuant
to the BioSig Technologies, Inc. 2011 Long-Term Incentive Plan or the BioSig Technologies, Inc. 2012 Equity Incentive Plan that are outstanding
on the Effective Date and that, on or after the Effective Date, (x) expire or otherwise terminate without having been exercised in full
or without Common Stock being issued pursuant to such awards, (y) are forfeited, or (z) are repurchased by us.

to be issued under the 2023 Plan may be made available from authorized but unissued shares of our Common Stock, Common Stock held in
our treasury, or shares purchased by us on the open market or otherwise. During the term of the 2023 Plan, we will at all times reserve
and keep enough shares available to satisfy the requirements of the 2023 Plan. Shares underlying awards granted under the 2023 Plan that
expire or are forfeited, or terminated without being exercised, or awards that are settled for cash, will again be available for the
grant of additional awards within the limits provided by in the 2023 Plan. If previously acquired shares of Common Stock are delivered
to the Company in full or partial payment of the exercise price for the exercise of a stock option granted under the 2023 Plan, the number
of shares of Common Stock available for future awards under the 2023 Plan shall be reduced only by the net number of shares of Common
Stock issued upon exercise of the stock option. Awards that may be satisfied either by the issuance of shares of Common Stock or by cash
or other consideration shall be counted against the maximum number of shares of Common Stock that may be issued under the 2023 Plan only
during the period that the award is outstanding or to the extent the award is ultimately satisfied by the issuance of shares. An award
will not reduce the number of shares that may be issued pursuant to the 2023 Plan if the settlement of the award will not require the
issuance of shares, such as, for example, SARs that can only be satisfied by the payment of cash. Only shares forfeited back to the us
or shares canceled on account of termination, expiration or lapse of an award, shares surrendered in payment of the exercise price of
a stock option or shares withheld for payment of applicable employment taxes and/or withholding obligations resulting from the exercise
of an option shall again be available for grant as incentive stock options under the 2023 Plan, but shall not increase the maximum number
of shares that may be delivered pursuant to incentive stock options.

 Administration.
Under the terms of the 2023 Plan, the 2023 Plan will be administered by our Board or such committee of the Board as is designated by
the Board to administer the 2023 Plan (the "Committee"), which, to the extent necessary to satisfy the requirements of Rule
16b-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), shall consist entirely of two or more "outside
directors" as defined in Rule 16b-3 under the Exchange Act. At any time there is no Committee to administer the 2023 Plan, any
reference to the Committee is a reference to our Board. The Committee will determine the persons to whom awards are to be made; determine
the type, size, and terms of awards; interpret the 2023 Plan; establish and revise rules and regulations relating to the 2023 Plan and
any sub-plans (including sub-plans for awards made to participants who do not reside in the United States); establish performance goals
applicable to awards and certify the extent of their achievement; and make any other determinations that it believes are necessary for
the administration of the 2023 Plan. The Committee may delegate certain of its duties to one or more of our officers as provided in the
2023 Plan.

 Eligibility.
The 2023 Plan provides for awards to the outside directors, officers, employees, and contractors of the Company and our subsidiaries.
As of April 15, 2024, there were 2 employees, 1 director, and approximately 5 consultants eligible to participate in the 2023 Plan. The
Company's current Section 16 executive officers and each member of our Board are among the individuals eligible to receive awards
under the 2023 Plan.

 Stock
Options. Subject to the terms and provisions of the 2023 Plan, options to purchase shares of our Common Stock may be granted to eligible
individuals at any time and from time to time as determined by the Committee. Stock options may be granted as incentive stock options,
which are intended to qualify for favorable treatment to the recipient under federal tax law, or as nonqualified stock options, which
do not qualify for such favorable tax treatment. Subject to the limits provided in the 2023 Plan, the Committee determines the number
of stock options granted to each recipient. Each stock option grant will be evidenced by a stock option agreement that specifies the
stock option's exercise price, whether the stock options are intended to be incentive stock options or nonqualified stock options,
the duration of the stock options, the number of shares to which the stock options pertain, and such additional limitations, terms, and
conditions as the Committee may determine.

 The
Committee determines the exercise price for each stock option granted, except that the exercise price may not be less than 100% of the
fair market value of a share of our Common Stock on the date of grant; provided, however, that if an incentive stock option is granted
to an employee who owns or is deemed to own more than 10% of the combined voting power of all classes of our Common Stock (or of any
parent or subsidiary), the exercise price must be at least 110% of the fair market value of a share of our Common Stock on the date of
grant. All stock options granted under the 2023 Plan will expire no later than ten years (or, in the case of an incentive stock option
granted to an employee who owns or is deemed to own more than 10% of the combined voting power of all classes of our Common Stock (or
of any parent or subsidiary), five years) from the date of grant. Stock options are nontransferable except by will or by the laws of
descent and distribution or, in the case of nonqualified stock options, as otherwise expressly permitted by the Committee. The granting
of a stock option does not accord the recipient the rights of a stockholder, and such rights accrue only after the exercise of a stock
option and the registration of shares of our Common Stock in the recipient's name.

 Stock
Appreciation Rights. The 2023 Plan authorizes the Committee to grant SARs, either as a separate award or in connection with a stock
option. A SAR entitles the holder to receive from us, upon exercise, an amount equal to the excess, if any, of the aggregate fair market
value of a specified number of shares of our Common Stock to which such SAR pertains over the aggregate exercise price for the underlying
shares. The exercise price of a SAR shall not be less than 100% of the fair market value of a share of our Common Stock on the date of
grant.

 Each
SAR will be evidenced by an award agreement that specifies the exercise price, the number of shares to which the SAR pertains, and such
additional limitations, terms, and conditions as the Committee may determine. We may make payment of the amount to which the participant
exercising SARs is entitled by delivering shares of our Common Stock, cash, or a combination of stock and cash as set forth in the award
agreement relating to the SARs. SARs are not transferable except as expressly permitted by the Committee.

Stock. The 2023 Plan provides for the award of shares of our Common Stock that are subject to forfeiture and restrictions on transferability
as set forth in the 2023 Plan, the applicable award agreement, and as may be otherwise determined by the Committee. Except for these
restrictions and any others imposed by the Committee, upon the grant of restricted stock, the recipient will have rights of a stockholder
with respect to the restricted stock, including the right to vote the restricted stock and to receive all dividends and other distributions
paid or made with respect to the restricted stock on such terms as will be set forth in the applicable award agreement; provided, however,
such dividends or distributions may, if provided in the applicable award agreement, be withheld by us for a participant's account
until the restrictions lapse with respect to such restricted stock. During the restriction period set by the Committee, the recipient
may not sell, transfer, pledge, exchange, or otherwise encumber the restricted stock.

Stock Units. The 2023 Plan authorizes the Committee to grant restricted stock units. Restricted stock units are not shares of our
Common Stock and do not entitle the recipients to the rights of a stockholder, although the award agreement may provide for rights with
respect to dividends or dividend equivalents. The recipient may not sell, transfer, pledge, or otherwise encumber restricted stock units
granted under the 2023 Plan prior to their vesting. Restricted stock units will be settled in shares of our Common Stock, in an amount
based on the fair market value of our Common Stock on the settlement date. If the right to receive dividends on restricted stock units
is awarded, then, if provided in the applicable award agreement, such dividends may be withheld by us for a participant's account
until the restrictions lapse with respect to such restricted stock units.

 Dividend
Equivalent Rights. The Committee may grant a dividend equivalent right either as a component of another award or as a separate award.
The terms and conditions of the dividend equivalent right will be specified by the grant and, when granted as a component of another
award, may have terms and conditions different from such other award. Dividend equivalent rights granted as a separate award also may
be paid currently or may be deemed to be reinvested in additional Common Stock. Any such reinvestment will be at the fair market value
at the time thereof. Dividend equivalent rights may be settled in cash or Common Stock.

 Performance
Awards. The Committee may grant performance awards payable at the end of a specified performance period in cash, shares of Common
Stock, or other rights based upon, payable in, or otherwise related to our Common Stock. Payment will be contingent upon achieving pre-established
performance goals (as described below) by the end of the applicable performance period. The Committee will determine the length of the
performance period, the maximum payment value of an award, and the minimum performance goals required before payment will be made, so
long as such provisions are not inconsistent with the terms of the 2023 Plan, and to the extent an award is subject to Section 409A of
the Internal Revenue Code of 1986, as amended (the "Code"), are in compliance with the applicable requirements of Section
409A of the Code and any applicable regulations or authoritative guidance issued thereunder. In certain circumstances, the Committee
may, in its discretion, determine that the amount payable with respect to certain performance awards will be reduced from the maximum
amount of any potential awards. If the Committee determines, in its sole discretion, that the established performance measures or objectives
are no longer suitable because of a change in our business, operations, corporate structure, or for other reasons that the Committee
deems satisfactory, the Committee may modify the performance measures or objectives and/or the performance period.

 Performance
Goals. The 2023 Plan provides that performance goals may be established by the Committee in connection with the grant of any award
under the 2023 Plan. Such goals shall be based on the attainment of specified levels of one or more business criteria, which may include,
without limitation: cash flow; cost; revenues; sales; ratio of debt to debt plus equity; net borrowing, credit quality or debt ratings;
profit before tax; economic profit; earnings before interest and taxes; earnings before interest, taxes, depreciation and amortization;
gross margin; earnings per share (whether on a pre-tax, after-tax, operational or other basis); operating earnings; capital expenditures;
expenses or expense levels; economic value added; ratio of operating earnings to capital spending or any other operating ratios; free
cash flow; net profit; net sales; net asset value per share; the accomplishment of mergers, acquisitions, dispositions, public offerings
or similar extraordinary business transactions; sales growth; price of our Common Stock; return on assets, equity or stockholders'
equity; market share; inventory levels, inventory turn or shrinkage; total return to stockholders; or any other criteria determined by
the Committee, in each case with respect to the Company or any one or more of our subsidiaries, divisions, business units, or business
segments, either in absolute terms or relative to the performance of one or more other companies (including an index covering multiple
companies).

 Other
Awards. The Committee may grant other forms of awards, based upon, payable in, or that otherwise relate to, in whole or in part,
shares of our Common Stock, if the Committee determines that such other form of award is consistent with the purpose and restrictions
of the 2023 Plan. The terms and conditions of such other form of award shall be specified in the grant. Such other awards may be granted
for no cash consideration, for such minimum consideration as may be required by applicable law, or for such other consideration as may
be specified in the grant.

 Vesting
of Awards; Forfeiture; Assignment. Except as otherwise provided below, the Committee, in its sole discretion, may determine that
an award will be immediately vested, in whole or in part, or that all or any portion may not be vested until a date, or dates, subsequent
to its date of grant, or until the occurrence of one or more specified events, subject in any case to the terms of the 2023 Plan.

 The
Committee may impose on any award, at the time of grant or thereafter, such additional terms and conditions as the Committee determines,
including terms requiring forfeiture of awards in the event of a participant's termination of service. The Committee will specify
the circumstances under which performance awards may be forfeited in the event of a termination of service by a participant prior to
the end of a performance period or settlement of awards. Except as otherwise determined by the Committee, restricted stock will be forfeited
upon a participant's termination of service during the applicable restriction period.

 Awards
granted under the 2023 Plan generally are not assignable or transferable except by will or by the laws of descent and distribution, except
that the Committee may, in its discretion and pursuant to the terms of an award agreement, permit transfers of nonqualified stock options
or SARs to: (i) the spouse (or former spouse), children, or grandchildren of the participant ("Immediate Family Members");
(ii) a trust or trusts for the exclusive benefit of such Immediate Family Members; (iii) a partnership in which the only partners are
(a) such Immediate Family Members and/or (b) entities that are controlled by the participant and/or his or her Immediate Family Members;
(iv) an entity exempt from federal income tax pursuant to Section 501(c)(3) of the Code or any successor provision; or (v) a split interest
trust or pooled income fund described in Section 2522(c)(2) of the Code or any successor provision, provided that (x) there shall be
no consideration for any such transfer, (y) the applicable award agreement pursuant to which such nonqualified stock options or SARs
are granted must be approved by the Committee and must expressly provide for such transferability, and (z) subsequent transfers of transferred
nonqualified stock options or SARs shall be prohibited except those by will or the laws of descent and distribution.

 Change
in Control. In connection with a change in control, outstanding awards may be converted into new awards, exchanged or substituted
for with new awards, or canceled for no consideration, provided participants were given notice and an opportunity to purchase or exercise
such awards, or cancelled and cashed out based on the positive difference between the per share amount to be received in connection with
the transaction and the purchase/exercise price per share of the award, if any. The description of a change in control and its effects
on awards granted under the 2023 Plan is qualified in its entirety by reference to the relevant terms and provisions of the 2023 Plan,
which is attached as Annex A to our Proxy Statement filed with the SEC on December 29, 2022.

 Recoupment
for Restatements. The Company may recoup all or any portion of any shares of our Common Stock or cash paid to a participant in connection
with an award, in the event of a restatement of our financial statements as set forth in our clawback policy as may be in effect from
time to time.

 Adjustments
Upon Changes in Capitalization. In the event that any dividend or other distribution (whether in the form of cash, shares of our
Common Stock, other securities, or other property), recapitalization, stock split, reverse stock split, rights offering, reorganization,
merger, consolidation, split-up, spin-off, split-off, combination, subdivision, repurchase, or exchange of shares of our Common Stock
or other securities, issuance of warrants or other rights to purchase shares of our Common Stock or other securities, or other similar
corporate transaction or event affects the fair market value of an award, the Committee shall adjust any or all of the following so that
the fair market value of the award immediately after the transaction or event is equal to the fair market value of the award immediately
prior to the transaction or event: (i) the number of shares and type of Common Stock (or other securities or property) that thereafter
may be made the subject of awards; (ii) the number of shares and type of Common Stock (or other securities or property) subject to outstanding
awards; (iii) the exercise price of each outstanding stock option; (iv) the amount, if any, we pay for forfeited shares in accordance
with the terms of the 2023 Plan; and (v) the number of or exercise price of shares then subject to outstanding SARs previously granted
and unexercised under the 2023 Plan, to the extent that the same proportion of our issued and outstanding shares of Common Stock in each
instance shall remain subject to exercise at the same aggregate exercise price; provided, however, that the number of shares of Common
Stock (or other securities or property) subject to any award shall always be a whole number. Notwithstanding the foregoing, no such adjustment
shall be made or authorized to the extent that such adjustment would cause the 2023 Plan or any stock option to violate Section 422 of
the Code or Section 409A of the Code. All such adjustments must be made in accordance with the rules of any securities exchange, stock
market, or stock quotation system to which we are subject.

 Amendment
or Discontinuance of the 2023 Plan. Our Board may, at any time and from time to time, without the consent of participants, alter,
amend, revise, suspend, or discontinue the 2023 Plan in whole or in part; provided, however, that (i) no amendment that requires stockholder
approval in order for the 2023 Plan and any awards under the 2023 Plan to continue to comply with Sections 421 and 422 of the Code (including
any successors to such sections or other applicable law) or any applicable requirements of any securities exchange or inter-dealer quotation
system on which our Common Stock is listed or traded, shall be effective unless such amendment is approved by the requisite vote of our
stockholders entitled to vote on the approval of the 2023 Plan; and (ii) unless required by law, no action by our Board regarding amendment
or discontinuance of the 2023 Plan may adversely affect any rights of any participants or obligations of the Company to any participants
with respect to any outstanding awards under the 2023 Plan without the consent of the affected participant.

 Repricing
of Stock Options or SARs. The Committee may not "reprice" any stock option or SAR without stockholder approval. For purposes
of the 2023 Plan, "reprice" means any of the following or any other action that has the same effect: (a) amending a stock
option or SAR to reduce its exercise price; (b) canceling a stock option or SAR at a time when its exercise price exceeds the fair market
value of a share of our Common Stock in exchange for cash or a stock option, SAR, award of restricted stock, or other equity award; or
(c) taking any other action that is treated as a repricing under generally accepted accounting principles, provided that nothing will
prevent the Committee from (x) making adjustments to awards upon changes in capitalization, (y) exchanging or cancelling awards upon
a merger, consolidation, or recapitalization, or (z) substituting awards for awards granted by other entities, to the extent permitted
by the 2023 Plan.

Pharmaceuticals, Inc. 2019 Equity Incentive Plan

 On
September 24, 2019, the board of directors (the "ViralClear Board") of ViralClear approved the ViralClear Plan, subject to
stockholder approval, which provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights
("SARs"), restricted stock, and restricted stock units to key employees, key contractors, and outside directors of ViralClear,
to be granted from time to time as determined by the ViralClear Board or its designee. An aggregate of 4,000,000 shares of the ViralClear
common stock are reserved for issuance under the ViralClear Plan. The material features of the ViralClear Plan are described below.

 Purpose.
The purpose of the ViralClear Plan is to enable ViralClear to attract and retain the services of key employees, key contractors, and
outside directors of ViralClear and its subsidiaries and to provide such persons with a proprietary interest in ViralClear. The ViralClear
Plan provides for the granting of incentive stock options, nonqualified stock options, SARs, restricted stock, and restricted stock units,
which may be granted singly, in combination, or in tandem; which may be paid in cash, shares of common stock, or a combination of cash
and shares of common stock, as described in more detail below; and which will increase the interest of such persons in ViralClear's
welfare, furnish an incentive to such persons to continue their services for ViralClear or its subsidiaries, and provide a means through
which ViralClear may attract able persons as employees, contractors, and outside directors.

 Effective
Date and Expiration. The ViralClear Plan became effective on September 24, 2019 and will continue in effect for a term of 10 years,
unless earlier terminated by the ViralClear Board.

 Share
Authorization. Subject to certain adjustments, the maximum aggregate number of shares of our common stock that may be delivered pursuant
to awards under the ViralClear Plan is currently 4,000,000 shares, 100% of which may be delivered pursuant to incentive stock options.

to be issued may be made available from authorized but unissued common stock, common stock held by ViralClear in its treasury, or common
stock purchased by ViralClear on the open market or otherwise. During the term of the ViralClear Plan, ViralClear will at all times reserve
and keep available the number of shares of common stock sufficient to satisfy the requirements of the ViralClear Plan. If an award under
the ViralClear Plan is forfeited, expires, or is canceled, in whole or in part, then the number of shares of common stock covered by
the award or stock option so forfeited, expired, or canceled may again be awarded pursuant to the provisions of the ViralClear Plan.
In the event that previously acquired shares of common stock are delivered to ViralClear in full or partial payment of the exercise price
for the exercise of a stock option granted under the ViralClear Plan, the number of shares of common stock available for future awards
under the ViralClear Plan shall be reduced only by the net number of shares of common stock issued upon the exercise of the stock option.
Awards that may be satisfied either by the issuance of shares of common stock or by cash or other consideration shall be counted against
the maximum number of shares of common stock that may be issued under the ViralClear Plan only during the period that the award is outstanding
or to the extent the award is ultimately satisfied by the issuance of shares of common stock. Awards will not reduce the number of shares
of common stock that may be issued pursuant to the ViralClear Plan if the settlement of the award will not require the issuance of shares
of common stock, as, for example, a SAR that can be satisfied only by the payment of cash. Notwithstanding any provisions of the ViralClear
Plan to the contrary, only shares forfeited back to ViralClear, shares canceled on account of termination, expiration or lapse of an
award, shares surrendered in payment of the exercise price of a stock option or shares withheld for payment of applicable employment
taxes and/or withholding obligations resulting from the exercise of an option shall again be available for grant of incentive stock options
under the ViralClear Plan, but shall not increase the maximum number of shares of common stock that may be delivered pursuant to awards
under the ViralClear Plan as the maximum number of shares of common stock that may be delivered pursuant to incentive stock options.

 Administration.
The ViralClear Plan may be administered by our ViralClear Board or such committee of the ViralClear Board as is designated by it to administer
the ViralClear Plan (the "Committee"). The ViralClear Board or the Committee will determine and designate the persons to
whom awards are to be made and set forth the award period, date of grant, terms, provisions, limitations, and performance requirements
of awards. The Committee will determine whether an award shall include one type of equity incentive, two or more equity incentives granted
in combination, or two or more equity incentives granted in tandem. The ViralClear Board may authorize one or more officers of ViralClear
to designate one or more employees as eligible persons to whom nonqualified stock options, incentive stock options, or SARs will be granted
under the ViralClear Plan and determine the number of shares of common stock that will be subject to such stock options, incentive stock
options, or SARs. The Committee will interpret the ViralClear Plan and award agreements; prescribe, amend, and rescind any rules and
regulations, as necessary or appropriate for the administration of the ViralClear Plan; and establish performance goals for an award
and certify the action as it deems necessary or advisable in the administration of the ViralClear Plan. The Committee may delegate to
officers of ViralClear the authority to perform specified functions under the ViralClear Plan. With respect to restrictions in the ViralClear
Plan that are based on the requirements of Section 422 of the Internal Revenue Code of 1986, as amended (the "Code"), the
rules of any exchange or inter-dealer quotation system upon which ViralClear's securities are listed or quoted, or any other applicable
law, to the extent that any such restrictions are no longer required by applicable law, the Committee shall have the sole discretion
and authority to grant awards that are not subject to such mandated restrictions and/or to waive any such mandated restrictions with
respect to outstanding awards. Subject to the provisions of the ViralClear Plan, the ViralClear Board and Committee's decisions,
determinations, and interpretations will be final, binding, and conclusive on all ViralClear Plan participants and any other award holders.

 Eligibility.
Employees (including any employee who is also a director or an officer), contractors, and outside directors of ViralClear whose judgment,
initiative, and efforts contributed to, or may be expected to contribute to, the successful performance of ViralClear are eligible to
participate in the ViralClear Plan, provided that only employees of a corporation shall be eligible to receive incentive stock options.

 Grant
of Awards. The grant of an award shall be authorized by the Committee and shall be evidenced by an award agreement setting forth
the applicable award being granted; the total number of shares or units to be granted; the price to be paid, if any; the award period;
the date of grant; and such other terms, provisions, limitations, and performance objectives, as are approved by the Committee. The Company
shall execute an award agreement with a participant after the Committee approves the issuance of an award. Any award granted pursuant
to the ViralClear Plan must be granted within 10 years of the date of adoption of the ViralClear Plan by the ViralClear Board. The ViralClear
Plan shall be submitted to ViralClear's stockholders for approval; however, the Committee may grant awards under the ViralClear
Plan prior to the time of stockholder approval. Any such award granted prior to such stockholder approval shall be made subject to such
stockholder approval. The grant of an award to a participant shall not be deemed either to entitle the participant to, or to disqualify
the participant from, receipt of any other award under the ViralClear Plan. If the Committee establishes a purchase price for an award,
the participant must accept such award within a period of 30 days (or such shorter period as the Committee may specify) after the date
of grant by executing the applicable award agreement and paying such purchase price. Any award under the ViralClear Plan that is settled
in whole or in part in cash on a deferred basis may provide for interest equivalents to be credited with respect to such cash payment.
Interest equivalents may be compounded and shall be paid upon such terms and conditions as may be specified by the grant.

 Stock
Options. The Committee may grant either incentive stock options, qualifying under Section 422 of the Code, or nonqualified stock
options, provided that only employees of ViralClear are eligible to receive incentive stock options. The option price for any share of
common stock which may be purchased under a nonqualified stock option for any share of common stock must be equal to or greater than
the fair market value of such share on the date of grant. The option price for any share of common stock which may be purchased under
an incentive stock option must be at least equal to the fair market value of such share on the date of grant. If an incentive stock option
is granted to an employee who owns or is deemed to own more than 10% of the combined voting power of all classes of stock of ViralClear
(or any parent or subsidiary), the option price shall be at least 110% of the fair market value of our common stock on the date of grant.
No dividends may be paid or granted with respect to any stock option. No stock option shall be granted with a term of greater than 10
years from its date of grant; however, if an employee owns or is deemed to own more than 10% of the combined voting power of all classes
of stock of ViralClear (or any parent or subsidiary), and an incentive stock option is granted to such employee, the term of such incentive
stock option shall be no more than five years from the date of grant. The Committee may not grant incentive stock options under the ViralClear
Plan to any employee that would permit the aggregate fair market value (determined on the date of grant) of the common stock with respect
to which incentive stock options (under the ViralClear Plan and any other plan of ViralClear and its subsidiaries) are exercisable for
the first time by such employee during any calendar year to exceed $100,000. To the extent any stock option granted under the ViralClear
Plan that is designated as an incentive stock option exceeds this limit or otherwise fails to qualify as an incentive stock option, such
stock option (or any such portion thereof) shall be a nonqualified stock option. In such case, the Committee shall designate which stock
will be treated as incentive stock option stock by causing the issuance of a separate stock certificate and identifying such stock as
incentive stock option stock on ViralClear's stock transfer records.

 If
a stock option is exercisable prior to the time it is vested, the common stock obtained on the exercise of the stock option shall be
restricted stock that is subject to the applicable provisions of the ViralClear Plan and the award agreement. If the Committee imposes
conditions upon exercise, then subsequent to the date of grant, the Committee may, in its sole discretion, accelerate the date on which
all or any portion of the stock option may be exercised. No stock option may be exercised for a fractional share of common stock. The
granting of a stock option shall impose no obligation upon the participant to exercise that stock option. The Committee will determine
the manner in which recipients of stock options may pay the option exercise price, which may include payment by cash or check, bank draft,
or money order payable to the order of ViralClear; by delivery of common stock owned by the participant on the exercise date, valued
at its fair market value on the exercise date, and which the participant has not acquired from ViralClear within six months prior to
the exercise date; by delivery (including by FAX or electronic transmission) to ViralClear or its designated agent of an executed irrevocable
option exercise form (or, to the extent permitted by ViralClear, exercise instructions, which may be communicated in writing, telephonically,
or electronically) together with irrevocable instructions from the participant to a broker or dealer, reasonably acceptable to ViralClear,
to sell certain of the shares of common stock purchased upon exercise of the stock option or to pledge such shares as collateral for
a loan and promptly deliver to ViralClear the amount of sale or loan proceeds necessary to pay such purchase price; by requesting ViralClear
to withhold the number of shares otherwise deliverable upon exercise of the stock option by the number of shares of Common Stock having
an aggregate fair market value equal to the aggregate option price at the time of exercise (i.e., a cashless net exercise); and/or in
any other form of valid consideration that is acceptable to the Committee in its sole discretion.

 Stock
Appreciation Rights. The Committee may grant SARs to any participant, either as a separate award or in connection with a stock option,
and impose terms and conditions on such SARs. A SAR may be exercised by the delivery (including by FAX) of written notice to the Committee
setting forth the number of shares of common stock with respect to which the SAR is to be exercised and the exercise date, which shall
be at least three days after giving such notice, unless an earlier time shall have been mutually agreed upon. The grant of the SAR may
provide that the holder may be paid for the value of the SAR either in cash, in shares of common stock, or a combination thereof. In
the event of the exercise of a SAR payable in shares of common stock, the holder of the SAR shall receive that number of whole shares
of common stock having an aggregate fair market value on the date of exercise equal to the value obtained by multiplying the difference
between the fair market value of a share of common stock on the date of exercise over the SAR price as set forth in such SAR (or other
value specified in the agreement granting the SAR), by the number of shares of common stock as to which the SAR is being exercised, with
a cash settlement to be made for any fractional shares of common stock. The SAR price for any share of common stock subject to a SAR
may be equal to or greater than the fair market value of such share on the date of grant. The Committee, in its sole discretion, may
place a ceiling on the amount payable upon exercise of a SAR, but any such limitation shall be specified at the time the SAR is granted.

Stock. Restricted stock consists of shares of our common stock that may not be sold, transferred, pledged, assigned, or otherwise
alienated or hypothecated and that may be forfeited in the event of certain terminations of employment or service prior to the end of
a restricted period, as specified by the Committee in the applicable award agreement. The Committee may, in its sole discretion, remove
any or all of the restrictions on such restricted stock. The Committee will set forth in the award agreement: the number of shares of
common stock awarded; the price, if any, to be paid by the participant for such restricted stock and the method of payment of the price;
the time or times within which such award may be subject to forfeiture; specified performance goals of ViralClear, a subsidiary, any
division thereof or any group of employees of ViralClear, or other criteria, which the Committee determines must be met in order to remove
any restrictions (including vesting) on such award; and all other terms, limitations, restrictions, and conditions applicable to the
restricted stock.

Stock Units. Restricted stock units are the right to receive shares of common stock, cash, or a combination thereof at a future date
in accordance with the terms of such grant upon the attainment of certain conditions specified by the Committee, which include a substantial
risk of forfeiture and restrictions on their sale or other transfer by the participant. Restricted stock units shall be subject to such
restrictions as the Committee determines, including, without limitation, a prohibition against sale, assignment, transfer, pledge, hypothecation,
or other encumbrance for a specified period of time or a requirement that the holder forfeit (or in the case of shares of common stock
or units sold to the participant, resell to ViralClear at cost) such shares or units in the event of termination of employment or service
during the applicable period of restriction.

 Vesting,
Forfeiture, Assignment. The Committee, in its sole discretion, may determine that an award will be immediately vested, in whole or
in part, or that all or any portion may not be vested until a date, or dates, subsequent to its date of grant, or until the occurrence
of one or more specified events, subject in any case to the terms of the ViralClear Plan. If the Committee imposes conditions upon vesting,
then, except as otherwise provided below, subsequent to the date of grant, the Committee may, in its sole discretion, accelerate the
date on which all or any portion of the award may be vested.

 The
Committee may impose on any award, at the time of grant or thereafter, such additional terms and conditions as the Committee determines.
Except as otherwise provided in the particular award agreement, upon termination of service during the applicable restriction period,
nonvested shares of restricted stock shall be forfeited by the participant.

 Incentive
stock options may not be transferred, assigned, pledged, hypothecated, or otherwise conveyed or encumbered other than by will or the
laws of descent and distribution and may be exercised during the lifetime of the participant only by the participant or the participant's
legally authorized representative, and each award agreement in respect of an incentive stock option shall so provide, except that the
Committee may waive or modify such limitation that is not required for compliance with Section 422 of the Code. Other awards granted
under the ViralClear Plan generally may not be transferred, assigned, pledged, hypothecated or otherwise conveyed or encumbered other
than by will or the laws of descent and distribution. Notwithstanding the foregoing, the Committee may, in its discretion, authorize
all or a portion of a nonqualified stock option or SAR to be granted to a participant on terms which permit transfer by such participant
to the spouse (or former spouse), children, or grandchildren of the participant ("Immediate Family Members"); a trust or
trusts for the exclusive benefit of such Immediate Family Members; a partnership in which the only partners are such Immediate Family
Members and/or entities which are controlled by the participant and/or Immediate Family Members; an entity exempt from federal income
tax pursuant to Section 501(c)(3) of the Code or any successor provision; or a split interest trust or pooled income fund described in
Section 2522(c)(2) of the Code or any successor provision, provided that there shall be no consideration for any such transfer; the award
agreement pursuant to which such nonqualified stock option or SAR is granted must be approved by the Committee and must expressly provide
for transferability in a manner consistent with the ViralClear Plan; and subsequent transfers of transferred nonqualified stock options
or SARs shall be prohibited except those by will or the laws of descent and distribution. Following any transfer, any such nonqualified
stock option and SAR shall continue to be subject to the same terms and conditions as were applicable to such award immediately prior
to transfer. The events of termination of service shall continue to be applied with respect to the original participant, following which
the nonqualified stock options and SARs shall be exercisable or convertible by the transferee only to the extent and for the periods
specified in the applicable award agreement. The Committee and ViralClear shall have no obligation to inform any transferee of a nonqualified
stock option or SAR of any expiration, termination, lapse, or acceleration of such stock option or SAR. The Company shall have no obligation
to register with any federal or state securities commission or agency any common stock issuable or issued under a nonqualified stock
option or SAR that has been transferred by a participant under the ViralClear Plan.

 Capital
Adjustments. In the event that any dividend or other distribution (whether in the form of cash, common stock, other securities, or
other property), recapitalization, stock split, reverse stock split, rights offering, reorganization, merger, consolidation, split-up,
spin-off, split-off, combination, subdivision, repurchase, or exchange of common stock or other securities of ViralClear, issuance of
warrants or other rights to purchase common stock or other securities of ViralClear, or other similar corporate transaction or event
affects the fair value of an award, then the Committee shall adjust any or all of the following so that the fair market value of the
award immediately after the transaction or event is equal to the fair market value of the award immediately prior to the transaction
or event: the number of shares and type of common stock (or the securities or property) which thereafter may be made the subject of awards;
the number of shares and type of common stock (or other securities or property) subject to outstanding awards; the number of shares and
type of common stock (or other securities or property) specified as the annual per-participant limitation; the option price of each outstanding
award; the amount, if any, ViralClear pays for forfeited shares of common stock; and the number of or SAR price of shares of common stock
then subject to outstanding SARs previously granted and unexercised under the ViralClear Plan, to the end that the same proportion of
ViralClear's issued and outstanding shares of common stock in each instance shall remain subject to exercise at the same aggregate
SAR price; provided, however, that the number of shares of common stock (or other securities or property) subject to any award shall
always be a whole number. Notwithstanding the foregoing, no such adjustment shall be made or authorized to the extent that such adjustment
would cause the ViralClear Plan or any stock option to violate Section 422 of the Code or Section 409A of the Code, and such adjustments
shall be made in accordance with the rules of any securities exchange, stock market, or stock quotation system to which ViralClear is
subject.

 Amendment
or Discontinuance of the ViralClear Plan. The ViralClear Board may at any time and from time to time, without the consent of participants,
alter, amend, revise, suspend, or discontinue the ViralClear Plan in whole or in part, except that we will obtain stockholder approval
of any ViralClear Plan amendment to the extent necessary and desirable to comply with the requirements relating to the administration
of equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation
system on which our common stock is listed or quoted, and the applicable laws of any foreign country or jurisdiction where awards are,
or will be, granted under the ViralClear Plan. Any amendments made shall, to the extent deemed necessary or advisable by the Committee,
be applicable to any outstanding awards theretofore granted under the ViralClear Plan, notwithstanding any contrary provisions contained
in any award agreement. In the event of any such amendment to the ViralClear Plan, the holder of any award outstanding under the ViralClear
Plan shall, upon request of the Committee and as a condition to the exercisability thereof, execute a conforming amendment in the form
prescribed by the Committee to any award agreement relating thereto. Notwithstanding anything contained in the ViralClear Plan to the
contrary, unless required by law, no action contemplated or permitted by the ViralClear Board or Committee for the alteration, amendment,
revision, suspension, or termination of the ViralClear Plan shall adversely affect any rights of participants or obligations of ViralClear
to participants with respect to any award theretofore granted under the ViralClear Plan without the consent of the affected participant.

 SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 Common
Stock

 The
following table sets forth information regarding the beneficial ownership of our voting securities as of April 15, 2024 by (i) each person
known to us to beneficially own five percent (5%) or more of any class of our voting securities; (ii) each of our named executive officers
and directors; and (iii) all of our named directors and executive officers as a group. The percentages of voting securities beneficially
owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the
rules of the SEC, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes
the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the
disposition of the security. Except as indicated in the footnotes to this table, to our knowledge and subject to community property laws
where applicable, each beneficial owner named in the table below has sole voting and sole investment power with respect to all shares
beneficially owned and each person's address is c/o BioSig Technologies, Inc, 55 Greens Farms Road 1 st Floor Westport,
Connecticut 06880. Percentage of common stock ownership is based on 11,198,174 shares of common stock issued and outstanding as of April
15, 2024. Percentage of Series C Preferred Stock ownership is based on 105 shares of Series C Preferred Stock issued and outstanding
as of April 15, 2024.

 Beneficial
ownership is determined in accordance with the rules of the SEC. For the purpose of calculating the number of shares beneficially owned
by a stockholder and the percentage ownership of that stockholder, shares of common stock subject to options or warrants that are currently
exercisable or exercisable within sixty (60) days of April 15, 2024 by that stockholder are deemed outstanding.

 Name

 of Shares of Common Stock Beneficially Owned (1)

 Percentage
 Class (1) (2)

 of Shares of Series C Preferred Stock Beneficially Owned

 Percentage
 Class (5)

 Total
 Voting Power

 5% Beneficial holder

 Donald E. Garlikov

 1,740,933
 (3)

 14.94
 %

 —

 —

 11.46

 %

 Directors and Named Executive
 Officers

 Frederick
 D. Hrkac

 564,501
 (4)

 5.01
 %

 —

 —

 4.54
 %

 All directors and executive officers as a group of one person

 564,501

 5.01
 %

 —

 —

 4.54
 %

 Series
 C Holders

 Ray
 Weber

 114,520
 (6)

 *

 %

 *

 StoneX
 C/F Raymond E Weber IRA

 89,244
 (7)

 *

 %

 *

 Martin
 F. Sauer

 63,745
 (8)

 %

 *

 *
Less than 1%.

 (1)

 of common stock beneficially owned and the respective percentages of beneficial ownership of common stock assume the exercise of
 all options and other securities convertible into common stock beneficially owned by such person or entity currently exercisable
 or exercisable within 60 days of April 15, 2024, except as otherwise noted. Shares issuable pursuant to the exercise of stock options
 and other securities convertible into common stock exercisable within 60 days are deemed outstanding and held by the holder of such
 options or other securities for computing the percentage of outstanding common stock beneficially owned by such person but are not
 deemed outstanding for computing the percentage of outstanding common stock beneficially owned by any other person.

 (2)

 These
 percentages have been calculated based on 11,198,174 shares of common stock outstanding as of April 15, 2024.

 (3)

 Comprised of (i) 1,285,707 shares of common stock and (ii) warrants to
purchase 455,226 shares of common stock.

 (4)

 Comprised of (i) 509,501 shares of common stock and (ii) options to purchase
55,000 shares of common stock that are currently exercisable or exercisable within 60 days of April 15, 2024.

 (5)

 These percentages have been calculated based on 105 shares of Series C
Preferred Stock outstanding as of April 15, 2024.

 (6)

 Comprised of shares of common stock issuable upon the conversion of shares
of our Series C Preferred Stock, including dividends accrued thereon as of April 15, 2024. Ray Weber may also be deemed beneficial owner
of shares held by StoneX Group Inc C/F Raymond E Weber IRA. Mr. Weber's address is 27 Zabriskie St., Jersey City, NJ 07307.

 (7)

 Comprised of shares of common stock issuable upon the conversion of shares
of our Series C Preferred Stock, including dividends accrued thereon as of April 15, 2024. This stockholder's address is 27 Zabriskie
St., Jersey City, NJ 07307.

 (8)

 Comprised of shares of common stock issuable upon the conversion of shares
of our Series C Preferred Stock, including dividends accrued thereon as of April 15, 2024. This stockholder's address is 1028 Steeplechase
Dr. Lancaster, PA 17601.

 ITEM
13 – CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 Certain
Relationships and Related Transactions

 Transactions
with related persons are governed by our Code of Conduct and Ethics, which applies to all of our directors, officers and employees. This
code covers a wide range of potential activities, including, among others, conflicts of interest, self-dealing and related party transactions.
Waiver of the policies set forth in this code will only be permitted when circumstances warrant. Such waivers for directors and executive
officers, or that provide a benefit to a director or executive officer, may be made only by our Board, as a whole, or the Audit Committee.
Absent such a review and approval process in conformity with the applicable guidelines relating to the particular transaction under consideration,
such arrangements are not permitted. All related party transactions for which disclosure is required to be provided herein were approved
in accordance with our Code of Conduct and Ethics.

 On
March 22, 2022, as an investor, but before appointment to the Board of Directors, James Klein purchased 11,000 shares of our common stock
and 11,000 warrants to purchase shares of our common stock at $14.00 as part of a registered direct offering. On November 3, 2022, we
offered all warrant holders of the March 22, 2022 offering a reduction in exercise price from $14.00 to $2.50. On November 14, 2022,
Mr. Klein exercised his 11,000 warrants for 11,000 shares of our common stock for net proceeds of $27,500.

 On
February 8, 2023, Mr. Buhaly, our former Chief Financial Officer participated in a private placement, acquiring 23,289 shares of the
Company's common stock and 11,645 warrants to acquire the Company's common stock at an exercise price of $7.963, expiring
August 8, 2028, for an investment of $200,000 as part of the February 8, 2023 offering.

 On
November 2, 2023, the Company appointed Mr. Hrkac, our then independent board member, as the new role of Executive Vice President. In
connection with the appointment, the Company entered into a consulting agreement at a rate of $12,500 per month. In addition, on December
28, 2023, the Company granted an aggregate of 90,000 restricted stock units to the new Executive Vice President, vesting based on certain
market conditions for services at a fair value of $426,780 and options to purchase 60,000 shares our common stock at an exercise price
of $4.472 per share, vesting over six months at a fair value of $222,422.

 Independent
Directors

 Due
to the recent resignations of our board of directors, we currently do not have independent board members within the meaning of Rule 5605(a)(2)
of the NASDAQ Listing Rules and the rules and regulations promulgated by the SEC. We plan to have independent directors in April 2024.
In making independence determinations, our sole director seeks to identify and analyze all of the facts and circumstances related to
any relationship between a director, his immediate family and our company and our affiliates and will not rely on categorical standards
other than those contained in the NASDAQ rule referenced above.

 ITEM
14 – PRINCIPAL ACCOUNTING FEES AND SERVICES

 Fees
to Independent Registered Public Accounting Firms

 The
following is a summary of the fees billed to us by Marcum LLP for professional services rendered in the years ended December 31, 2023
and 2022:

 2023

 2022

 Audit Fees

 $
 154,875

 $
 140,700

 Audit-Related Fees

 78,225

 86,600

 Tax Fees

 -

 -

 Total Fees

 $
 233,100

 $
 227,300

 Audit
Fees. This category includes the audit of our annual consolidated financial statements, reviews of our financial statements included
in our Form 10-Qs and services that are normally provided by our independent registered public accounting firm in connection with its
engagements for those years. This category also includes advice on audit and accounting matters that arose during, or as a result of,
the audit or the review of our interim financial statements.

 Audit-Related
Fees. This category consists of assurance and related services by our independent registered public accounting firm that are reasonably
related to the performance of the audit or review of our financial statements and are not reported above under "Audit Fees."
The services for the fees disclosed under this category include consents regarding equity issuances.

 Tax
Fees. This category typically consists of professional services rendered by our independent registered public accounting firm for
tax compliance and tax advice.

 Pre-Approval
Policies and Procedures

 Our
audit committee pre-approves all auditing services and all permitted non-auditing services (including the fees and terms thereof) to
be performed by our independent registered public accounting firm, except for de minimis non-audit services that are approved by the
audit committee prior to the completion of the audit. The audit committee may form and delegate authority to subcommittees consisting
of one or more members when appropriate, including the authority to grant pre-approvals of audit and permitted non-auditing services,
provided that decisions of such subcommittee to grant pre-approval is presented to the full audit committee at its next scheduled hearing.

 PART
IV

 ITEM
15 – EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 The
following documents are filed as part of this report:

 (1)

 Financial
 Statements

 The
following financial statements are included herein:

 Report of Independent Registered Public Accounting Firm (PCAOB ID 688)

 Consolidated Balance Sheets as of December 31, 2023, and 2022

 Consolidated Statements of Operations for the years ended December 31, 2023, and 2022

 Consolidated Statement of Changes in Equity (Deficit) for the Years ended December 31, 2023 and 2022

 Consolidated Statements of Cash Flows for the years ended December 31, 2023, and 2022

 Notes to Consolidated Financial Statements

 (2)

 Exhibits

 Exhibit
 No.

 Description

 3.1

 Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form S-1 filed on July 22, 2013)

 3.2

 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.2 to the Form S-1 filed on July 22, 2013)

 3.3

 Certificate of Second Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.3 to the Form S-1 filed on July 22, 2013)

 3.4

 Certificate of Third Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.5 to the Form S-1/A filed on January 21, 2014)

 3.5

 Certificate of Fourth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.6 to the Form S-1/A filed on March 28, 2014)

 3.6

 Certificate of Fifth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on August 21, 2014)

 3.7

 Certificate of Sixth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on November 25, 2016)

 3.8

 Certificate of Seventh Amendment to the Amended and Restated Certificate of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on September 10, 2018)

 3.9

 Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on November 9, 2017)

 3.10

 Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on February 16, 2018)

 3.11

 Certificate of Designations of Series F Junior Participating Preferred Stock of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on July 17, 2020)

 3.12

 Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to the Exhibit 3.1 to the Form 8-K filed on September 27, 2019)

 3.13

 Amendment No. 1 to Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on October 22, 2019)

 3.14

 Amendment No. 2 to Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on December 28, 2022)

 3.15

 Amendment No. 3 to the Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on November 8, 2023)

 3.16

 Certificate of Amendment of Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc., dated January 31, 2024 (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on January 31, 2024)

 4.1*

 Description of Securities.

 4.2

 Form of Underwriter Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on February 24, 2020)

 4.3

 Form of Underwriter Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on July 2, 2021)

 4.4

 Form of Common Stock Purchase Warrant dated March 22, 2022 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on March 24, 2022)

 4.5

 Form of Underwriter Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on June 29, 2022)

 4.6

 Form of Common Stock Purchase Warrant dated December 27, 2022 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on December 28, 2022)

 4.7

 Form of Common Stock Purchase Warrant dated January 13, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on January 17, 2023)

 4.8

 Form of Laidlaw Warrant dated January 13, 2023 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on February 8, 2023)

 4.9

 Form of Common Stock Purchase Warrant dated January 24, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on January 24, 2023)

 4.10

 Form of Laidlaw Warrant dated January 24, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on February 7, 2023)

 4.11

 Form of Common Stock Purchase Warrant dated January 26, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on January 26, 2023)

 4.12

 Form of Common Stock Purchase Warrant dated February 8, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on February 8, 2023)

 4.13

 Form of Laidlaw Warrant dated February 8, 2023 (incorporated by reference to Exhibit 4.3 to the Form 8-K filed on February 8, 2023)

 4.14

 Form of Common Stock Purchase Warrant dated February 13, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on February 13, 2023)

 4.15

 Form of Laidlaw Warrant dated March 16, 2023 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on March 15, 2023)

 4.16

 Form of Common Stock Purchase Warrant dated March 16, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on March 15, 2023)

 4.17

 Form of Laidlaw Warrant dated March 29, 2023 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on March 29, 2023)

 4.18

 Form of Common Stock Purchase Warrant dated March 29, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on March 29, 2023)

 4.19

 Form of Common Stock Purchase Warrant dated April 21, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on April 21, 2023)

 4.20

 Form of Laidlaw Warrant dated April 21 2023 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on April 21, 2023)

 4.21

 Form of Common Stock Purchase Warrant dated April 21, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on April 21, 2023)

 4.22

 Form of Laidlaw Warrant dated May 22, 2023 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on May 22, 2023)

 4.23

 Form of Common Stock Purchase Warrant dated July 31, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on July 31, 2023)

 4.24

 Form of Laidlaw Warrant dated July 31, 2023 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on July 31, 2023)

 4.25

 Form of Common Stock Purchase Warrant dated September 12, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on September 12, 2023)

 4.26

 Form of Laidlaw Warrant dated September 12, 2023 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on September 12, 2023)

 4.27

 Form of Common Stock Purchase Warrant dated September 27, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on September 27, 2023)

 4.28

 Form of Laidlaw Warrant dated September 27, 2023 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on September 27, 2023)

 4.29

 Form of Common Stock Purchase Warrant dated October 16, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on October 16, 2023)

 4.30

 Form of Laidlaw Warrant dated October 16, 2023 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on October 16, 2023)

 4.31

 Form of Series A Warrant dated November 13, 2023 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on November 13, 2023)

 4.32

 Form of Series B Warrant dated November 13, 2023 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on November 13, 2023)

 4.33

 Form of Placement Agent Warrant dated November 13, 2023 (incorporated by reference to Exhibit 4.3 to the Form 8-K filed on November 13, 2023)

 4.34

 Form of Common Stock Purchase Warrant dated January 12, 2024 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on January 12, 2024)

 10.1

 Common Stock Purchase Warrant of BioSig Technologies, Inc., dated November 20, 2019, issued to Mayo Foundation for Medical Education and Research (EP Software Warrant)

 10.2

 Common Stock Purchase Warrant of BioSig Technologies, Inc., dated November 20, 2019, issued to Mayo Foundation for Medical Education and Research (Tools Warrant)

 10.3

 Common Stock Purchase Warrant of NeuroClear Technologies, Inc., dated November 20, 2019, issued to Mayo Clinic Ventures

 10.4

 Form of Securities Purchase Agreement dated as of March 21, 2022 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on March 24, 2022)

 10.5

 Form of Securities Purchase Agreement dated as of November 18, 2022 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on November 21, 2022)

 10.6

 Form of Securities Purchase Agreement dated as of December 21, 2022 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on December 28, 2022)

 10.7

 Form of Securities Purchase Agreement dated as of January 10, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on January 17, 2023)

 10.8

 Form of Securities Purchase Agreement dated as of January 23, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on January 24, 2023)

 10.9

 Form of Securities Purchase Agreement dated as of January 25, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on January 26, 2023)

 10.10

 General Release and Severance Agreement dated January 29, 2023 by and between Steve Chaussy and BioSig Technologies, Inc. (incorporated by reference to Exhibit 10.1 to the amended Form 8-K filed on February 7, 2023)

 10.11

 Form of Securities Purchase Agreement dated as of February 3, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on February 8, 2023)

 10.12+

 BioSig Technologies, Inc. 2023 Long-Term Incentive Plan dated February 7, 2023 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on February 9, 2023)

 10.13

 Form of Securities Purchase Agreement dated as of February 8, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on February 13, 2023)

 10.14

 Form of Securities Purchase Agreement dated as of March 14, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on March 15, 2023)

 10.15

 Form of Securities Purchase Agreement dated as of March 24, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on March 29, 2023)

 10.16

 Form of Securities Purchase Agreement dated as of April 18, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on April 21, 2023)

 10.17

 Form of Securities Purchase Agreement dated as of May 16, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on May 22, 2023)

 10.18

 Form of Securities Purchase Agreement dated as of June 30, 2023 by and between BioSig AI Sciences, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on June 30, 2023).

 10.19

 Form of Securities Purchase Agreement dated as of July 21, 2023 by and between BioSig AI Sciences, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on July 19, 2023).

 10.20

 Form of Securities Purchase Agreement dated as of July 31, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on July 31, 2023)

 10.21

 Form of Securities Purchase Agreement dated as of September 12, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on September 12, 2023)

 10.22

 Form of Securities Purchase Agreement dated as of September 12, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on September 27, 2023)

 10.23

 Form of Securities Purchase Agreement dated as of October 12, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on October 16, 2023)

 10.24

 Form of Securities Purchase Agreement dated as of November 8, 2023 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on November 13, 2023)

 10.25+

 First Amendment to the BioSig Technologies, Inc. 2023 Long-Term Incentive Plan effective as of December 18, 2023 (incorporated by reference to the Exhibit 10.1 to the Form 8-K filed on December 18, 2023)

 10.26

 Form of Securities Purchase Agreement dated as of January 12, 2024 by and between BioSig Technologies, Inc. and certain purchasers set forth therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on January 12, 2024)

 21.1

 Subsidiary List of BioSig Technologies, Inc. (incorporated by reference to Exhibit 21.1 to the Form 10-K filed on March 15, 2021).

 23.1*

 Consent of Marcum LLP

 31.01*

 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 32.01**

 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 97*

 Compensation Recovery Policy adopted November 6, 2023

 INS*

 SCH*

 CAL*

 LAB*

 PRE*

 DEF*

 104*

 Cover

 *
Filed herewith.

 **
Furnished herewith.

 +
Indicates a management contract or compensatory plan.

 ITEM
16 – FORM 10-K SUMMARY

 None.

 SIGNATURES

 In
accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

 BIOSIG
 TECHNOLOGIES, INC.

 Date:
 April 16, 2024

 By:

 /s/
 FREDERICK D. HRKAC

 Frederick
 D. Hrkac

 Principal
 Executive & Financial Officer